Dr. Kenneth Blum received his Ph.D. in Neuropharmacology from New York Medical College and graduated from Columbia University and New Jersey College of Medicine. He trained at the Institute of Behavioral Genetics, Colorado University at Boulder, Colorado. Dr. Blum also received a Doctor Of Humane Letters from St. Martins University. He has published over 720 abstracts, peer-reviewed articles, and 17 books. Currently, with Dr. Thomas McLaughlin, who is Harvard-trained, he is completing a book entitled “Death by Neuron.”

He has been the recipient of many grants and awards, including a Life-Time Achievement in Addiction Medicine (Holistic Institute on Addiction Studies); Marquis Who Who’s Life –Time Achievement Award, and Presidential Award for Scientific Excellence (National Council of Alcohol & Drug Abuse Councilors), Scientific Achievement Award (City of Life Miami) and Best Abstract (2012) Award ASRA (Pain); Path Foundation Lifetime Achievement Award (2014) and Honorary Full Professor, Eötvös Loránd University, Institute of Psychology, Budapest, Hungary, Honorary Full Professor of Adelson University, Ariel, Israel, and American Society of Addiction Medicine Millennium Laboratory Award and Top Registry Professional of the Year Award 2018 among many others. He coined the term “Reward Deficiency Syndrome“ in 1995, now in Microsoft Dictionary, Gates Scientific dictionary, and featured in SAGE Encyclopedia of Abnormal Psychology (2017). Selected Marquis Who’s Who Scientist of the Year (medical) 2019 and Marquis Who’s Who in the world (2021).Recipient of Biographical Record in the field of Psychiatric Genetics (2021). Featured researcher in Scientia (2022). Dr. Blum was named by Stanford University top 2% world best scientist. He  has been nominated for the life-time Achievement Award from the International Society of Behavioral Addictions (2023).his work as a 3% top producer Marquis Who Who’s  has been recently featured in the Wall Street Journal (2023).

Currently, he serves as Editor-in-chief (EIC) of INNOSC Theragnostics and Pharmacological Sciences (ITPS) ; Addiction Psychiatry (Editor-in-chief), EIC of Journal of Systems & Integrative Neuroscience; EIC of Current Psychopharmacology, Regional Editor of Current Pharmaceutical & Biotechnology, and Section Editor (Neurogenetics and Nutrigenomics) and Current Psychiatry & Research and Reviews and is on the editorial board of 23 other scientific journals. As the lead author on the first genetic association of a dopaminergic gene with severe alcoholism, he is considered by some as the “[Father of Psychiatric Genetics.” He is the holder of many US and foreign patents involving nutrigenomics (North of over 100). Recently he has been awarded the USA patent on Genetic Addiction Risk Score (GARS). Dr. Blum received 22 patents on GARS across Europe. He is the lead author of the Springer Neuroscience Brief book on the 12 Steps -entitled “Molecular Neurobiology of Addiction Recovery.” Dr. Blum and Mark Gold (St. Louis) have been named Editor-In-Chief of Frontiers of Bioscience Special Issue on Reward Deficiency Syndrome (RDS). Dr. Blum was a Volunteer Professor in the Department of Psychiatry at the University of Florida College of Medicine and McKnight Brain Institute. Currently serves as adjunct Full-Professor in the Department of Psychiatry at the University of Vermont. He was an Adjunct Full Professor in the Department of Psychiatry & Behavioral Science, Keck School of Medicine, University of Southern California. He is currently a Clinical Full Professor in the Department of Psychiatry, Wright University Boonshoft School of Medicine, Dayton, Ohio. He is currently serving on the research faculty of Western University Health Sciences, Pomona, California. He also served as Neuroscience advisor to many companies and foundations, including Dominion Diagnostics (Chief Scientific Adviser), Path Foundation NY (Director of Science), Victory Nutrition, Impact Genomics, Shores Treatment & Recovery Center (Neuroscience Advisor). He also served as Chief Scientific Officer and is the Emeritus Chairman of Geneus Health and Restoregen, San Antonio, Texas. He is Emeritus Faculty of The Institute of Applied Genomics and Biotechnology, Nagpur, India. Major media outlets worldwide have covered his work on addiction. Dr. Blum was Chief Neurogenetic & Addiction Therapy Advisor, The Florida House Experience. He is currently serving as Founding President of United Science Group (USG). H e serves as scientific advisor to the Sunder Foundation, Cross Cultural Reseach Foundation, Peak Logic LLC, and Awareness Integration Tool Foundation. he currently serves as a scientific consultant for the Electronic Waveform Lab and Bajaj Chiropractic Clinic as well as EPIC with Stan Pierce. He is a member of the scientific advisory board of Ketamine Clinics of South Florida. 

Dr. Blum has developed the first-ever patented Genetic Addiction Risk Score (GARS) with Geneus Health. He was a frequent contributor to Sober World and Addiction Professional magazines(no longer published). In conjunction with Merlene Miller and David Miller, they published their award-winning book “Staying Clean and Sober.” He is co-author with Eric Braverman and Carl Pfeiffer’s book ‘Healing Nutrients Within. He is a sought-after speaker on a global basis for insights into RDS and genetics. He has published in almost every major peer-review journal globally, including Science, Nature, Lancet, JAMA, JAMA Psychiatry, PNAS, Plus One, Oncotarget, Cureus, Psychopharmacology, Current Neuropharmacology, amongst many other prestigious journals. Every major newspaper, magazine, television network worldwide, and the Harvard Review featured his work. He is indeed the father of Amino-Acid Therapy for Reward Deficiency Syndrome developing Pro –Dopamine Regulation to induce “dopamine Homeostasis “coupled with genetic testing for “Precision Addiction Management”(PAM)® and Precision Behavioral Management”(PBM).® He also has vast business experience, including former Chairman of a Public Company. Most recently, with Dr. Marjorie Gondre-Lewis Howard University and the National Human Genome Center (NHGC), he was Principal Investigator of a grant from the NIH selected to be funded related to both GARS and Pro-dopamine regulation in the African-American population along. He is a nominee to the National Whole Genome Science Foundation board of directors. Currently, he serves as Executive Chairman of Transplicegen Holdings, LLC, & TransplceGen Therapeutics, Inc. He serves as Chairman of Reward Deficiency Clinics of America, LLC., Chairman and CSO of The Kenneth Blum Behavioral & Neurogenetic Institute (Division of iVitalize, Inc.). Dr. Blum along with Dr. Eric R Braverman serve as EIC for the special issue on Global Addiction for the International Journal of Environmental Research & Public Health with associate editors. Dr. Mark Gold, David Baron and Jean Lud cadet. He is quest editor for the journal of Psychological Research & Behavioral Management concerning a collective on addiction neuroscience in the genomic era.

• Genetics & Psychopharmacology

• Blum, K. The effect of dopamine and other catecholamines on neuromuscular transmission. Arch. Int. Pharmacodyn. Ther. 181:297‑306, October 1969.
• Blum, K. Effects of chlordiazepoxide and pentobarbital on conflict behavior in rats. Psychopharmacologia 17(5):391‑8, 1970.
• Blum, K., Ryback, R.S. and Geller, I. Effects of vodka and bourbon on sleeping time in mice. Q. J. Stud. Alcohol (Suppl) 5:62‑6, May 1970.
• Geller, I. and Blum, K. The effects of 5‑HTP on para‑chlorphenylalanine (p‑CPA) attenuation of "conflict" behavior. Eur. J. Pharmacol. 9(3):319‑24, March 1970.
• Geller, I., Campbell, N.D. and Blum, K. Protection against acute alcoholic intoxication with diethanolamine ‑rutin. Res. Commun. Chem. Pathol. Pharmacol. 1(3):383‑94, May 1970.
• Blum, K., Seifter, E. and Seifter, J. The pharmacology of d‑ and 1‑choline and d‑ and 1‑acetylcarnitine. Comparison with choline and acetylcholine. J. Pharmacol. Exp. Ther. 178(2):331‑8, August 1971.
• Blum, K., Geller, I. and Wallace, J.E. Interaction effects of ethanol and pyrazole in laboratory rodents. Br. J. Pharmacol. 43(1):67‑73, September 1971.
• Geller, I., Hartmann, R. and Blum, K. Effects of nicotine, nicotine mono‑methiodide, lobeline, chlordiaze­poxide, meprobamate and caffeine on a discrimination task in laboratory rats. Psychopharmacologia 20(4):355‑65, 1971.
• Payte, J.T., Wallace, J.E. and Blum, K. Hydrolysis: A requisite for morphine detection in urine. Curr. Ther. Res. 13(6):412‑6, June 1971.
• Blum, K., Ryback, R.S. and Geller, I. Effects of vodka and bourbon on lever‑ pressing behavior of mice. Curr. Ther. Res. 14(2):95‑8, February 1972.
• Blum, K., Wallace, J.E. and Geller, I. Synergy of ethanol and putative neurotrans­mitters: Glycine and serine. Science 176(32):292‑4, April 21, 1972.
• Blum, K., Merritt, J.H., Wallace, J.E., Owen, R., Hahn, J.W. and Geller, I. Effects of catecholamine synthesis inhibition on ethanol narcosis in mice. Curr. Ther. Res. 14(6):324‑9, June 1972.
• Blum, K., Huizenga, C.G., Ryback, R.S., Johnson, D.K. and Geller, I. Toxicity of diethanolamine in mice. Toxicol. Appl. Pharmacol. 22(2):185‑85, June 1972.
• Blum, K., Wallace, J.E., Ryback, R.S. and Geller, I. Diethanolamine: A possible weak agonist ‑antagonist to ethanol. Eur. J. Pharmacol. 19(2):218‑22, August 1972.
• Geller, I., Hartmann, R.J. and Blum, K. The effects of low‑dose combinations of D‑amphet­amine and cocaine on experimentally induced conflict in the rat. Curr. Ther. Res. 14(4):220‑4, April 1972.
• Wallace, J.E., Biggs, J.D. and Blum, K. Gas‑liquid and thin‑layer chromatographic determination of morphine in biologic specimens. Clin. Chem. Acta. 36(1):85‑91, January 1972.
• Wallace, J.E., Biggs, J.D., Merritt, J.H., Hamilton, H.E. and Blum, K. A sensitive thin‑layer chromatographic technique for determining morphine in urine. J. Chromatogr. 71(1):35‑40, August 23, 1972.
• Wallace, J.E., Hamilton, H.E., Payte, J.T. and Blum, K. Sensitive spectrophotometric method for determining methadone in biological specimens. J. Pharm. Sci. 61(9):1397‑400, September 1972.
• Wallace, J.E., Ladd, S.L. and Blum, K. Determination of propoxyphene in biological materials by ultraviolet spectrophotometry and gas chromatography. J. Forensic Sci. 17(1):164‑73, January 1972.
• Blum, K., Merritt, J.H., Reiter, R.J. and Wallace, J.E. A possible relationship between the pineal gland and ethanol preference in the rat. Curr. Ther. Res. 15(1):25‑30, January 1973.
• Blum, K., Calhoun, W., Merritt, J. and Wallace J.E. L‑DOPA: Effect on ethanol narcosis and brain amines in mice. Nature 242(397):407‑9, April 6, 1973.
• Blum, K., Calhoun, W., Wallace, J.E., Merritt, J.H. and Geller, I. Soporific action of ethanol in mice: Possible role of biogenic amines. Pharmacol. Biochem. Behav. 1(3):271‑6, May‑June 1973.
• Blum, K., Calhoun, W., Merritt, J.H. and Wallace, J.E. Synergy of ethanol and alcohol‑like metabolites: Tryptophol and 3,4‑dihydroxyphenylethanol. Pharmacology 9(5):294‑9, 1973.
• Wallace, J.E., Biggs, J.D., Hamilton, H.E., Foster, L.L. and Blum, K. UV spectrophotometric method for determination of phenacetin in biological specimens. J. Pharm. Sci. 62(4):599‑601, April 1973.
• Reiter, R.J., Blum, K., Wallace, J.E. and Merritt, J.H. Effect of the pineal gland on alcohol consumption by congenitally blind male rats. Q. J. Stud. Alcohol 34(3):937‑9, September 1973.
• Blum, K., Hudson, K. and Wallace, J.E. Tetrahydrocannabinol blockade of alcohol‑induced withdrawal symptoms in mice. 2nd International Symposium on Drug Addiction, New Orleans, Louisiana, March 7‑9, 1973.
• Blum, K., Eubanks, J.D., Wiggins, B., Tabor, R.G., Wallace, J.E. and Friedman, R.N. The effects of acceleration on ethanol‑induced narcosis in mice. IRCS 2:1468, 1974.
• Blum, K., Wallace, J.E. and Eubanks, J.D. Effects of alanine and disulfiram on blood acetaldehyde and ethanol in rats. IRCS 3:332, 1974.
• Blum, K., Wallace, J.E. and Friedman, R.N. Reduction of acute alcoholic intoxication by alpha amino acids: Glycine and serine. Life Sci. 14(3): 557‑65, February 1, 1974.
• Blum, K. and Wallace, J.E. Effects of catecholamine synthesis inhibition on ethanol‑induced withdrawal symptoms in mice. Br. J. Pharmacol. 51(1):109‑11, May 1974.
• Blum, K., Wallace, J.E., Calhoun, W., Tabor, R.G. and Eubanks, J.D. Ethanol narcosis in mice: Serotonergic involvement. Experientia 30(9):1053‑4, September 15, 1974.
• Hamilton, H.E., Wallace, J.E. and Blum, K. Improved methods for quantitative determination of methadone. J. Pharm. Sci. 63(5):741‑5, May 1974.
• Wallace, J.E., Hamilton, H.E., Riloff, J.A. and Blum, K. Spectrophotometric determination of ethchlorvynol in biologic specimens. Clin. Chem. 20(2): 159‑62, February 1974.
• Wallace, J.E., Blum, K., Foster, K. and Eubanks, J.D. Drug identification: Spectroscopy, colorimetry and flurometry. J. Pharmaceut. Sci. 63(2):741, 1974.
• Wallace, J.E., Hamilton, H.E. and Blum, K. Microdetermination of dephenylhydantoin in serum and plasma by ultraviolet spectrophotometry. J. Pharm. Sci. 63:1795, 1974.
• Wallace, J.E., Hamilton, H.E., Farquhar, J.K., Everhart, B.E. and Blum, K. Comments on the determination of dephenylhydantoin. Clin. Chem. 20:515, 1974.
• Wallace, J.E., Hamilton, H.E., Blum, K. and Petty, C. Determination of morphine in biologic fluids by electron capture gasliquid chromatography. Anal. Chem. 46(14):2107‑11, December 1974.
• Wallace, J.E., Blum, K. and Singh, J.M. Determination of drugs in biologic specimens review. Clin. Toxicol. 7(5):477‑95, 1974.
• Reiter, R.J., Blum, K., Wallace, J.E. and Merritt, J.H. Pineal gland: Evidence for an influence on ethanol preference in male Syrian hamsters. Comp. Biochem. Physiol. (A) 47(1):11‑6, January 1974.
• Wallace, J.E., Blum, K. and Singh, J. Determination of drugs in biological specimens. Toxicol. Annals 2:167, 1975.
• McDonald, L.K., Maddux, J.F. and Blum, K. Fetal consequences of chronic methadone administration to pregnant rats: Methodological problems. Curr. Ther. Res. 17(3):308‑17, March 1975.
• Hamilton, H.E., Wallace, J.E. and Blum, K. Spectrophotometric and gas‑liquid chromatographic determination of amitriptyline. Anal. Chem. 47(7):1139‑43, June 1975.
• Wallace, J.E., Hamilton, H.E., Goggin, L.K. and Blum, K. Determination of amitriptyline at nanogram levels in serum by electron capture gas‑liquid chromatography. Anal. Chem. 47(9):1516‑9, August 1975.
• Wallace, J.E., Hamilton, H.E., Schwertner, H., King, D.E., McNay, J.L. and Blum, K. Thin‑layer chromatographic analysis of cocaine and benzoylecgonine in urine. J. Chromatogr. 114(2):433‑41, November 1975.
• Blum, K., Wallace, J.E. and Eubanks, J.D. Effects of naloxone on ethanol withdrawal: Preference and narcosis. Pharmacologist 17(197), 1975.
• Blum, K., Eubanks, J.D., Wallace, J.E., Schwertner, H.A. and Futterman, S. Possible rationale for differential chemotherapy of depression in humans: A review of the biogenic amine hypothesis, Part I. J. Psychedelic Drugs, 8(3): 223‑234, 1976.
• Blum, K. Depressive states induced by drugs of abuse: Clinical evidence, theoretical mechanism(s) and proposed treatment, Part II. J. Psychedelic Drugs, 8(3): 235‑262, 1976.
• Wallace, J.E., Hamilton, H.E., Goggin, K.K. and Blum, K. Determination of chlorprothixine by electron capture gas‑liquid chromatography. J. Forensic Sci., 1976.
• Blum, K., Eubanks, J.D., Wiggins, B. and Wallace, J.E. Morphine withdrawal reactions in male and female mice. Am. J. Drug. Alcohol Abuse 3(2):363‑8, 1976.
• Blum, K., Eubanks, J.D., Wallace, J.E., Schwertner, H. and Morgan, W.W. Possible role of tetrahydroisoquinoline alkaloids in postalcohol intoxication states. Ann. NY Acad. Sci. 273:234‑46, 1976.
• Blum, K., Wallace, J.E., Schwertner, H.A. and Eubanks, J.D. Enhancement of ethanol‑induced withdrawal convulsions by blockade of 5‑hydroxytryptamine receptors. J. Pharm. Pharmacol. 28(11):832‑5, November 1976.
• Blum, K., Eubanks, J.D., Wallace, J.E. and Hamilton, H. Enhancement of alcohol withdrawal convulsions by haloperidol. Clin. Toxicol. 9(3):427‑34, 1976.
• Blum, K., Eubanks, J.D., Wallace, J.E. and Schwertner, H.A. Suppression of ethanol withdrawal by dopamine. Experientia 32(4):493‑5, April 15, 1976.
• Blum, K., Wallace, J.E., Schwertner, H.A. and Eubanks, J.D. Morphine suppression of ethanol withdrawal in mice. Experientia 32(1):79‑82, January 15, 1976.
• Blum, K., Meyer, E., Futterman, S., Wallace, J.E. and Schwertner, H.A. Possible neurochemical mechanisms of ethanol dependence in mice. Pharmacologist 18:681, 1976.
• Blum, K. and Futterman, S.L. Drugs: Have it your way. J. Psychedelic Drugs 9(1):81‑2, 1977.
• Blum, K., Futterman, S.L. and Pascarosa, P. Peyote, a potential ethnopharmacologic agent for alcoholism and other drug dependencies: Possible biochemical rationale. Clin. Toxicol. 11(4):459‑72, 1977.
• Marshall, A., Hirst, M. and Blum, K. Analgesic effects of 3‑carboxysalsolinol alone and in combination with morphine. Experientia 33(6):754‑5, June 15, 1977.
• Schwertner, H.A., Blum, K., Wallace, J.E. and Eubanks, J.D. Alterations in brain electrolytes during acceleration in mice. Aviat. Space Environ. Med. 48(8):705‑7, August 1977.
• Blum, K., Wallace, J.E., Schwertner, H.A., Meyer, E. and Morgan, W.W. Central super sensitivity to norepinephrine and amphetamine following brain chemical sympathectomy by 6‑hydroxy­dopamine. Life Sci. 20(10):1705‑13, May 15, 1977.
• Wallace, J.E., Hamilton, H.E., Shimek, E.L., Jr., Schwertner, H.A. and Blum, K. Determination of primidone by electron‑capture gas chromatography. Anal. Chem. 49(7):903‑6, June 1977.
• Hamilton, M.G., Blum, K. and Hirst, M. Ethanol dependence: Modification by administration of calcium gluconate and phenoxybenzamine alcoholism. Clin. and Exp. Res. 1(2):153, 1977.
• Blum, K., Hamilton, M.G., Meyer, E.K., Hirst, M. and Marshall, A. Isoquinoline alkaloids as possible regulators of alcohol addiction (Letter). Lancet 1(8015):799‑800, April 9, 1977.
• Blum, K., Wallace, J.E., Meyer, E. and Schwertner, H.A. Intensification of amphetamine‑induced excitation by methysergide, a sertonergic receptor blocker. Experientia 33(2):213‑5, February 15, 1977.
• Blum, K. and Briggs, A.H. Effects of delta9 tetrahydrocannabinol (delta9‑THC) on amphetamine‑aggregate toxicity in mice. Curr. Ther. Res. 21(2):241‑4, February 1977.
• Blum, K., Futterman, S., Wallace, J.E. and Schwertner, H.A. Naloxone‑induced inhibition of ethanol dependence in mice. Nature 265(5589):49‑51, January 6, 1977.
• Pollock, S.H. and Blum, K. Metabolic stereospecificity of opiate agonist and antagonist drugs. In: Alcohol and Opiates: Neurochemical and Behavioral Mechanisms. Editor: K. Blum. Academic Press, New York, pp. 359, 1977.
• Blum, K., Newmeyer, J. Inaba, D. Whitehead, C., Smith, D.E. Acupuncture as a common treatment modality in drug and alcohol dependence: Possible neurochemical rationale. J. Psychedelic Drugs, 10: 105‑115, 1978.
• Blum, K., Hamilton, M.G., Hirst, M. and Wallace, J.E. Putative role of isoquinoline alkaloids in alcoholism: A link to opiates. Alcoholism: Clin. Exp. Res. (NY) 2(2):113‑20, April 1978.
• Hamilton, M.G., Blum, K. and Hirst, M. Identification of an isoquinoline alkaloid after chronic exposure to ethanol. Alcoholism: Clin. Exp. Res. (NY) 2(2):133‑7, April 1978.
• Carter, P., Wallace, J.E. and Blum, K. Improved ultraviolet spectrophotometry of serum theophylline. Clin. Chem. 24(2):360‑1, February 1978.
• Schwertner, H.A., Wallace, J.E. and Blum, K. Improved ultraviolet spectrophotometry of serum theophylline. Clin. Chem. 24:360‑361, 1978.
• Hamilton, M.G., Hirst, M. and Blum, K. Opiate‑like activity of salsolinol on the electrically stimulated guinea pig ileum. Life Sci. 25(26):2205‑10, December 24, 1979.
• Verebey, K. and Blum, K. Alcohol euphoria: Possible mediation via endorphinergic mechanisms. J. Psychedelic Drugs 11(4):305‑11, October‑December 1979.
• Blum, K., Eubanks, J.D., Elston, S.F.A. and Briggs, A.H. Differential brain receptor stimulation by norepinephrine and serotonin: Possible rationale for differential chemotherapy or depression in humans. Acupuncture and Electrotherapeutic Res. 4:185‑94, 1979.
• Blum, K., Briggs, A.H., Elston, S.F. and Delallo, L. Psychogenetics of drug seeking behavior (Letter) Subst. Alcohol Actions Misuse 1(3):255‑7, 1980.
• Blum, K., Cull, D.L., Briggs, A.H. An improved technique for the induction of barbiturate dependence in mice. J. Pharmacol. Methods 3(1):89‑92, January 1980.
• Blum, K., Briggs, A.H., Delallo, L. and Elston, S.F. Genotype dependent responses to ethanol and normorphine on vas deferens of inbred strains of mice. Subst. Alcohol Actions Misuse 1(5‑6):459‑65, 1980.
• Blum, K., Briggs, A.H., Delallo, L., Elston, S.F. and Hirst, M. Naloxone antagonizes the action of low ethanol concentrations on mouse vas deferens. Subst. Alcohol Actions Misuse 1(4):327‑34, 1980.
• Dalterio, S., Blum, K., Delallo, L., Sweeney, C., Briggs, A. and Bartke, A. Perinatal exposure to delta 9‑THC in mice: Altered enkephalin and norepinephrine sensitivity in vas deferens. Subst. Alcohol Actions Misuse 1(5‑6): 467‑71, 1980.
• Hamilton, M.G., Blum, K. and Hirst, M. In vivo formation of isoquinoline alkaloids: Effect of time and route of administration of ethanol. Adv. Exp. Med. Biol. 126:73‑86, 1980.
• Blum, K. "The Psychogenetics of Drug Seeking Behavior." FIDIA Laboratories, Aldana, Terne, Italy, June 1980.
• Blum, K., Elston, S.F., Schwertner, H., Delallo, L. and Briggs, A.H. A rapid method to evaluate acute ethanol intoxication in mice. Pharmacol. Biochem. Behav. 14(6):835‑8, June 1981.
• Blum, K., Elston, S.F.A., DeLallo, L. and Briggs, A.H. A rapid method for the evaluation of ethanol intoxication in mice. Pharmacol. Biochem. and Behavior, 14:835‑8, 1981.
• Blum, K., Briggs, A.H., Elston, S.F. and DeLallo, L. Ethanol preference as a function of genotypic levels of whole brain enkephalin in mice. Toxicol. Eur. Res. 3(5):261‑2, September 1981.
• Blum, K., Briggs, A.H. and Cull, J.G. Holism: A social pharmacological approach to drug‑seeking behavior. J. Psychoactive Drugs 13(4):369‑71, October­‑December 1981.
• Dalterio, S., Bartke, A., Blum, K. and Sweeney, C. Marihuana and alcohol: Perinatal effects on development of male reproductive functions in mice. Prog. Biochem. Pharmacol. 18:143‑54, 1981.
• Blum, K. Evidence for the psychogenetic theory of drug seeking behavior. Symposium: Ethanol, Nucleic Acid and Protein Synthesis in Brain and Other Organs. Subs. Alco. Act./Misuse 2(4):196, 1981.
• Blum, K., Briggs, A.H., DeLallo, L., Elston, S.F. and Ochoa, R. Whole Brain methionine‑enkephalin of ethanol‑avoiding and ethanol‑preferring C57BL mice. Experientia 38(12):1469‑70, December 15, 1982.
• Wallace, J.A. and Blum, K. An evaluation of the TRI dipstick test for the detection of drugs of abuse in urine. Subst. Alcohol Actions Misuse 3(1‑2): 129‑32, 1982.
• Blum, K., Briggs, A.H. and DeLallo, L. On the mechanism of methadone‑induced alcohol consumption in humans (Letter). Subst. Alcohol Actions Misuse 3(1‑2): 1‑4, 1982.
• Blum, K., DeLallo, L., Briggs, A.H. and Hamilton, M.G. Opioid responses of isoquinoline alkaloids (TIQs). Prog. Clin. Biol. Res. 90:387‑98, 1982.
• Blum, K., Briggs, A.H., Elston, S.F., DeLallo, L., Sheridan, P.J. and Sar, M. Reduced leucine‑enkephalin──like immunoreactive substance in hamster basal ganglia after long‑term ethanol exposure. Science 216(4553):1425‑7, June 25, 1982.
• Elston, S.F., Blum, K., DeLallo, L. and Briggs, A.H. Ethanol intoxication as a function of genotype dependent responses in three inbred mice strains. Pharmacol. Biochem. Behav. 16(1):13‑5, January 1982.
• Blum, K., Briggs, A.H. and Verebey, A.K. The pharmacology of addictive drugs: Similarities and differences. In: Perspectives in Alcohol and Drug Abuse: Similarities and Differences. Editor: J. Solomon, 1982. Academic Press, New York.
• Blum, K. Special Guest Invitation of Correo Medico Magazine Conference on Drug Dependence. "The Psychogenetic Theory of Drug Seeking Behavior," Milan, Italy, 1982.
• Blum, K. Alcohol and central nervous system peptides. Subst. Alcohol Actions Misuse 4(2‑3):73‑87, 1983.
• Blum, K., Elston, S.F., DeLallo, L., Briggs, A.H. and Wallace, J.E. Ethanol acceptance as a function of genotype amounts of brain (Met)enkephalin. Proc. Natl. Acad. Sci. USA 80(21):6510‑2, November 1983.
• Blum, K., Briggs, A.H. and DeLallo, L. Clonidine enhancement of ethanol withdrawal in mice. Subst. Alcohol Actions Misuse 4(1):59‑63, 1983.
• Blum, K., Dalterio, S., Briggs, A.H., DeLallo, L.J. and Hall, C.W. Super‑sensitivity to norepinephrine induced by prenatal exposure to ethanol. Eur. J. Pharmacol. 106(2):415‑7, November 13, 1984.
• Blum, K., Gaskill, H., DeLallo, L., Briggs, A.H. and Hall, W. Methionine enkephalin as a possible neuromodulator of regional cerebral blood flow. Experientia 41(7):932‑3, July 15, 1985.
• Blum, K. and Wallace, J.E. A commentary on the biochemical pathogenesis of alcohol‑induced depression. J. Psychoactive Drugs, 1985 18(2):161‑2, 1986.
• Blum, K., Wallace, J.E., Briggs, A.H. and Trachtenberg, M.C. Evidence for the "Genotype" theory in alcohol seeking behavior: A commentary. Alch. Drug Res. 6:455‑61, l986.
• Blum, K., Trachtenberg, M.L. "Neurochemistry and Alcohol Craving." Calif. Soc. Treat. Alc. Other ­Drug Dependence News 13(2):1‑7, 1986.
• Blum, K. Alcoholism: Scientific Basis and Chemotherapeutic Control. Dental School Quarterly (UTHSC) 2(1):1‑5, 1986.
• Blum, K., Wallace, J.E., Briggs, A.H., DeLallo, L. and Trachtenberg, M.C. Enkepha­linase inhibition by thiorphan and subsequent response to ethanol, normorphine and enkephalins on mouse vas deferens. Functional Neurology, 1:156‑64, 1986.
• Blum, K., and Topel, H. Opioid peptides and alcoholism: Genetic deficiency and chemical management. Func. Neurol. 1:71‑83, 1986.
• Blum, K., Trachtenberg, M.C. New insights into the causes of alcoholism. Prof. Counselor 1(5):33‑36, 1987.
• Blum, K., DeLallo, L., Briggs, A.H. and Hall, C.W. Salsolinol and D‑Ala2‑MeT5­‑Enkephalinamide on guinea pig ileum: Possible opioid agonist/antagonist interaction. Biogenic Amines 4(5):193‑198, 1987.
• Blum, K., Briggs, A.H., Wallace, J.E., Hall, C.W., Trachtenberg, M.C. Regional brain (MET) ‑ enkephalin in alcohol‑preferring and non‑alcohol‑preferring inbred strains of mice. Experientia 43:408‑410, 1987.
• Blum, K., Wallace, J.E., Trachtenberg, M.C. Enkephalinase inhibition: Regulation of ethanol intake in genetically predisposed mice. Alcohol 4(6): 449‑456, 1987.
• Trachtenberg, M.C., Blum, K. Alcohol and opioid peptides: Neuroparmacological rationale for physical craving of alcohol. Am. J. Drug Abuse 13(3):365‑372, 1987.
• Blum, K., Trachtenberg, M.C., Elliott, C.E., Dingler, M.L., Sexton, R.L., Samuels, A.I. and Cataldie, L. Enkephalinase inhibition and precursor amino acid loading improves inpatient treatment of alcohol and poly drug abusers: Double‑blind placebo‑controlled study of the nutritional adjunct SAAVE Alcohol 5:481‑493, 1988.
• Blum, K. and Trachtenberg, M.C. Alcoholism: Scientific basis of a neuropsycho­genetic disease. Intl. J. Addict. 23:781‑796, 1988.
• Blum, K., Trachtenberg, M.C. and Ramsey, J.C. Improvement of inpatient treatment of the alcoholic as a function of neurotransmitter restoration: A pilot study. Intl. J. Addict. 23:991‑998, 1988.
• Trachtenberg, M.C. and Blum, K. Improvement of cocaine‑induced neuromodulator deficits by the neuronutrient Tropamine' J. of Psycho. Drugs 20:315‑331, 1988.
• Blum, K. and Trachtenberg, M.C. Neurogenetic deficits caused by alcoholism: Restoration by SAAVETM, a neuronutrient intervention adjunct. J. of Psycho. Drugs 20:297‑313, 1988.
• Blum, K., Briggs, A.H. Opioid peptides and genotypic responses to ethanol. Biogenic Amines 5:527‑533, 1988.
• Blum, K. Narcotic antagonism of seizures induced by a dopamine‑derived tetra­hydroiso­quinoline alkaloid. Experientia 44:751‑753, 1988.
• Blum, K., Allison, D., Trachtenberg, M.C., Williams, R.W. and Loeblich, L.A. Reduction of both drug hunger and withdrawal against advice rate of cocaine abusers in a 30‑day inpatient treatment program by the neuronutrient Tropamine' Curr. Ther. Res. 43:1204‑1214, 1988.
• Blum, K. A commentary on neurotransmitter restoration as a common mode of treatment for alcohol, cocaine and opiate abuse. Integr. Psych. 6:199‑204, 1989.
• Blum, K., Briggs, A.H., Trachtenberg, M.C. Ethanol ingestive behavior as a function of central neurotransmis­sion. (Review). Experientia 45:444‑452, 1989.
• Blum, K. Multi‑authored review on molecular basis of alcoholism. Molecular mechanism of intracellular ethanol action. Experientia 45:406, (7 reviews), 1989.
• Blum, K. Neuro‑nutrition as an adjunct to therapy for addictive disease. The Nutrition Report. I(6), 1989.
• Blum, K., Briggs, A.H., Delallo, L., Hall, C.W., and Parvez, S.H. Potentiation of the inhibitory action of methionine ‑ enkephalamide by low ethanol concentrations on mouse vas deferens. Biogenic Amines 7(3):249‑255, 1990
• Blum, K., Trachtenberg, M.L., and Cook, D.W. Neuronutrient effects on weight loss in carbohydrate bingers: An open clinical trial. Current Therapeutic Research. 48(2):217‑233, 1990.
• Blum, K., Noble, E.P., Sheridan, P.J., Montgomery, A, Ritchie, T., Jagadeeswaran, P., Nosam, H., Briggs, A.H., and Cohn, J.B. Allelic Association of human dopamine D2 receptor gene in alcoholism. JAMA. 263(15):2055‑2060, 1990.
• Blum, K. and Noble, E.P. Allelic association of human dopamine D2 receptor gene in alcoholism (Reply). JAMA 264(14):1807‑1809. (Letter)
• Brown, R.J., Blum, K. and Trachtenberg, M.C. Neurodynamics of relapse prevention: A neuronutrient approach to outpatient DUI offenders. J. Psychoactive Drugs. 22(2):173‑187, 1990.
• Braverman, E.R., Blum, K., and Smayda, R.J. A commentary on brain mapping in 60 substance abusers: Can the potential for drug abuse be predicted and prevented by treatment. Cur. Therap. Res. 48(4):569‑ 585, 1990.
• Braverman, E., Smith, R., Smayda, R., and Blum, K. Modification of P300 amplitude and other e electrophysiological parameters of drug abuse by cranial electrical stimulation. Cur. Therap. Res. 48(4):586‑596, 1990.
• Blum, K., Rassner, M. and Payne, J.E. Neuronutrient therapy for compulsive disease: Rationale and clinical evidence. Addiction and Recovery 10(2):12‑16, 1990.
• Blum, K. The "Alcoholic" Gene, Professional Counselor. Sept/Oct 39‑47, 1990.
• Blum, K. The background for abuse, Sixth Edition of the Psychiatric Knowledge and Skills Self‑Assessment Program VI. (PKSAP VI), pp 43‑59, 1990.
• Noble, E.P., Blum, K., Ritchie, T., Montgomery, A., and Sheridan, P.J. Allelic association of the dopamine D2 receptor gene with receptor binding characteristics in alcoholism. Arch. Gen. Psyc. 48:648‑654, 1991.
• Noble, E.P. and Blum, K. Rebuttal Letter: Population and pedigree studies reveal a lack of association between the dopamine D2 receptor gene with alcoholism. JAMA 265(20):2667‑2668. 1991.
• Blum, K., Noble, E.P., Sheridan, P.J., Finley, O., Montgomery, A., Ritchie, T., Ozkaragoz, T., Fitch, R.J., Sadlack, F., Sheffield, D., Dahlmann, T., Halbardier, S., and Nogami, H. Association of the A1 allele of the D2 dopamine receptor gene with severe alcoholism. Alcohol 8, 1991.
• Kaats, G.R., Wise, J.A., Blum, K., Morin, R.J., Adelman, J.A., Craig, J. and Croft, H.A. The short‑term therapeutic efficacy of treating obesity with a plan of improved nutrition and moderate caloric restriction. Cur. Thera. Res. 51:261‑274, 1992.
• Blum, K., Noble, E.P., Sheridan, P.J., Montgomery, A., Ritchie, T., Ozkaragoz, T., Fitch, R.J., Wood, R., Finley, O. and Sadlack, F. Genetic predisposition in alcoholism: association of the D2 dopamine receptor TaqI B1 RFLP with severe alcoholics. Alcohol 10:59‑67, 1993.
• Noble, E.P., Blum, K., Khalsa, M.E., Ritchie, T., Montgomery, A., Wood, R.C., Fitch, R.J., Ozkaragoz, T., Sheridan, P.J., Anglin, D., Paredes, A., Treiman, L.J. and Sparkes, R.S. Allelic association of the D2 dopamine receptor gene with cocaine dependence. Alcohol and Drug Dependence 33:271-285, 1993.
• Noble, E.P. and Blum, K. Alcoholism and the D2 dopamine receptor gene. Letter to JAMA 270:1547, 1993.
• Blum, K. Braverman, E.R., Dinardo, M.J., Wood, R.C. and Sheridan, P.J., Prolonged P300 latency in a neuropsychiatric population with the D2 dopamine receptor A1 allele, Pharmacogenetics, 4:313-322, 1994.
• Gejman, P.V., Ram, A., Gelernter, J., Friedman, E., Cao, Q., Pickar, D., Blum, K., Noble, E.P., Kranzler, H.R., O'Malley, S., Hamer, D.H., Whitsitt, F., Rao, P., DeLisi, L.E., Virkkunien, M., Linnoila, M., Goldman, D. and Gershon, E.S. No structural mutation in the dopamine D2 receptor gene in alcoholism or schizophrenia: Analysis using denaturing gradient gel electrophoresis. JAMA 271: 204-208, 1994.
• Noble, E.P., Syndulko, K., Fitch, R.J., Ritchie, T., Bohlman, M.C., Guth, P., Sheridan, P.J., Montgomery, A., Heinzmann, C., Sparkes, R.S. and Blum, K., D2 dopamine receptor Taq I alleles in medically ill alcoholic and nonalcoholic patients. Alcohol & Alcoholism, 29:729-744, 1994.
• Blum, K., Noble, E.P., Balducci, G., Pasculli, E. and Ceccanti, M. Psychoneurogenetics and behavioral aspects of alcoholism. The cascade theory of reward and the role of tetrahydro-isoquinoline (TIQs): the alcohol-opiate linkage, Alcologia 6: 89-98, 1994.
• Blum, K. and Noble, E.P. The sobering D2 story. Science, 265, 1346, 1994.
• Blum, K., Braverman ER, Dinardo M., Wood R., Sheridan P., “Prolonged P300 Latency in a Neuropsychiatric Population with the D2 Dopamine Receptor A1 Allele," American Psychiatric Electrophysiology Association, 2nd annual meeting, Philadelphia, PA., May 20, 1994. Pharmacogenetics, 1994; 4: 313-322.
• Defrance J., Hymel C., Trachtenberg M., Ginsberg L., Braverman ER, Blum, K., “Enkephalinase-inhibition and Precursor Amino Acid Loading Enhances Attention Processing and P300 in Healthy Humans," American Psychiatric Electrophysiology Association, 2nd annual meeting, Philadelphia, PA., May 20, 1994.
• Blum, K., Braverman, E.R., Wood, R.C. and Sheridan, P.J. Increased prevalence of the Taq I A1 allele of the Dopamine D2 receptor gene in obesity with comorbid polysubstance abuse. Pharmacogenetics 6, 297-305, 1995
• Blum, K., Sheridan. P.J., Wood, R.C., Braverman, E.R., Chen, T.J.H.and Comings, D.E. Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behavior. Pharmacogenetics 5:121-141, 1995.
• Blum, K., Sheridan, P.J., Wood, R. and Braverman, E.R. Dopamine D2 receptor gene polymorphisms in Scandinavian chronic alcoholics: a reappraisal. Eur. Arch. Psychiatry Clin. Neurosci 244: 50-52, 1995.
• Blum, K., Wood, R.C., Braverman, E.P., Chen, T.J.H. and Sheridan, P.J. D2 dopamine receptor gene as a predictor of compulsive disease: Bayes' theorem. Functional Neurology: 10(1):37-44, 1995.
• Blum, K., Sheridan, P.J., Wood, R. and Braverman, ER, “Dopamine D2 receptor gene polymorphisms in Scandinavian chronic alcoholics: a reappraisal.” Eur. Arch. Psychiatry Clin. Neuroscience 244:50-52, 1995.
• Blum, K., Sheridan, P.J., Wood, R. C., Braverman, E.R., Chen, T.J.H., Cull, J.G. and Comings, D.E. The D2 dopamine receptor gene as a predictor of impulsive-addictive-compulsive behavior: Bayes' theorem. J. Royal Society of Medicine 89, 396-400, 1996.
• Blum, K., Cull, J.G. and Comings, E.D. Biogenetics of Reward Deficiency Syndrome. American Scientist 84, 132-145, 1996.
• Braverman, E.E. and Blum, K. Substance Use Disorder Exacerbates Brain Electrophysiological Abnormalities in a psychiatrically ill population. Clinical EEG suppl. 27(4), 5-28, 1996
• Wise, J.A., Morin, R.J., Sanderson, R. and Blum, K. Changes in plasma Carotenoid, Alpha-tocopherol and lipid peroxide levels in response to supplementation with concentrated fruit and vegetable extracts: a pilot study. Current Therapeutic Research 57)6), 446-462, 1996
• Kaats, G.R., Blum, K., Fisher, J.A., Adelman, J.A. and Wood, R. Effects of chromium picolinate supplementation on body composition: a randomized double-blindplacebo-controlled study. Current Therapeutic Research 57(10),747-756, 1996.
• Blum, K. Braverman, E.R., Cull, J.G., Gill, J., Chen, T.H.J., Eisenberg, A., Sherman, M., Wood, R. and Comings, D.E. Polymorphism of the dopamine D2 receptor gene associates with brain electrophysiological abnormalities in humans: Exacerbation with Substance Use Disorder . Clinical EEG,27(4 Suppl):5-27.  1996.
• Braverman E., Blum, K,Comorbid Psychiatric Disorders in a Holistic Health Clinic Society of Medicine, Vol 89, 1996.
• Blum, K., Braverman, ER, Wu, S., Cull, JG., Wood, R. et al. Association of polymorphisms of dopamine D2 receptor (DRD2 ), and dopamine transporter (DAT1) genes with schizoid/ avoidant behaviors (SAB). Molecular Psychiatry 2 : 239-246, 1997.
• Blum, K. Cull, JG. Chen TJH, Garcia-Swan Susan, Holder,JM, Wood,R. Braverman, ER, Bucci, LR., & Trachtenberg,MC. Clinical evidence For Effectiveness of PhencalTM in maintaining weight loss in an open-label, controlled, 2-year study. Current Therapeutic Research. 58 (10) 1997.
• DeFrance, J.F., Hymel, C., Trachtenberg, M.C., Ginsberg, L.D., Schweitzer, F.C., Estes, S., Chen, T.J.H., Braverman, E.R., Cull, J.G. and Blum, K. Enhancement of attention processing by Kantrol TM in healthy humans: A pilot study. Clinical EEG, 1997
• Comings DE, Blum, K. Reward deficiency syndrome: genetic aspects of behavioral disorders.Prog Brain Res.;126:325-41, 2000.
• Blum, K. and E.R. Braverman “Reward Deficiency Syndrome: A biogenetic Model for the treatment of impulsive, addictive and compulsive behaviors. Journal Psychoactive Drugs, 32: 1-12. 2001.
• Blum, K. and Noble, EP. First Conference on “Reward deficiency syndrome’: Genetic Antecedents and Clinical Pathways. Molecular Psychiatry vol. 6 supplement Feb.1, 2001.
• Blum,K. and Noble,EP Reward Deficiency Syndrome (RDS) : A biogenic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. Molecular Psychiatry 6: S2, 2001.
• Blum, K. and Braverman, ER “Reward Deficiency Syndrome”: An emerging concept. Molecular Psychiatry, 6: S3, 2001.
• Braverman, ER, Blum, K. Lubar, J, Lubar, Jo, Lubar, and Comings, DE. Genetic dopaminergic deficits: Clinical correlates to schizoid/avoidant personality, ADHD probands, pathological violence. P300 event related potential and TOVA attention test. Molecular psychiatry, 6: S5, 2001.
• Holder, JM., Duncan, RC, Gissen, M., Miller,M., Braverman,ER and Blum, K. Increasing retention rates among the chemically dependent in residential treatment: auriculotherapy and subluxation-based chiropractic care. Molecular Psychiatry, 6 S8, 2001.
• Braverman, E. and Blum, K., American Academy of Anti-Aging Medicine, 10th International Conference, December 2002. Poster Session: Adult Growth Hormone Deficiency: A Higher Compliance Delivery System.
• Braverman ER, Blum, K. P300 (latency) event-related potential: an accurate predictor of memory impairment. Clin Electroencephalogr. Jul; 34(3):124-39, 2003.
• Braverman E, Blum, K, Stanford M. “From Brain Science to Brain Based Medicine”, Medical Hypotheses; 63(5):919-20, 2004.
• Chen, T.J.H, Blum, K, Payte, James, T., Schoolfield, J, Hopper, D., Stanford, M, Braverman, ER, “Narcotic Antagonists in Drug Dependence: Pilot Study Showing Enhancement of Compliance with Amino Acid and Enkephalinase Inhibition Therapy”, Medical Hypotheses, Feb. 25, 2004.
• Chen J.H, T; Blum, K, Mathews D, Fisher L, Schnautz N, Braverman ER, Schoolfield J, Downs BW, Comings DE. Are dopaminergic genes involved in a predisposition to pathological aggression? Hypothesizing the importance of “super normal controls” in psychiatric genetic research of complex behavioral disorders. Medical hypotheses, volume 65, Issue 4;703-707, 2005.
• Braverman, E &Blum, K. “P300 (Latency) Event-Related Potential: An Accurate Predictor of Memory Impairment: Hormonal Correlates,” Accepted into Alzheimer’s Conference on Prevention of Dementia in Washington, DC; Published Alzheimer’s & Dementia, Vol 1, issue 1, Suppl 1, July 2005
• Comings DE, Chen TJ, Blum, K, Mengucci JF,Blum SH, Meshkin B. Neurogenetic interactions and aberrant behavioral co-morbidity of attention deficit hyperactivity disorder (ADHD): dispelling myths.Theor Biol Med Model. 23;2: 50, 2005.
• Blum, K, Chen TJ, Ross BD. Innate properties of H-Wave device, a small fiber stimulator provides the basis for a paradigm shift of electro-therapeutic treatment of pain with increased functional restoration associated with human neuropathies by affecting tissue circulation: a hypothesis.Med Hypotheses. 64(5):1066-7, 2005.
• Braverman ER, Chen TJ, Schoolfield J, Martinez-Pons M, Arcuri V, Varshavskiy M, Gordon CA, Mengucci J, Blum SH, Meshkin B, Downs BW, Blum, K. Delayed P300 latency correlates with abnormal Test of Variables of Attention (TOVA) in adults and predicts early cognitive decline in a clinical setting. Adv Ther. (4):582-600, 2006.
• Blum, K, Chen T, Meshkin B, Downs WB, Gorden C, Blum S, Braverman ER, Arcuri V. Varshavskiy M, Deutsch R, Martinez-Pons M. Reward Deficiency Syndrome in Obesity: A Preliminary Cross-Secontional Trail With a Genotrim Variant. Advances in Therapy. 23 (6) 1040-1051, 2006.
• Blum, K, Chen TJ, Martinez-Pons M, Dinubile NA, Waite RL, Schoolfield J, Blum SH, Mengucci J, Downs BW, Meshkin B. The H-Wave small muscle fiber stimulator, a nonpharmacologic alternative for the treatment of chronic soft-tissue injury and neuropathic pain: an extended population observational study.Adv Ther. 23(5):739-49, 2006.
• Blum, K, Chen TJH, Blum SH, Comings DE, Mengucci JF, Meshkin B, Downs BW, Braverman ER. Reward Deficiency Syndrome (RDS): Neurogenetic Aspects of Aging and Related Behavioral Disorders Specific To Dopaminergic Pathways. Anti-Aging Therapeutics, 8: 9-26, 2006.
• Blum, K, Chen TJ, Meshkin B, Downs BW, Gordon CA, Blum S, Mengucci JF, Braverman ER, Arcuri V, Varshavskiy M, Deutsch R, Martinez-Pons M. Reward deficiency syndrome in obesity: a preliminary cross-sectional trial with a Genotrim variant. Adv Ther. 23(6):1040-51, 2006.
• Blum, K, DiNubile NA, Tekten T, Chen TJ, Waite RL, Schoolfield J, Martinez-Pons M, Callahan MF, Smith TL, Mengucci J,Blum SH, Meshkin B. H-Wave, a nonpharmacologic alternative for the treatment of patients with chronic soft tissue inflammation and neuropathic pain: a preliminary statistical outcome study. Adv Ther. 2006 May-Jun: 23(3):446-55.
• Blum, K, DiNubile NA, Tekten T, Chen TJ, Waite RL, Schoolfield J, Martinez-Pons M, Callahan MF, Smith TL, Mengucci J, Blum SH, Meshkin B. H-Wave, a nonpharmacologic alternative for the treatment of patients with chronic soft tissue inflammation and neuropathic pain: a preliminary statistical outcome study.Adv Ther. 23(3):446-55, 2006.
• Blum, K, Meshkin B, Downs BW. DNA based customized nutraceutical "gene therapy" utilizing a genoscore: a hypothesized paradigm shifts of a novel approach to the diagnosis, stratification, prognosis and treatment of inflammatory processes in the human. Med Hypotheses. 66(5):1008-18, 2006.
• Braverman ER, Chen T, Prihoda T, Sonntag W, Meshkin B, Downs W, Mengucci J, Blum S, Notaro A, Arcuri V, Varshavskiy M, Blum, K. Plasma Growth Hormones, P300 Event-Related Potential and Test of Variables of Attention (T.O.V.A) Are Important Neuroendocrinological Predictors of Early Cognitive Decline in Clinical Setting: Evidence supported by structural Equation Modeling Parameter Estimates. Age 29(2-3):55-67, 2006.
• Blum, K, Chen, TJ, Meshkin B, Downs WB, Gordon, CA, Blum S, Mengucci JF, Braverman ER, Arcuri V, Deutch R, Martinez-Pons M. Genotrim a DNA-customized nutrigenomic product, targets genetic factors of obesity: Hypothesizing a dopamine-glucose correlation demonstrating reward deficiency syndrome (RDS). Medical Hypotheses, pages 68, 844-852, 2007.
• Meshkin B, Blum, K. pharmacogenetics. Drug Metab Lett. 1(1):55-60, 2007.
• Blum, K, Chen T, Meshkin B, Blum S, Mengucci J, Notaro A, Arcuri V, Waite R, Braverman ER. The PPAR-gamma Pro12Ala allele polymorphism of the Peroxisome Proliferator-Activated Receptor (gamma) Gene (PPARG2) Is a Risk Factor With a Self-Identified Obese Dutch Population. Gene Therapy & Molecular Biology.11:37-42, 2007
• Chen T, Blum, K, Waite R, Meshkin B, Schoolfield J, Downs WB, Braverman ER, Arcuri V, Varshavskiy M, Blum S, Mengucci, J Reuben C, Palomo T. Reward Deficiency Syndrome (RDS) and Substance Use Disorder (S.U.D.): The Gene Narcotic Attenuation Program (GNAP) including Haveos** (Synaptamine) Attenuates Addictive Related Behaviors. Advances in Therapy. 24(2): 402-14, 2007.
• Braverman ER, Chen TJ, Prihoda TJ, Sonntag W, Meshkin B, Downs BW, Mengucci JF, Blum SH, Notaro A, Arcuri V, Varshavskiy M, Blum, K. Plasma growth hormones, P300 event-related potential and test of variables of attention (TOVA) are important neuroendocrinological predictors of early cognitive decline in a clinical setting: evidence supported by structural equation modeling (SEM) parameter estimates. Age (Dordr). 29(2-3):55-67. doi: 10.1007/s11357-007-9030-3, 2007. 
• Blum, K, Chen TJ, Meshkin B, Waite RL, Downs BW, Blum SH, Mengucci JF, Arcuri V, Braverman ER, Palomo T. Manipulation of catechol-O-methyl-transferase (COMT) activity to influence the attenuation of substance seeking behavior, a subtype of Reward Deficiency Syndrome (RDS), is dependent upon gene polymorphisms: a hypothesis. Med Hypotheses. 69(5):1054-60, 2007.
• Blum, K, Chen TJ, Meshkin B, Downs BW, Gordon CA, Blum S, Mangucci JF, Braverman ER, Arcuri V, Deutsch R, Pons MM. Genotrim, a DNA-customized nutrigenomic product, targets genetic factors of obesity: hypothesizing a dopamine-glucose correlation demonstrating reward deficiency syndrome (RDS). Med Hypotheses. 68(4):844-52, 2007. 
• Chen T, Blum, K, Kaats G, Braverman ER, Eisenberg A, Sherman M, Davis K, Comings D, Wood R, Pullin D, Arcuri V, Varshavski M, Mengucci J,Blum S, Downs, B, Meskin B, Waite R, Williams L, Schoolfield J, Prihoda T, White L. “Cromium Picolinate (CrP) a putative anti-obesity nutrient induces changes in body composition as a function of the Taq1 dopamine D2 receptor polymorphisms in a randomized double-blind placebo controlled study.” Gene Therapy and Molecular Biology Vol 11, 161-170, 2007.
• Blum, K, Chen TJH, Meshkin B, Waite RL, Downs BW, Blum SH, Mengucci JF, Arcuri V, Braverman ER, Palomo T. Manipulation of Catechol-O Methyl Transferase (COMT) Activity to influence the attenuation of substance seeking behavior, a subtype of Reward Deficiency Syndrome (RDS), is dependent upon gene polymorphisms: A hypothesis. Med Hypotheses. 69(50: 1054-1060, 2007.
• Blum, K, Chen TJH, Downs BW, Meshkin B,Blum SH, Martinez Pons M, Mengucci JF, Waite RL, Arcuri V, Varshafski M, Braverman ER. Synaptamine (SG8839) An Amino-Acid Enkephalinase Inhibition Nutraceutical Improves Recovery of Alcoholics, A Subtype of Reward Deficiency Syndrome (RDS). Trends in Applied Sciences Research. 2(2): 132-138, 2007.
• Chen TJH, Blum, K, Mathews D, Fisher L, Schnautz N, Braverman ER, Schoolfield J, Downs BW,Blum SH, Mengucci J, Meskin B, Arcuri V, Bajaj A, Comings DE. Preliminary Association Of Both the Dopamine D2 Receptor (DRD2) [Taq1 A1 Allele] And The Dopamine Transporter (DAT1) [480 bp Allele] Genes With Pathological Aggressive Behavior, A Clinical Subtype Of Reward Deficiency Sybdrome (RDS) in Adolescents. Gene Ther Mol Biol. Volume 11, 93-112, 2007
• Chen TJH, Blum, K, Kaats G, Braverman ER, Pullin D, Downs BW, Martinez-Pons M, Blum SH, Mengucci J, Bagchi D, Bagchi M, Robarge A, Meskin B, Arcuri V, Varshavsky M, Notaro A, Comings DE, White L. Reviewing the role of putative candidate genes in “Neurobesigenics”, a clinical subtype of Reward Deficiency Syndrome (RDS). Gene Ther Mol Biol. Volume 11, 61-74, 2007
• Braverman ER, Chen TJH, Prihoda T, Sonntag W, Meshkin B, Downs BW, Mengucci J,Blum SH, Notaro A, Arcuri V, Varshavski M, Blum, K. Plasma growth hormones, P300 event-related potential and test of variables of attention (TOVA) are important neuroendocrinological predictors of early cognitive decline in a clinical setting: Evidence supported by structural equation modeling (SEM) parameter estimates. Springer, American Aging Association 2007.
• Thomas JH Chen, Blum, K., Daniel Mathews, Larry Fisher, Nancy Schnautz, Eric R. Braverman, John Schoolfield, Bernard W. Downs, Seth H. Blum, Julie Mengucci, Brian Meshkin, Vanessa Arcuri, Anish Bajaj, Roger L. Waite, David E. Comings. Preliminary association of both the Dopamine D2 Receptor (DRD2) [Taq1 A1 Allele] and the Dopamine Transporter (DAT1) [480 bp Allele] genes with pathological aggressive behavior, a clinical subtype of Reward Deficiency Syndrome (RDS) in adolescents. Gene Therapy & Mol. Biol. 11; 93-112. 2007
• Blum, K, THJ Chen, B W Downs, Waite RL, Meshkin B, Braverman R. Nutrigenomics : A Scientific Wonderland. Journal Of Social Sciences; Life Science issue (French Journal National Academy Sciences of France) 2007.
• Thomas JH Chen, Blum, K., Gilbert Kaats, Eric R. Braverman, Arthur Eisenberg, Mark Sherman, Katharine Davis, David E. Comings, Robert Wood, Dennis Pullin, Vanessa Arcuri, Michael Varshavski, Julie F. Mengucci, Seth H. Blum, Bernard W. Downs, Brian Meshkin, Roger L. Waite, Lonna Williams, John Schoolfield, Thomas J Prihoda, Lisa White. Chromium Picolinate (CrP) a putative anti-obesity nutrient induces changes in body composition as a function of the Taq1 dopamine D2 receptor polymorphisms in a randomized double-blind placebo controlled study. Gene Therapy & mol. Biol. 11: 161-170, 2007.
• Blum, K, Chen AL, Braverman ER, Comings DE, Chen TJ, Arcuri V, Blum SH, Downs BW, Waite RL, Notaro A, Lubar J, Williams L, Prihoda TJ, Palomo T, Oscar-Berman M. Attention-deficit-hyperactivity disorder and reward deficiency syndrome. Neuropsychiatr Dis Treat. 4(5):893-918, 2008.
• Blum, K, Chen AL, Chen TJ, Prihoda TJ, Schoolfield J, DiNubile N, Waite RL, Arcuri V, Kerner M, Braverman ER, Rhoades P, Tung H. The H-Wave device is an effective and safe non-pharmacological analgesic for chronic pain: a meta-analysis. Adv Ther. 25(7):644-57. doi: 10.1007/s12325-008-0073-3, 2008.
• Oben JE, Ngondi JL, Blum, K. Inhibition of Irvingia gabonensis seed extract (OB131) on adipogenesis as mediated via down regulation of the PPARgamma and leptin genes and up-regulation of the adiponectin gene. Lipids Health Dis.13;7: 44, 2008.
• Blum, K, Chen AL, Chen TJ, Braverman ER, Reinking J, Blum SH, Cassel K, Downs BW, Waite RL, Williams L, Prihoda TJ, Kerner MM, Palomo T, Comings DE, Tung H, Rhoades P, Oscar-Berman M. Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary. Theor Biol Med Model. 12;5:24, 2008.
• Chen AL, Chen TJ, Braverman ER, Acuri V, Kemer M, Varshavskiy M, Braverman D, Downs WB, Blum SH, Cassel K, Blum, K. Hypothesizing that marijuana smokers are at a significantly lower risk of carcinogenicity relative to tobacco-non-marijuana smokers: evidenced based on statistical reevaluation of current literature. J Psychoactive Drugs. 40(3):263-72, 2008.
• Brian Meshkin, Thomas JH Chen, Amanda LC Chen, Thomas JH Prihoda, Hayley Morrisette4, Eric R. Braverman, Seth H. Blum, Kimberly Cassel, Lonna Williams, Roger L. Waite, B. Willliam Downs, Howard Tung, Patrick Rhoades, Blum, K. Health economics of nutrigenomics in weight management Gene Therapy & Mol. Boil. 12: 25-30. 2008.
• Blum, K, Chen AL, Chen TJ, Rhoades P, Prihoda TJ, Downs BW, Waite RL, Williams L, Braverman ER, Braverman D, Arcuri V, Kerner M, Blum SH, Palomo T. syndrome Ther. 25(9):894-913, 2008.
• Amanda LC Chen, Blum, K., Thomas JH Chen, Jeffrey Reinking, Roger L Waite, Bernard W. Downs, Eric R. Braverman, Vanassa Arcuri, Mallory Kerner, Alison Notaro, Kimberly Cassel, Seth H. Blum, Debasis Bagchi, Manashi Bagchi, Ariel Robarge, Gilbert Kaats, David E. Comings, Patrick Rhoades, Lonna Williams, Howard Tung. The impact of biomics technology and DNA directed anti-obesity targeting of the brain reward circuitry. Gene Therapy & Mol Bio. 12: 45-68, 2008.
• Blum, K, Chen AL, Chen TJ, Prihoda TJ, Schoolfield J, DiNubile N, Waite RL, Arcuri V, Kerner M, Braverman ER, Rhoades P, Tung H. The H-Wave device is an effective and safe non-pharmacological analgesic for chronic pain: a meta-analysis. Adv Ther. 25(7):644-57, 2008.
• Blum, K., Thomas JH Chen, Amanda LC Chen, Patrick Rhoades, Thomas J Prihoda, B. William Downs, Debasis Bagchi, Manashi Bagchi, Seth H. Blum, Lonna Williams, Eric R. Braverman, Mallory Kerner, Roger L Waite, Brien Quirk, Lisa White, Jeffrey Reinking. Dopamine D2 Receptor Taq A1 allele predicts treatment compliance of LG839 in a subset analysis of pilot study in the Netherlands. Gene Therapy &Mol. Biol. 12: 129-140. 2008.
• Blum, K, Ho CK, Chen AL, Fulton M, Fulton B, Westcott WL, Reinl G, Braverman ER, Dinubile N, Chen TJ. The H-Wave((R)) Device Induces NO Dependent Augmented Microcirculation and Angiogenesis, Providing Both Analgesia and Tissue Healing in Sports Injuries. Phys Sportsmed. 36(1):103-14, 2008.
• Blum, K, Chen AL, Braverman ER, Comings DE, Chen TJ, Arcuri V, Blum SH, Downs BW, Waite RL, Notaro A, Lubar J, Williams L, Prihoda TJ, Palomo T, Oscar-Berman M. Attention-deficit-hyperactivity disorder and reward deficiency syndrome. Neuropsychiatr Dis Treat. 4(5):893-918, 2008.
• Oben JE, Ngondi JL, Blum, K. Inhibition of Irvingia gabonensis seed extract (OB131) on adipogenesis as mediated via down regulation of the PPARgamma and leptin genes and up-regulation of the adiponectin gene. Lipids Health Dis.13;7:44, 2008.
• Blum, K, Chen AL, Chen TJ, Braverman ER, Reinking J, Blum SH, Cassel K, Downs BW, Waite RL, Williams L, Prihoda TJ, Kerner MM, Palomo T, Comings DE, Tung H, Rhoades P, Oscar-Berman M. Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary. Theor Biol Med Model. 12;5: 24, 2008.
• Chen AL, Chen TJ, Braverman ER, Acuri V, Kemer M, Varshavskiy M, Braverman D, Downs WB, Blum SH, Cassel K, Blum, K. Hypothesizing that marijuana smokers are at a significantly lower risk of carcinogenicity relative to tobacco-non-marijuana smokers: evidenced based on statistical reevaluation of current literature. J Psychoactive Drugs. 40(3):263-72, 2008.
• Blum, K., Thomas JH Chen, Lonna Williams, Amanda LC Chen, William B. Downs, Roger L. Waite, T. Huntington, Simon Sims, Thomas Prihoda, Patrick Rhoads, Jeffrey Reinking, Dasha Braverman, Mallory Kerner, Seth H. Blum, Brien Quirk, Eric R Braverman. A short-term pilot open label study to evaluate efficacy and safety of LG839, a customized DNA directed nutraceutical in obesity: Exploring Nutrigenomics. Gene Therapy & Mol. Boil. 12: 371-382. 2008
• Blum, K, Ho CK, Chen LC, Fulton M, Fulton B, Westcott WL, Reinl G, Braverman ER, DiNubile N, Chen TJH. The H-Wave Device Induces No-Dependent Augmented Microcirculation and Angiogenesis Providing Both Analgesia and Tissue Healing in Sports Injuries. The Physician and Sports Medicine. 36 (1): 103-115.
• Smith TL, Blum, K, Callahan MF, Dinubile NA, Chen TJ, Waite RL H-Wave(R) induces arteriolar vasodilation in rat striated muscle via nitric oxide-mediated mechanisms. J Orthop Res. 27(9):1248-5, 2009.
• Blum, K, Chen TJ, Downs BW, Bowirrat A, Waite RL, Braverman ER, Madigan M, Oscar-Berman M, DiNubile N, Stice E, Giordano J, Morse S, Gold M. Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing "deprivation-amplification relapse therapy" (DART). Postgrad Med. 121(6):176-96. Review, 2009.
• Chen AL, Chen TJ, Waite RL, Reinking J, Tung HL, Rhoades P, Downs BW, Braverman E, Braverman D, Kerner M, Blum SH, DiNubile N, Smith D, Oscar-Berman M, Prihoda TJ, Floyd JB, O'Brien D, Liu HH, Blum, K. Hypothesizing that brain reward circuitry genes are genetic antecedents of pain sensitivity and critical diagnostic and pharmacogenomic treatment targets for chronic pain conditions. Med Hypotheses. Jan:72(1):14-22, 2009.
• B. William Downs, Amanda, LC Chen, Thomas JH Chen, Roger L. Waite, Eric R. Braverman, Mallory Kerner, Dasha Braverman, Patrick Rhoades, Thomas J Prihoda, Tomas Palomo, Marlene Oscar –Berman, Jeffrey Reinking, Seth H Blum, Nicholas A. DiNublie, Blum, K., Nutrigenomic targeting of carbohydrate craving behavior: Can we manage obesity and aberrant craving behaviors with neurochemical pathway manipulation by Immunological Compatible Substances (nutrients) using a Genetic Positioning System (GPS) Map? Medical Hypotheses, 73(3):427-34. doi: 10.1016/j.mehy.2009.02.037, 2009.
• Braverman ER, Chen TJ, Chen AL, Arcuri V, Kerner MM, Bajaj A, Carbajal J, Braverman D, Downs BW,Blum, K. Age-related increases in parathyroid hormone may be antecedent to both osteoporosis and dementia. BMC Endocr Disord. 13; 9:21. doi: 10.1186/1472-6823-9-21, 2009.
• Fritch D, Blum, K, Nonnemacher S, Haggerty BJ, Sullivan MP, Cone EJ. spectrometry Anal Toxicol. 33(9):569-77, 2009.
• Braverman ER, Chen TJ, Chen AL, Kerner MM, Tung H, Waite RL, Schoolfield J, Blum, K. Preliminary investigation of plasma levels of sex hormones and human growth factor(s), and P300 latency as correlates to cognitive decline as a function of gender. BMC Res Notes. 7;2:126, 2009.
• Downs BW, Chen AL, Chen TJ, Waite RL, Braverman ER, Kerner M, Braverman D, Rhoades P, Prihoda TJ, Palomo T, Oscar-Berman M, Reinking J, Blum SH, DiNubile NA, Liu HH, Blum, K. Nutrigenomic targeting of carbohydrate craving behavior: can we manage obesity and aberrant craving behaviors with neurochemical pathway manipulation by Immunological Compatible Substances (nutrients) using a Genetic Positioning System (GPS) Map? Med Hypotheses. 73(3):427-34, 2009.
• Eric R. Braverman, Amanda LC Chen, Thomas JH. Chen, John Schoolfield, Mallory Kerner,Roger L. Wait, Howard Tung, Blum, K.,Low Plasma Levels of Sex Hormones and Human Growth Factor(s) Correlate to Cognitive Decline as a Function of Gender. BMC-Research Notes. 2:126. doi:10.1186/1756-0500-2-126, 2009.
• Blum, K., Amanda LH Chen, Thomas JH Chen, Roger L. Waite, B William Downs, Eric R. Braverman, Mallory Kerner, Howard Tung. Healing Enhancement of Chronic Venous Stasis Ulcers Utilizing H-Wave® Device Therapy: A Case Series. The Case Journal, 10; 3:54. doi: 10.1186/1757-1626-3-54, 2010.
• Braverman ER, Chen AL, Chen TJ, Schoolfield JD, Notaro A, Braverman D, Kerner M, Blum SH, Arcuri V, Varshavskiy M, Damle U, Downs BW, Waite RL, Oscar-Berman M, Giordano J, Blum, K. Test of variables of attention (TOVA) as a predictor of early attention complaints, an antecedent to dementia .Neuropsychiatr Dis Treat. 15;6: 681-90. 2010.
• Blum, K., Amanda LH Chen, Thomas JH Chen, Roger L. Waite, B William Downs, Eric R. Braverman, Mallory Kerner, Howard Tung. Healing Enhancement of Chronic Venous Stasis Ulcers Utilizing H-Wave® Device Therapy: A Case Series. The Case Journal, 10;3:54. doi: 10.1186/1757-1626-3-54, 2010.
• Braverman ER, Chen AL, Chen TJ, Schoolfield JD, Notaro A, Braverman D, Kerner M, Blum SH, Arcuri V, Varshavskiy M, Damle U, Downs BW, Waite RL, Oscar-Berman M, Giordano J, Blum, K. Test of variables of attention (TOVA) as a predictor of early attention complaints, an antecedent to dementia .Neuropsychiatr Dis Treat. 15;6: 681-90. 2010.
• Chen AL, Chen TJ, Waite RL, Reinking J, Tung HL, Rhoades P, Downs BW, Braverman E, Braverman D, Kerner M, Blum SH, DiNubile N, Smith D, Oscar-Berman M, Prihoda TJ, Floyd JB, O'Brien D, Liu HH, Blum, K. Hypothesizing that brain reward circuitry genes are genetic antecedents of pain sensitivity and critical diagnostic and pharmacogenomic treatment targets for chronic pain conditions. Med Hypotheses. 72(1):14-22. 2010.
• Braverman ER, Bowirrat A, Damle UJ, Yeldandi S, Chen TJ, Madigan M, Kerner M, Huang SX, Savarimuthu S, Blum, K. Adult growth hormone deficiency treatment with a combination of growth hormone and insulin-like growth factor-1 resulting in elevated sustainable insulin-like growth factor-1 and insulin-like growth factor binding protein 3 plasma levels: a case report. J Med Case Reports. 15; 4(1):305, 2010.
• Miller DK, Bowirrat A, Manka M, Miller M, Stokes S, Manka D, Allen C, Gant C, Downs BW, Smolen A, Stevens E, Yeldandi S,Blum, K. Acute intravenous synaptamine complex variant KB220™ "normalizes" neurological dysregulation in patients during protracted abstinence from alcohol and opiates as observed using quantitative electroencephalographic and genetic analysis for reward polymorphisms: part 1, pilot study with 2 case reports. Postgrad Med. 2010 Nov; 122(6):188-213. doi: 10.3810/pgm. 11.2236, 2010.
• Blum, K, Chen TJ, Morse S, Giordano J, Chen AL, Thompson J, Allen C, Smolen A, Lubar J, Stice E, Downs BW, Waite RL, Madigan MA, Kerner M, Fornari F, Braverman ER. Overcoming qEEG abnormalities and reward gene deficits during protracted abstinence in male psychostimulant and polydrug abusers utilizing putative dopamine D₂ agonist therapy: part 2. Postgrad Med. 122(6):214-26. doi: 10.3810/pgm.2010.11.2237, 2010.
• Blum, K, Giordano J, Morse S, Liu Y, Tan J, Bowirrat A, Smolen A, Waite R, Downs W, Madigan M, Kerner M, Fornari F, Stice E, Braverman, E, Miller D. Bailey J. Genetic Addiction Risk Score (GARS) Analysis: Exploratory development of polymorphic risk alleles in poly-drug addicted males. International J. Omics and Biotechnology, DOI:http://www.doaj.org/doaj, 2010.
• Bowirrat A, Chen TJ, Blum, K, Madigan M, Bailey JA, Chuan Chen AL, Downs BW, Braverman ER, Radi S, Waite RL, Kerner M, Giordano J, Morse S, Oscar-Berman M, Gold M. Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress Disorder: Unlocking the Mysteries of Resilience and Vulnerability. Curr Neuropharmacol. 8(4):335-58. doi: 10.2174/157015910793358123, 2010.
• Braverman ER, Chen AL, Chen TJ, Schoolfield JD, Notaro A, Braverman D, Kerner M, Blum SH, Arcuri V, Varshavskiy M, Damle U, Downs BW, Waite RL, Oscar-Berman M, Giordano J, Blum, K. Test of variables of attention (TOVA) as a predictor of early attention complaints, an antecedent to dementia. Neuropsychiatr Dis Treat. 15;6: 681-90, 2010.
• Blum, K, Chen AL, Chen TJ, Downs BW, Braverman ER, Kerner M, Savarimuthu S, Bajaj A, Madigan M, Blum SH, Reinl G, Giordano J, Dinubile N. Healing enhancement of chronic venous stasis ulcers utilizing H-WAVE(R) device therapy: a case series. Cases J. 10; 3:54, 2010.
• Blum, K, Giordano J, Morse S, Bowirrat A, Madigan M, Downs W, Waite R, Kerner M, Damle U, Braverman ER, Bauer G, Femino J, Bailey J, DiNubile N, Miller D, Archer T, Simpatico T. Understanding the high mind Humans are still evolving genetically. IIOAB-India 1(2)1-14, 2010.
• Stice E, Yokum S, Blum, K, Bohon C. Weight gain is associated with reduced striatal response to palatable food. J Neurosci. 30(39):13105-9., 2010.
• Blum, K, Chen TJ, Chen AL, Madigan M, Downs BW, Waite RL, Braverman ER, Kerner M, Bowirrat A, Giordano J, Henshaw H, Gold MS. Do dopaminergic gene polymorphisms affect mesolimbic reward activation of music listening response? Therapeutic impact on Reward Deficiency Syndrome (RDS).Med Hypotheses. 74(3):513-20, 2010.
• Smith TL, Callahan MF, Blum, K, Dinubile NA, Chen TJ, Waite RL.(2011) H-Wave® effects on blood flow and angiogenesis in longitudinal studies in rats. J Surg Orthop Adv. 2011 Winter; 20(4):255-9.
• Blum, K, Chen AL, Oscar-Berman M, Chen TJ, Lubar J, White N, Lubar J, Bowirrat A, Braverman E,Schoolfield J, Waite RL, Downs BW, Madigan M, Comings DE, Davis C, Kerner MM, Knopf J, Palomo T,Giordano JJ, Morse SA, Fornari F, Barh D, Femino J, Bailey JA. Generational association studies of dopaminergic genes in reward deficiency syndrome (RDS) subjects: selecting appropriate phenotypes for reward dependence behaviors. Int J Environ Res Public Health.  8(12):4425-59. doi: 10.3390/ijerph8124425, 2011.
• Blum, K.,Amanda LC Chen, Thomas JH Chen, Roger L. Waite, Nicholas DiNubile, B. William Downs, Mallory Kerner, Eric Braverman, Thomas J Prihoda, Howard Tung. Chronic H-Wave® Device Stimulation and Program Induces Significant Increases in the Range of Motion of Post- Operative Rotator Cuff Reconstruction in a Double-Blinded Randomized Placebo Controlled Human Study. BMC Musculoskeletal Disorders. 10:132. doi:10.1186/1471-2474-10-132
• Westcott WL, Chen T, Neric FB, DiNubile N, Bowirrat A, Madigan M, Downs BW, Giordano J, Morse S, LC Chen A, Bajaj A, Kerner M, Braverman E, Reinl G, Blakemore M, Whitehead S, Sacks L, Blum, K. The Marc ProTM Device Improves Muscle Performance and Recovery from Concentric and Eccentric Exercise Induced Muscle Fatigue in Humans: A Pilot Study. JEPonline 14(2):55-67, 2011.
• Blum, K, Han D, Hauser M, Downs BW, Giordano J, Borten J, Winchell W, Simpatico T, Barh D. Neurogeneticimpairments of brain reward circuitry links to Reward Deficiency Syndrome (RDS) as evidenced by genetic addiction risk score (GARS): A case study. IIOAB 4(1): 4-9.
• Chen TJ, Blum, K, Chen AL, Bowirrat A, Downs WB, Madigan MA, Waite RL, Bailey JA, Kerner M, Yeldandi S, Majmundar N, Giordano J, Morse S, Miller D, Fornari F, Braverman ER. Neurogenetics and clinical evidence for the putative activation of the brain reward circuitry by a neuroadaptagen: proposing an addiction candidate gene panel map. J Psychoactive Drugs. 43(2):108-27, 2011.
• Blum, K, Giordano j, Morse S, Liu Y, Tian J, Bowirrat A, Smolen A, Waite R, Down B, Madigan M, Kerner M, Fornari F, Braverman E, Miller D, Bailey J. Addiction Risk Score (Gars) Analysis: Exploratory Development of Polymorphic risk Alleles in Polydrug addicted males. IIOAB Vol1(20), 1-14.
• Blum, K., John Giordano, Siobhan Morse, Arthur Anderson, Javier Carbajal, Roger Waite, Bernard Downs, Jaclyn Downs, Margaret Madigan, Debmalya Barh, Eric Braverman. Hypothesizing Synergy between Acupuncture/ Auriculotherapy and Natural Activation of Mesolimbic Dopaminergic Pathways: Putative Natural Treatment Modalities for the Reduction of Drug Hunger and Relapse IIOAB Letters Vol 1, No 1, 2011.
• Westcott WL, Chen T, Neric FB, DiNubile N, Bowirrat A, Madigan M, Downs BW, Giordano J, Morse S, LC Chen A, Bajaj A, Kerner M, Braverman E, Reinl G, Blakemore M, Whitehead S, Sacks L, Blum, K. The Marc ProTM Device Improves Muscle Performance and Recovery from Concentric and Eccentric Exercise Induced Muscle Fatigue in Humans: A Pilot Study. JEP online 14(2):55-67, 2011.
• Blum, K, Chen TJ, Bailey J, Bowirrat A, Femino J, Chen AL, Simpatico T, Morse S, Giordano J, Damle U,Kerner M, Braverman ER, Fornari F, Downs BW, Rector C, Barh D, Oscar-Berman M. Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential? Mol Neurobiol. 44(3):250-68. doi: 10.1007/s12035-011-8206-0, 2011.
• Blum, K, Fornari F, Downs BW, Waite RL, Giordano J, Smolen A, Lui Y, Tian J, Majmundar N, Braverman ER. Chapter 19: Genetic Addiction Risk Score (GARS): Testing for Polygenetic Predisposition and Risk for Reward Deficiency Syndrome (RDS). in Gene Therapy Applications (Ed. C King) pages 327-362.
• DiNubile N, Westcott W, Reinl G, Bajaj A, Braverman ER, Madigan MA, Giordano J, Blum, K. The Marc ProDevice is a Novel Paradigm Shift in Muscle Conditioning, Recovery and Performance: Induction of Nitric Oxide (NO) Dependent Enhanced Microcirculation Coupled with Angiogenesis Mechanisms. JEPonline,14(5):10-19, 2011.
• Westcott W, Varghesse J, Dinubile N, Moynih N, Loud RL, Whitehead S, Brothers S, Giordano J, Morse S, Madigan M, Blum, K. Exercise and Nutrition More Effective than Exercise Alone for Increasing Lean Weight and Reducing Resting Blood Pressure. Exercise and Nutrition More Effective than Exercise Alone for Increasing Lean Weight and Reducing Resting Blood Pressure. JEP online. 14 (3), 2011.
• Blum, K, Bowirrat A, Downs BW, Waite RL, Giordano J, Morse S, Madigan M, Downs JM, Braverman ER, Polanin M, Fornari F, Simpatico T. Nutrigenomics of Neuroadaptogen Amino-Acid-Therapy (NAAT)™: Overcoming Carbohydrate Bingeing and Overeating Through Neurometabolic Mechanisms Journal of Functional Food in Health and Chronic Disease. (9):310-378, 2011.
• Blum, K, Bailey J, Gonzalez AM, Oscar-Berman M, Liu Y, Giordano J, Braverman E, Gold M. (2011) Neuro-Genetics of Reward Deficiency Syndrome (RDS) as the Root Cause of "Addiction Transfer": A New Phenomenon Common after Bariatric Surgery. J Genet Syndr Gene Ther.23;2012(1). pii: S2-001.
• Blum, K, Chen ALCH, Chen TJH, Lubar J, White N, Lubar J, Bowirrat A, Braverman ER, Scholfield J, Waite RL, Downs BW, Madigan M, Comings DE, Davis C Kerner M, Palomo T, Stice E, Oscar-Berman M, Giordano J, Morse S, Bailey J. Generational association studies of dopaminergic genes in reward deficiency syndrome (RDS) subjects: selecting appropriate phenotypes for reward dependence behaviors. International Journal of environmental Research and Public Health. 8(2) 4425-4459, 2011.
• Archer T, Oscar-Berman M, Blum, K. Epigenetics in Developmental Disorder: ADHD and EndophenotypesJ 2(104). pii: 1000104, 2011.
• Braverman ER, Braverman D, Acuri V, Kerner K, Downs BW and Blum, K. Sustainable weight loss and muscle gain utilizing the Rainbow Diet, Diethypropion (Tenuate) [A noradrenergic Agonist], Synaptamine Complex {Kb220} {a dopaminergic agonist], hormonal deficiency repletion therapy and exercise. The Bariatrician: American journal of bariatric medicine, 2011.
• Blum, K, Liu Y, Shriner R, Gold MS. Reward circuitry dopaminergic activation regulates food and drug craving behavior. Curr Pharm Des. 17(12):1158-67, 2011.
• Blum, K, Gold MS. Neuro-chemical activation of brain reward meso-limbic circuitry is associated with relapse prevention and drug hunger: a hypothesis. Med Hypotheses. 76(4):576-84, 2011.
• Blum, K, Chen AL, Oscar-Berman M, Chen TJ, Lubar J, White N, Lubar J, Bowirrat A, Braverman E, Schoolfield J, Waite RL, Downs BW, Madigan M, Comings DE, Davis C, Kerner MM, Knopf J, Palomo T, Giordano JJ, Morse SA, Fornari F, Barh D, Femino J, Bailey JA. Generational association studies of dopaminergic genes in reward deficiency syndrome (RDS) subjects: selecting appropriate phenotypes for reward dependence behaviors. Int J Environ Res Public Health. 8(12):4425-59, 2011.
• Blum, K, Oscar-Berman M, Giordano J, Downs B, Simpatico T, Han D, Femino J. Neurogenetic Impairments of Brain Reward Circuitry Links to Reward Deficiency Syndrome (RDS): Potential Nutrigenomic Induced Dopaminergic Activation. J Genet Syndr Gene Ther. 2012 Oct 17;3(4). doi:pii: 1000e115.
• Archer T, Oscar-Berman M, Blum, K, Gold M. Neurogenetics and Epigenetics in Impulsive Behaviour: Impact on Reward Circuitry. J Genet Syndr Gene Ther. 3(3):1000115, 2012.
• Blum, K, Chen AL, Giordano J, Borsten J, Chen TJ, Hauser M, Simpatico T, Femino J, Braverman ER, Barh D. The addictive brain: all roads lead to dopamine. J Psychoactive Drugs. 44(2):134-43, 2012.
• Blum, K, Werner T, Carnes S, Carnes P, Bowirrat A, Giordano J, Oscar-Berman M, Gold M. Sex, drugs, and rock 'n' roll: hypothesizing common mesolimbic activation as a function of reward gene polymorphisms. J Psychoactive Drugs. 44(1):38-55, 2012.
• Miller M, Chen A, Stokes S, et al., Early intervention of intravenous KB220IV_neuroadaptagen amino-acid therapy (NAAT)TM improves behavioral outcomes in a residential addiction treatment program: a pilot study. Journal of Psychoactive Drugs, 44:398-409, 2012.
• Correlation of the Taq1 Dopamine D2 Receptor Gene and Percent Body Fat in Obese and Screened Control Subjects: A Preliminary Report. Chen Alc, Blum, K, Chen TJH, Giordano J, Downs BW, Han D., Barh D., Braverman. Journal of Food & Function (J Royal Society of Chemistry). 3(1): 40-48, 2012
• Blum, K, Oscar-Berman M, Stuller E, et al., Neurogenetics and nutrigenomics of neuro-nutrient therapy for Reward Deficiency Syndrome (RDS): clinical ramifications as a function of molecular neurobiological mechanisms. Journal of Addiction Research & Therapy, 3:1-44, 2012.
• Blum, K, Bailey J, Giordano J, Borsten J, Waite RL, Downs BW, Downs JM, Madigan M, Fornari F., Simpatico T, Jones D, Braverman, Barh D. Diagnosis and Healing in Veterans Suspected of Suffering From Post-traumatic Stress Disorder (PTSD) Using Reward Gene Testing and Reward Circuitry Natural Dopaminergic Activation. Omics Genetic Syndromes & Gene Therapy 3 (3) 100116,2012.
• Morse S, Giordano J, Perrine K, Downs BW, Waite RL, Madigan M, Bailey J, Braverman, Damle U, Simpatico T, Moelelr MD, Blum, K. Audio Therapy Significantly Attenuates Aberrant Mood in Residential Patient Addiction Treatment: Putative Activation of Dopaminergic Pathways in the Meso-Limbic Reward Circuitry of Humans. Journal of Addiction Research & Therapy S3:001. doi:10.4172/2155-6105.S3- 001
• Neuropsychiatric Genetics of Happiness, Friendships and Politics: Hypothesizing that “Birds of a Feather (Homophily)” Flock Together as a Function of “Reward Gene (s)” Polymorphisms.Blum, K, Oscar-Berman M, Bowirrat A, Giordano J, Madigan M, Braverman ER, Fornari F. Journal Genetic Syndromes & Gene Therapy 3(2) in press 2012
• Neuropsychiatric Genetics of Happiness, Friendships and Politics: A new era in understanding social interface. Blum, K, Oscar-Berman-M, Giordano J, Simpatico T, Lohman R, Hauser M, Borsten J, Braverman ER. Genetic Syndromes & Gene Therapy 3(2) 1000e106, 2012.
• Blum, K, Giordano J, Oscar-Berman M, Bowirrat A, Simpatico T, Barh D. Diagnosis and Healing In Veterans Suspected of Suffering from Post-Traumatic Stress Disorder (PTSD) Using Reward Gene Testing and Reward Circuitry Natural Dopaminergic Activation. J Genet Syndr Gene Ther. 3(3):1000116, 2012.
• Bowirrat A, Amanda LCH, Madigan M, Chen TJH, Bailey J, Braverman ER, Kerner M, Giordano J, Morse S, Downs BW, Waite RL, Oscar –Berman M, Blum, K. Neuropsychopharmacology and Neurogenetic Aspects of Executive Functioning: Are Humans “Hard Wired” To Achieve Appropriate Goals? Molecular Neurobiology, 45(2):298-313, 2012.
• Blum, K Oscar-Berman, Femino J, Waite RL, Benya L, Giordano J, B.W. Downs, Braverman Er, Loehmann R, Dushaj K, Simpatico T, Hauser M, Barh D, McLaughlin (2013) Withdrawal from Buprenorphine/naloxone and Maintenance with a Natural Dopaminergic Agonist: a Cautionary Note. J Addict Res Ther. 4: 146. Dol: 10.4172/2155-6105.1000146.
• Blum, K, Werner T, Carnes S, et al., Drugs and Rock ‘N’ Roll: Hypothesizing Common mesolimbic activation as a function of reward gene polymorphisms. Journal of Psychoactive Drugs, 44:38-55, 2012.
• Blum, K, Gardner E, Oscar-Berman M, Gold M. “Liking” and “Wanting” Linked to Reward Deficiency Syndrome (RDS): Hypothesizing differential responsivity in brain reward circuitry Cur Pharm Des. 18(1):113-8, 2012.
• Blum, K, Bagchi D, Barh D, Giordano J, Morse S, Downs BW, Waite RL, Downs JM, Madigan M, Ross –Coker C, Archer T, Braverman ER. Sugar craving a world epidemic: Is there a nutrigenomic solution? Journal of Functional Foods. 1(9) 310-378, 2012.
• Archer T, Oscar-Berman-M, Blum, K, Gold M. Neurogenetics and Epigenetics in Impulsive Behavior Impact in Reward Circuitry. Genetic Syndromes & Gene Therapy 3(3) 1000115, 2012.
• Blum, K, Giordano J, Borsten J, Downs BW, Hauser M, Simpatico T, Lohman R, Braverman ER, Barh D. Translational research to uncover diagnostic & therapeutic gene targets emerging in a genomic era: From bench to bedside. Journal of Genetic Disorders & Disease Information. 1(1) 100e103 .2012.
• Blum, K, Chen AL, Giordano J, Borsten J, Chen TJ, Hauser M, Simpatico T, Femino J, Braverman ER, Barh D. The addictive brain: all roads lead to dopamine. J Psychoactive Drugs. 44(2):134-43, 2012.
• Miller M, Chen ALC, Stokes S, Silverman S, Bowirrat A, Manka M, Manka D, Miller D, Perrine K, Chen TJH, Bailey J, Downs BW, Waite RL, Madigan M, Braverman ER, Damle U, Kerner M, Giordano J, Morse S, Oscar-Berman M, Barh D, Blum, K. Early intravenous KB220V-Neuroadaptagen Amino-Acid Therapy (NAAT) improves behavioral outcomes in a residential addiction treatment program: A pilot study. Journal Psychoactive Drugs, 44(5):398-409, 2012.
• Blum, K, Oscar-Berman M, Stuller E, Miller D, Giordano J, Morse S, McCormick L, Downs BW, Wait RL, Barh D, Neal D, Braverman ER, Lohmann R, Borsten J, Hauser M, Han D, Liu Y, Simpatico T. Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a function of Molecular Neurobiological Mechanisms. Omics Journal of Addiction Research &Therapy 3:139. doi:10.4172/2155-6105.1000139.
• Blum, K, Oscar-Berman, M, Giordano J, Downs BW, Simpatico T, Han D, Femino J. Neurogenetic impairments of brain reward circuitry links to Reward Deficiency syndrome (RDS): Potential Nutrigenomic Induced Dopaminergic Activation. Omics Journal of Genetic Syndromes & Gene Therapy, 3(4), 2012. 
• Blum, K, Oscar-Berman M, Bowirrat A, Giordano J, Madigan M, Braverman ER, Barh D, Hauser M, Borsten J, Simpatico T.  Polymorphisms Genet Syndr Gene Ther. 13;3(112), 2012.
• Blum, K (with J. Giordano, J Borsten, M Hauser, BW Downs, M Madigan, T. Simpatico, J Femino and ER Braverman . The Addiction Gene: Why millions are inherently at risk ? Colliers April 2012.
• Braverman E, Oscar-Berman M, Lohmann R, Kennedy R, Kerner M, Dushaj K, Blum, K. Low and Normal IGF-1 Levels in Patients with Chronic Medical Disorders (CMD) is Independent of Anterior Pituitary Hormone Deficiencies: Implications for Treating IGF-1 Abnormal Deficiencies with CMD. J Genet Syndr Gene Ther.; 4(123). doi:pii: 1000123, 2013.
• Archer T, Oscar-Berman M, Blum, K, Gold M. Epigenetic Modulation of Mood Disorders. J Genet Syndr Gene Ther. 4(120), 2013.
• Blum, K, Oscar-Berman M, Barh D, Giordano J, Gold M. Dopamine Genetics and Function in Food and Substance Abuse. J Genet Syndr Gene Ther. 4(121), 2013.
• Campbell H, Oscar-Berman M, Giordano J, Beley T, Barh D, Downs B, Blum, K. Common Phenotype in Patients with Both Food and Substance Dependence: Case Reports. J Genet Syndr Gene Ther. 6;4(122), 2013. 
• Braverman ER, Blum, K, Damle UJ, Kerner M, Dushaj K, Oscar-Berman M. Evoked Potentials and Neuropsychological Tests Validate Positron Emission Topography (PET) Brain Metabolism in Cognitively Impaired Patients. PLoS One. 8(3):e55398. doi: 10.1371/journal.pone.0055398, 2013.
• Barh D, Barve N, Gupta K, Chandra S, Jain N, Tiwari S, Leon-Sicairos N, Canizalez-Roman A, dos Santos AR, Hassan SS, Almeida S, Ramos RT, de Abreu VA, Carneiro AR, Soares, C, Castro TL, Miyoshi A, Silva A, Kumar A, Misra AN, Blum, K, Braverman ER, Azevedo V. Exoproteome and secretome derived broad spectrum novel drug and vaccine candidates in Vibrio cholerae targeted by Piper betel derived compounds. PLoS One. 8(1): e52773. doi: 10.1371/journal.pone.0052773, 2013.
• Hill, E, Han D, Dumouchel P, et al., Long Term Suboxone Emotional Reactivity As Measured by Automatic Detection in Speech. PLOS ONE, 8:1-14, 2013.
• Blum, K, Femino J, Teitelbaum S, Giordano J, Oscar-Berman M. Molecular Neurobiology of Addiction recovery: 12 step program & Fellowship. SpringerNeuroscience Brief, 2013.
• Yarnell S, Oscar-Berman M, Avena N, Blum, K, Gold M. Pharmacotherapies for Overeating and Obesity. J Genet Syndr Gene Ther. 4(3):131, 2013.
• Braverman E, Oscar-Berman M, Lohmann R, Kennedy R, Kerner M, Dushaj K, Blum, K. Low and Normal IGF-1 Levels in Patients with Chronic Medical Disorders (CMD) is Independent of Anterior Pituitary Hormone Deficiencies: Implications for Treating IGF-1 Abnormal Deficiencies with CMD.J Genet Syndr Gene Ther. 4(123). doi:pii: 1000123, 2013.
• Archer T, Oscar-Berman M, Blum, K, Gold M. Epigenetic Modulation of Mood Disorders. J Genet Syndr Gene Ther. 4(120). doi:pii: 1000120, 2013.
• Blum, K, Oscar-Berman M, Barh D, Giordano J, Gold M. Dopamine Genetics and Function in Food and Substance Abuse. J Genet Syndr Gene Ther. 10;4(121). doi:pii: 1000121, 2013.
• Braverman ER, Blum, K, Damle UJ, Kerner M, Dushaj K, Oscar-Berman M. Evoked potentials and neuropsychological tests validate Positron Emission Topography (PET) brain metabolism in cognitively impaired patients. PLoS One. 8(3):e55398. doi: 10.1371/journal.pone.0055398, 2013. 
• Barh D, Barve N, Gupta K, Chandra S, Jain N, Tiwari S, Leon-Sicairos N, Canizalez-Roman A, dos Santos AR, Hassan SS, Almeida S, Ramos RT, de Abreu VA, Carneiro AR, Soares Sde C, Castro TL, Miyoshi A, Silva A, Kumar A, Misra AN, Blum, K, Braverman ER, Azevedo V. Exoproteome and secretome derived broad spectrum novel drug and vaccine candidates in Vibrio cholerae targeted by Piper betel derived compounds. PLoS One. 8(1):e52773. doi: 10.1371/journal.pone.0052773, 2013. 
• Barh D, Gupta K, Jain N, Khatri G, León-Sicairos N, Canizalez-Roman A, Tiwari S, Verma A, Rahangdale S, Shah Hassan S, dos Santos AR, Ali A, Guimarães LC, Thiago Jucá Ramos R, Devarapalli P, Barve N, Bakhtiar M, Kumavath R, Ghosh P, Miyoshi A, Silva A, Kumar A, Misra AN, Blum, K, Baumbach J, Azevedo V. Conserved host-pathogen PPIs. Globally conserved inter-species bacterial PPIs based conserved host-pathogen interactome derived novel target in C. pseudotuberculosis, C. diphtheriae, M. tuberculosis, C. ulcerans, Y. pestis, and E. coli targeted by Piper betel compounds. Integr Biol (Camb). 5(3):495-509. doi: 10.1039/c2ib20206a, 2013.
• Downs B, Oscar-Berman M, Waite R, et al., Have we hatched the addiction egg: reward efficiency syndrome solution system. Journal of Genetic Syndromes & Gene Therapy, 4:1-9, 2013.
• Blum, K, Oscar-Berman M, Gardner E, Simpatico T, Gold MS. Neurogenetics and Neurobiology of Dopamine in Anhedonia. Chapter in Anhedonia Book, (ed M. Ritsner) Frontiers of Neuroscience, 2013.
• Blum, K, Olive MF, Wang KW, Marcelo F, Borsten J, Giordano J, Hauser M, Gold MS. Hypothesizing that designer drugs containing Cathinone’s (“Bath Salts”) have profound neuro-inflammatory effects and dangerous neurotoxic response following human consumption. Med Hyp Med Hypotheses. doi:pii: S0306-9877(13)00285-5. 10.1016/j.mehy.2013.06.007, 2013.
• Barh D, Gupta K, Jain N, Khatri G, León-Sicairos N, Canizalez-Roman A, Tiwari S, Verma A, Rahangdale S, Shah Hassan S, dos Santos AR, Ali A, Guimarães LC, Thiago Jucá Ramos R, Devarapalli P, Barve N, Bakhtiar M, Kumavath R, Ghosh P, Miyoshi A, Silva A, Kumar A, Misra AN, Blum, K, Baumbach J, Azevedo V. Conserved host-pathogen PPIs. Globally conserved inter-species bacterial PPIs based conserved host-pathogen interactome derived novel target in C. pseudotuberculosis, C. diphtheriae, M. tuberculosis, C. ulcerans, Y. pestis, and E. coli targeted by Piper betel compounds. Integr Biol (Camb). Mar;5(3):495-509, 2013.
• Kushner S, Han D, Oscar-Berman, et al., Declinol a complex containing Kudzu, Bitter Herbs (Gentian, Tangerine Peel) and Bupleurum, significantly reduced Alcohol Use Disorder (AUD) Scores in moderate to heavy drinkers: a pilot study. Journal of Addiction Research & Therapy, 4:1-18, 2013.
• Blum, K, Thompson B, Oscar-Berman M, et al., Geneospirituality: Our Beliefs, Our Genomes, and Addictions. Journal of Addiction Research & Therapy, 5:1-18, 2013.
• Blum, K, Oscar-Berman M, DiNubile N, et al., Coupling genetic addiction risk scores (GARS) with electrotherapy: fighting iatrogenic opioid dependence. Journal of Addiction Research & Therapy, 4:1-8, 2013.
• Blum, K, Han D, Hauser M, Downs B, Giordano J, Borsten J, Winchell E, Simpatico T, Madigan M, Barh D, Neurogenetic impairments of brain reward circuity links to reward deficiency syndrome (RDS) as evidenced by genetic addiction risk score (GARS): A case study. The Institute of Integrative Omics & Applied BioTechnology Journal, 4:4-9, 2013.
• Ashton J, Blum, K, Everything you need to know about global alcohol policy. Addiction Research & Therapy, 5: 1-2, 2014.
• Berkinbayev S, Rysuly M, Mussayev A, Blum, K, et al., Apolipoprotein gene polymorphisms (APOB, APOC111, APOE) in the development of coronary heart disease in ethnic groups of Kazakhstan. 5:1-22 2014.
• Blum, K, Oscar-Berman M, Badgaiyan R, Palomo T, Gold M, Hypothesizing dopaminergic genetic antecedents in schizophrenia and substance seeking behavior. Medical Hypotheses, 82:606-614, 2014.
• Blum, K, Schoenthaler S, Oscar-Berman M, Giordano J, Madigan M, Braverman E, Jones S, Han D, Drug abuse relapse rates linked to level of education: can we repair hypodopaminergic-induced cognitive decline with nutrient therapy? The Physician and Sports Medicine, 42:1-16, 2014.
• Blum, K, Oscar-Berman M, Blum S, Madigan M, Walte R, McLaughlin T, Barh D, Can genetic testing coupled with enhanced dopaminergic activation reduce recidivism rates in the workers compensation legacy cases? Alcoholism and Drug Dependence, 2:1-3, 2014.
• Blum, K, Oscar-Berman M, Badgaiyan R, et al., Dopaminergic neurogenetics of sleep disorders in Reward Deficiency Syndrome (RDS). Sleep Disorders & Therapy, 3:1-3, 2014.
• Blum, K, Oscar-Berman M, Downs W, et al., Hypothesizing that putative dopaminergic, melatonin, benzodiazepine reward circuitry receptor(s) activator provides sleep induction benefits. Sleep Disorders & Therapy, 3:1-10, 2014.
• Blum, K, Oscar-German M, Waite R, A multi-locus approach to treating fibromyalgia by boosting dopaminergic activity in the meso-limbic system of the brain. Journal of Genetic Syndromes & Gene Therapy, 5: 1-5, 2014.
• Blum, K, Oscar-Berman M, Badgaiyan R, et al., Hypothesizing darkness induced alcohol intake linked to dopaminergic regulation of brain function. Psychology (Irvine), 5:282-288, 2014.
• Blum, K, Oscar-Berman M, Braverman E, et al., Raising endogenous brain levels of kynurenic acid may produce anti-reward and enhance suicide ideation. Journal of Alcoholism & Drug Dependence, 2:1-1, 2014.
• Gold M, Blum, K, Oscar-Berman M, et al., Low dopamine function in attention deficit/hyperactivity disorder: should genotyping signify early diagnosis in children? 126:153-177, 2014.
• Vital M, Napolitano C, Oscar-Berman M, et al., Neurophysiological measures and alcohol use disorder (AUD): hypothesizing links between clinical severity index and molecular neurobiological patterns. Addiction Research & Therapy, 5: 1-7, 2014.
• Waite R, Oscar-Berman M, Braverman E, et al., Quantitative Electroencephalography Analysis (qEEG) of Neuro-Electro-Adaptive Therapy 12™ [NEAT12] Up-Regulates Cortical Potentials in an Alcoholic During Protracted Abstinence: Putative Anti-Craving Implications. Addiction Research & Therapy, 5:1-7, 2014.
• Blum, K, Simpatico T, Waite R., Blum S, Dushaj K, Madigan M, Braverman, ER, Oscar-Berman, M. (2014) "Reward" Gene Polymorphisms May Predict High Rates of Injury and Addiction in the Workforce: a nutrient and electrotherapeutic based solution. Health;Vol.6 No.16(2014), Article ID:49876,25 pagesDOI:10.4236/health.2014.616262
• Blum, K, Gold MS. “Depressed Dopamine Function is Attention- Deficit/Hyperactivity Disorder: Should Genotyping of Dopaminergic Polymorphisms Constitute Early Diagnosis in Children?” Pediatrics, Postgrad med126(1):153-77.
• Braverman ER, Han D., Oscar-Berman M, Loehmann R, Dushaj D, Damle U, Blum, K. Multi-Hormonal Bio-identical Replacement Therapy Map (MHRT) in Menopause: Significant Associations as a Function of Somatic and Neurological Symptom Clusters PlosOne2014 Sep 24;9(9):e105048. doi: 10.1371/journal.pone.0105048. eCollection 2014.
• Blum, K, Han D, Oscar-Berman M, Reinl G, DiNubile,N, Madigan MA, Bajaj A, Dows BW, Giordano J, Westcott W, Smith L, Braverman Er, Dushaj, Loehmann R, Hauser M, Simpatico T, McLaughlin T, Beley t, Borsten J, Barh D. Iatrogenic Opioid Dependence is Endemic and Legal: Coupling Genetic Addiction Risk Score (GARS) with Electrotherapy as a new paradigm shift in pain relief programs. Heath Vol.5, No.11A, 16-34 (2013).
• Blum, K, Han D, Madigan M, Loehmann R, Dushaj K, Braverman ER. Cold” X5 Hair laser™ used to treat male androgenic alopecia: Preliminary report trends significant hair growth. BMC-Research Notes. 7:103
• Blum, K, Febo M, Mclaughlin T, Cronje F, Han D, Gold M. (2014) Hatching the behavioral addiction egg: Reward Deficiency Solution System (RDSS)™ as a function of dopaminergic neurogenetics and brain functional connectivity linking all addictions under a common rubric. Journal of Behavioral Addictions. Do1: 10.1556/jba.3.20.2014.019.
• Blum, K, Smith DE, Femino J, Roy AK, Simpatico T, Inaba D, Agan G, Fratantonio J, Febo M, Barh D. (2014) Hypothesizing benefits of the incorporation of genetic addiction risk (GARSRX™) and Dopamine Agonist Modalities (DAM) in clinical Addiction Medicine. Journal of Addiction Therapy & Research. 1(2): 009.
• Blum, K, Oscar-Berman M, Jacobs W., McLaughlin T, Gold MS. (2014) Buprenorphine response as a function of neurogenetic polymorphic antecedents: Can dopamine genes affect clinical outcomes in Reward Deficiency Syndrome (RDS)? Addiction Research & Therapy. 5.3.
• Blum, K, Smith DE, Femino J, Roy AK. (2014) Clinical Integration of Innovative Genetic Risk/Medical Monitoring in Reward Deficiency Syndrome (RDS). Presented at the 45th Annual ASAM meeting, Orlando Florida (won Best Abstract Lab Award).
• Blum, K, Oscar-Berman M, Gardner EL, Simpatico T, Braverman ER, Gold MS. Neurogenetics &Neurobiology of Dopamine in Anhedonia. In: Anhedonia: A Comprehensive Handbook (vol1) editor Ritsner M. Chapter 9 Springer, London, pp. 179-208.
• Blum, K, Femino J, Teitelbaum S, Giordano J, Oscar-Berman, Gold MS. (2013) “Molecular Neurobiology of Addiction Recovery: The 12-step program & Fellowship. Springer, New York.
• Westcott, Aprovian CM, Corina L, Loud RL, Whitehead S, Blum, K, DiNubile N (2013). Nutrition Programs Enhance Exercise effects on Body Composition and resting state blood pressure. The Physician andSports medicine. 41: 85-91.
• Blum, K., Han D, Hauser M, Downs BW, Giordano, J, Borsten J, Winchell E, Simpatico T, Madigan M, Barh D. (2013) Neurogenetic impairments of brain reward circuitry links to Reward Deficiency Syndrome (RDS) as evidenced by Genetic Addiction Risk Score (GARS): A case study. IIOAB 4L1)-4-9.
• Blum, K, Braverman ER, Kreuk F, Dushaj K, Li M, Barh D, Oscar-Berman M. (2014) Genome wise sequencing compared to candidate gene association studies for predisposition to substance abuse a subset of Reward Deficiency Syndrome (RDS) : Are we throwing the baby out with bathwater? Epidemiology 4(3) 1000158.
• Blum, K, Febo M, Thanos PK, Baron D, Gold MS. (2014). Clinically Combatting Reward Deficiency Syndrome (RDS) with Dopamine Agonist Therapy as a Paradigm Shift: Dopamine for Dinner? Mol Neurobiology 2015 Mar 10
• Blum, K&Rajendra Badgaiyan(2013)Addiction Research & Therapy in the 21st Century: Providing a Forum for Evidence –Based Addiction Medicine.: Journal of Addiction Res&Therapy. Editorial. 3(1) eCollection
• Blum, K, Badgaiyan R, Agan G, Fratantonio J, Gold MS (2014) Reward Deficiency Syndrome (RDS): Is there a Solution? J Alcohol Drug Depend 2:177. doi: 10.4172/2329-6488.1000177
• Barh D, Jain N, Tiwari S, Field JK, Padin-Iruegas E, Ruibal A, López R, Herranz M, Bhattacharya A, Juneja L, Viero C, Silva A, Miyoshi A, Kumar A, Blum, K, Azevedo V, Ghosh P, Liloglou T (2013). A novel in silico reverse-transcriptomics-based identification and blood-based validation of a panel of sub-type specific biomarkers in lung cancer. BMC Genomics. 2013;14 Suppl 6:S5. doi: 10.1186/1471-2164-14-S6-S5.
• Braverman ER, Oscar-Berman M, Kreuk F, Kerner M, Dushaj K, Li M, Stratton D, Truesdell C, Blum, K. Preliminary Hormonal Correlations in Female Patients as a Function of Somatic and Neurological Symptom Clusters: An Exploratory Development of a Multi-Hormonal Map for Bio-Identical Replacement Therapy (MHRT).J Genet Syndr Gene Ther. 2013 Dec 6;4. pii: 206.
• Blum, K, Thanos PK, Gold MS. syndrome. Front Psychol. 2014 Sep 17;5:919. doi: 10.3389/fpsyg.2014.00919. eCollection 2014.
• Braverman ER, Han D, Oscar-Berman M, Karikh T, Truesdell C, Dushaj K, Kreuk F, Li M, Stratton D, Blum, K. Menopause Analytical Hormonal Correlate Outcome Study (MAHCOS) and the Association to Brain Electrophysiology (P300) in a Clinical Setting. PLoS One. 2014 Sep 24;9(9):e105048.
• Blum, K, Han D, Femino J, Smith DE, Saunders S, Simpatico T, Schoenthaler SJ, Oscar-Berman M, Gold MS. Systematic evaluation of "compliance" to prescribed treatment medications and "abstinence" from psychoactive drug abuse in chemical dependence programs: data from the comprehensive analysis of reported drugs. PLoS One. 2014 Sep 23;9(9):e104275. doi: 10.1371/journal.pone.0104275. 
• Blum, K, Oscar-Berman M, Badgaiyan R, Braverman ER, Gold MS. Hypothesizing Darkness Induced Alcohol Intake Linked to Dopaminergic Regulation of Brain Function. Psychology (Irvine). 2014 Mar;5(4):282-288.
• Blum, K, Oscar-Berman M, Waite RL, Braverman ER, Kreuk F, Li M, Dushaj K, Madigan MA, Hauser M, Simpatico T, Barh D. Brain Genet Syndr Gene Ther. 2014 Jan 27;5(1):213. 
• Blum, K, Rajendra D. Badgaiyan, Gold MS. Reward Deficiency Solution System (RDS): A Tale of Three Scientists. Journal of Addiction Medicine&Therapeutic Science. 1(10:104, 2014).
• Blum, K, Smith DE, Femino J, Roy AK, Simpatico T, Inaba D, Agan G, Fratantonio, Febo M, Fornari F, Hauser M, Barh D. Hypothesizing Benefits of the Incorporation of Genetic Addiction Risk Score (GARSRX™Rx™) and Dopamine Agonist Modalities (DAM) in Clinical Addiction Medicine Add Thpy. 2014, Volume 1, Issue 2: 009
• Blum, K, Liu Y, Wang W, Wang Y, Zhang Y, Oscar-Berman M, Smolen A, Febo M, Han D, Simpatico T, Cronjé FJ, Demetrovics Z, Gold MS. rsfMRI effects of KB220Z™ on neural pathways in reward circuitry of abstinent genotyped heroin addicts. .Postgrad Med. 2014 Dec 16:1-10.
• Blum, K, Oscar-Berman M, Jacobs W, McLaughlin T, Gold MS. Buprenorphine Response as a Function of Neurogenetic Polymorphic Antecedents: Can Dopamine Genes Affect Clinical Outcomes in Reward Deficiency Syndrome (RDS)? J Addict Res Ther. 2014;5. pii: 1000185.
• Blum, K, Oscar-Berman M, Badgaiyan RD, Khurshid KA, Gold MS.Dopaminergic Neurogenetics of Sleep Disorders in Reward Deficiency Syndrome (RDS).J Sleep Disord Ther. 2014 Feb 18;3(2):126.
• Blum, K, Braverman, ER, Waite RL, Archer T, Thanos PK, Badgaiyan RD, Febo M, Dushaj K, Li M, Gold MS. Neuroquantum Theories of Psychiatric Genetics: Can Physical Forces induce epigenetic influence on future genomes. NeuroQuantology | March 2015 | Volume 13 | Issue 1 | Page 90-103
• Blum, K. (2015) Reward Deficiency Syndrome Solution System™ (RDSS): A 50 year sojourn. Journal of Behavioral Addictions. 4: (1) suppl 1-3.
• Blum, K, Badgaiyan RD, Gold MS. Reward Deficiency Syndrome (RDS) A Tale of Three Scientists. J Addiction Medicine & Therapeutic Science. 1(1) 104.
• Blum, K and Badgaiyan RD (2015) Reward Deficiency Syndrome: Entering the Genomic & Neuroscience Era of Addiction Medicine. JRDS 1(1) : 1-2
• Blum, K, Badgaiyan RD, Anges D, Gold MS. (2015) Should we embrace vaccines for treating substance related disorder, a subset of Reward Deficiency Syndrome (RDS). JRDS 1(1) : 3-5.
• Modestino EJ, Blum, K, Oscar-Berman M, Gold MS, Duane DD, Sultan SG, Auerbach SH. (2015) Reward Deficiency Syndrome: Attentional/Arousal Subtypes: Limitations of Current Diagnostic Nosology, and Future Research. JRDS 1(1) : 6-9
• Badgaiyan RD, Sinha S, Blum, K. (2015) Do We Really Need to Continue Pharmacotherapy for Opioid Use Disorder Indefinitely? JRDS 1(1) :16-19.
• Blum, K, Oscar-Berman M, Braverman ER, Febo M, Li M, Gold MS. (2015) Enhancing Brain Pregnenolone May Protect Cannabis Intoxication but should not be considered as an Anti-Addiction Therapeutic: Hypothesizing Dopaminergic Blockade and Promoting Anti-Reward. JRDS 1(1) : 20-23.
• McLaughlin T, Blum, K, Oscar-Berman M, Febo M, Demetrovics Z, Gozde A, Fratantonio J, Gold MS. (2015) Using the Neuroadaptagen KB220Z ™ to ameliorate terrifying Lucid Nightmares in PTSD/RDS Patients: Role of Enhanced, Brain-Reward, Functional Connectivity, and Dopaminergic Homeostasis. JRDS 1(1): 24-35.
• Schoenthaler S, Blum, K, Braverman ER, Giordano J, Thompson B, Oscar-Berman M, Badgaiyan RD, Madigan M, Dushaj K, Li M, Demetrovics Z, Waite RL, MS Gold (2015) NIDA-Drug Addiction Treatment Outcome Study (DATOS) Relapse as a Function of Spirituality/Religiosity. JRDS 1(1) : 36-45
• Blum, K, Thompson B, Demetrovics Z, Femino J, Giordano J, Oscar-Berman M, Teitelbaum S, Smith DE, Roy AK, Agan G, Fratantonio J, Badgaiyan RD, Gold MS. (2015) The Molecular Neurobiology of the Twelve Steps Program & Fellowship: Connecting the Dots for Recovery. JRDS 1(1) :46-64.
• Blum, K, Badgaiyan RD, Agan G, Fratantonio J, Simpatico T, Febo M, Haberstick BC, Smolen A, Gold MS. (2015) Molecular Genetic Testing in Reward Deficiency Syndrome (RDS): Facts and Fiction. JRDS 1(1): 65-68
• Roger L Waite, Marlene Oscar-Berman, Eric R Braverman, Debmalya Barh and Blum, K. (2014)Quantitative Electroencephalography Analysis (qEEG) of Neuro-Electro- Adaptive Therapy 12™ [NEAT12] Up-Regulates Cortical Potentials in an Alcoholic during Protracted Abstinence: Putative Anti-Craving Implications. Case Report:  J Addict Res Ther 2014, 5: 171.
• McLaughlin T, Blum, K, Oscar-Berman M, Febo M, Agan G, Fratantonio J, Simpatico T, Gold MS (2015). Putative dopamine agonist (KB220Z) attenuates lucid dreams in PTSD patients: Role of enhanced brain reward functional connectivity and homeostasis redeeming joy. J Behav Addict. 4(2): 106-15.
• Blum, K, Thanos PK, Badgaiyan RD, Febo M, Oscar-Berman M, Fratantonio J, Demetrovics Z, Gold MS (2015). Neurogenetics and gene therapy for Reward Deficiency Syndrome: are we going to the promised land. Exp Opin Biol Ther 15(7): 973.
• Blum, K, Febo M, Smith DE, Roy AK 3rd, Demetrovics Z, Cronjé FJ, Femino J, Agan G, Fratantonio JL, Pandey SC, Badgaiyan RD, Gold MS (2015). Neurogenetic and epigenetic correlates of adolescent predisposition to and risk for addictive behaviors as a function of prefrontal cortex dysregulation. J Child Adolesc Psychopharmacol.25(4):286-92
• Braverman ER, Blum, K, Hausman K. et al. Evoked Potentials and Memory/Cognition Tests Validate Brain Atrophy as Measured by 3T MRI (NeuroQuant®) in Cognitively Impaired Patients
• PLOS ONE 10(8):e0133609. 
• Gold MS, Badgaiyan RD, and Blum, K (2015) A shared Molecular and Genetic Basis for Food & Drug Addiction: Overcoming Hypodopaminergic Trait/Sate by Incorporating Dopamine Agonistic Therapy in Psychiatry. Psych. Clin N Am. 38(3):419-62. 
• Blum, K, Badgaiyan RD, Gold MS (2015). Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics. Cureus. 2015 Oct 12;7(10):e348.
• Barh D, Kamapantula B, Jain N, Nalluri J, Bhattacharya A, Juneja L, Barve N, Tiwari S, Miyoshi A, Azevedo V, Blum, K, Kumar A, Silva A, Ghosh P (2015). miRegulome: a knowledgebase of miRNA regulomics and analysis. Sci Rep. 5:12832.
• Blum, K, Badgaiyan RD, Demetrovics Z, Fratantonio J, Agan G, Febo M (2015). Syndrome? Clin Med Rev Case Rep. 2015;2(1). pii: 018.
• McLaughlin T, Blum, K, Oscar-Berman M, Febo M, Agan G, Fratantonio JL, Simpatico T, Gold MS (2015). Putative dopamine agonist (KB220Z) attenuates lucid nightmares in PTSD patients: role of enhanced brain reward functional connectivity and homeostasis redeeming joy. J Behav Addict. 4(2):106-15.
• Blum, K, Thanos PK, Oscar-Berman M, Febo M, Baron D, et al. 2015. Dopamine in the Brain: Hypothesizing Surfeit or Deficit Links to Reward and Addiction. J Reward Defic Syndr 1(3): 95-104.
• Miller D, Miller M, Blum, K, Badgaiyan RD, Febo M. 2015. Addiction Treatment in America: After Money or Aftercare? J Reward Defic Syndr 1(3): 87-94.
• Blum, K, Simpatico T, Badgaiyan RD, Demetrovics Z, Fratantonio J, et al. 2015. Coupling Neurogenetics (GARS™) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome (RDS): Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms. J Reward Defic Syndr 1(2): 75-80.
• Blum, K, Febo M, Fahlke C, Archer T, Berggren U, Demetrovics Z, Dushaj K, Badgaiyan RD. Hypothesizing Balancing Endorphinergic and Glutaminergic Systems to Treat and Prevent Relapse to Reward Deficiency Behaviors: Coupling D-Phenylalanine and N-Acetyl-L-Cysteine (NAC) as a Novel Therapeutic Modality. Clin Med Rev Case Rep. 2015;2(8). pii: 076.
• Miller D, Miller M, Blum, K, Badgaiyan RD, Febo M. Addiction Treatment in America: After Money or Aftercare? J Reward Defic Syndr. 2015 Oct 21;1(3):87-94.
• Blum, K, Hauser M, Fratantonio J, Badgaiyan RD. Molecular Genetic Testing in Pain and Addiction: Facts, Fiction and Clinical Utility. Addict Genet. 2015 Jul 1;2(1):1-5. Epub 2015 Aug 28.
• Blum, K, Oscar-Berman M, Braverman ER, Febo M, Li M, Gold MS. RewardReward Defic Syndr. 2015;1(1):20-23.
• Colon-Perez LM, Tran K, Thompson K, Pace MC, Blum, K, Goldberger BA, Gold MS, Bruijnzeel AW, Setlow B, Febo M. Connectivity. Neuropsychopharmacology. 2016 Mar 21. doi: 10.1038/npp.2016.40.
• Thanos PK, Hamilton J, O'Rourke JR, Napoli A, Febo M, Volkow ND, Blum, K, Gold M. Dopamine D2 gene expression interacts with environmental enrichment to impact lifespan and behavior. Oncotarget. 2016 Mar 15. doi: 10.18632/oncotarget.8088.
• Blum, K, Febo M, Badgaiyan RD, Braverman ER, Dushaj K, Li M, You S, Demetrovics Z.(2016). Neuronutrient Amino-Acid Therapy Protects Against Reward Deficiency Syndrome: Dopaminergic Key to Homeostasis and Neuroplasticity. Curr Pharm Des. 2016 Jul 19.
• Beitscher-Campbell H, Blum, K, Febo M, Madigan MA, Giordano J, Badgaiyan RD, Braverman ER, Dushaj K, Li M, Gold MS.(2016). Pilot clinical observations between food and drug seeking derived from fifty cases attending an eating disorder clinic. J Behav Addict. 2016 Aug 9:1-9. 
• Blum, K, Simpatico T, Febo M, Rodriquez C, Dushaj K, Li M, Braverman ER, Demetrovics Z, Oscar-Berman M, Badgaiyan RD (2016). Hypothesizing Music Intervention Enhances Brain Functional Connectivity Involving Dopaminergic Recruitment: Common Neuro-correlates to Abusable Drugs. Mol Neurobiol. 2016 May 31.
• Blum, K, Febo M, Badgaiyan RD, Demetrovics Z, Simpatico T, Fahlke C, Oscar-Berman M, Li M, Dushaj K, Gold MS (2016), and Meso-Limbic Manipulation of Hypodopaminergic Function in Reward Deficiency Syndrome (RDS): Changing the Recovery Landscape. Curr Neuropharmacol. 2016 May 12. 
• Blum, K, Febo M, Fahlke C, Archer T, Berggren U, Demetrovics Z, Dushaj K, Badgaiyan RD (2016). Hypothesizing Balancing Endorphinergic and Glutaminergic Systems to Treat and Prevent Relapse to Reward Deficiency Behaviors: Coupling D-Phenylalanine and N-Acetyl-L-Cysteine (NAC) as a Novel Therapeutic Modality. Clin Med Rev Case Rep. 2015;2(8). pii: 076.
• Blum, K, Febo M, Badgaiyan RD, Braverman ER, Dushaj K, Li M, You S, Demetrovics Z.(2016). Neuronutrient Amino-Acid Therapy Protects Against Reward Deficiency Syndrome: Dopaminergic Key to Homeostasis and Neuroplasticity. Curr Pharm Des. 2016 Jul 19.
• Blum, K, Haberstick, HC Smolen A, Han D, Oscar-Berman M, Smith DE, Simpatico T, Borsten J, Winchel E, Giordano J, Jones S., Braveman Er, Dushaj K, Li M, Hauser M, Campenella C, Femino J, Villapiano A, Butler S, Roy AK, Cook H. McCormick L, Lindsey C, McLaughlin T, Jaffe A, Holiday B, Barh D, Agan G, Fratantonio JL, Marzilli L, Cronjé, F, Demetrovics Z, Baron D, Gold MS (2015). Quantification of Addiction Risk Utilizing the Genetic Addiction Risk Score (GARSRX™) in Multiple- Treatment Centers in the United States: Prediction of Addiction Severity Index-Alcohol- Risk Sore, Family History and Illicit Drug Abuse. submitted to PLoS Medicine
• Blum, K., B.W. Downs, Kristina Dushaj, Mona Li, Eric R. Braverman, Lyle Fried, Roger Waite, Zsolt Demetrovics, Rajendra D. Badgaiyan. The benefits of customized DNA directed nutrition to balance the brain reward circuitry and reduce addictive behaviors. Precision Medicine Journal. 1(1): 18-33(2016).
• Steinberg B, Blum, K, McLaughlin T, Lubar J, Febo M, Braverman ER, Badgaiyan RD. Low-Resolution Electromagnetic Tomography (LORETA) of changed Brain Function Provoked by Pro-Dopamine Regulator (KB220z) in one Adult ADHD case. Open J Clin Med Case Rep. 2016;2(11). pii: 1121.
• Blum, K, Azman G, Baron D, Badgaiyan RD. Hypothesizing molecular genetics of the Holocaust: Were dopaminergic genes involved or brain wash? SOJ Psychology. 3(1) :1-5, 2016.
• Blum, K, Febo M, Badgaiyan RD. Fifty Years in the Development of a Glutaminergic-Dopaminergic Optimization Complex (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome: A Pictorial. Austin Addict Sci. 2016;1(2). pii: 1006.
• Baron D Blum, K, Chen A, Gold MS, Badgaiyan RD. Conceptualizing Addiction from a Osteopathic Perspective: Dopamine Homeostasis. J. Am Osteopath Assoc. 2018 Feb 1.: 118(2): 115-118
• Blum, K, Gondré-Lewis MC, Baron D, Thanos PK, Braverman ER, Neary J, Elman I, Badgaiyan RD. Introducing Precision Addiction Management of Reward Deficiency Syndrome, the Construct That Underpins All Addictive Behaviors. Front Psychiatry. 2018 Nov 27;9:548. doi: 10.3389/fpsyt.2018.00548. eCollection 2018.
• Steinberg B, Blum, K, McLaughlin T, Lubar J, Febo M, Braverman ER, et al. (2016) Low-Resolution Electromagnetic Tomography (LORETA) of changed Brain Function Provoked by Pro-Dopamine Regulator (KB220z) in one Adult ADHD case. Open J Clin Med Case Rep. 2:11
• Duquette LL, Mattiace F, Blum, K, Waite RL, Boland T, McLaughlin T, et al. (2016) Neurobiology of KB220Z-Glutaminergic-Dopaminergic Optimization Complex [GDOC] as a Liquid Nano: Clinical Activation of Brain in a Highly Functional Clinician Improving Focus, Motivation and Overall Sensory Input Following Chronic Intake. Clin Med Rev Case Rep. 3:5.
• McLaughlin T, Oscar-Berman M, Simpatico T, Giordano J, Jones S, Barh D, Downs WB, et al. (2013) Hypothesizing repetitive paraphilia behavior of a medicationrefractive Tourette's syndrome patient having rapid clinical attenuation withKB220Z-nutrigenomic amino-acid therapy (NAAT). J Behav Addict. 2013 2:117-24.
• Blum, K, et al. Introducing “Precision Addiction Management (PAM™)” as an Adjunctive Genetic Guided Therapy for Abusable Drugs in America. OA J Behavioural Sci Psych 2018, 1(2): 180007.
• Blum, K., Gondré-Lewis, M. C., Baron, D., Thanos, P. K., Braverman, E. R., Neary, J., Elman, I., … Badgaiyan, R. D. (2018). Introducing Precision Addiction Management of Reward Deficiency Syndrome, the Construct That Underpins All Addictive Behaviors. Frontiers in psychiatry, 9, 548. doi:10.3389/fpsyt.2018.00548
• Blum, K., Modestino, E. J., Neary, J., Gondré-Lewis, M. C., Siwicki, D., Moran, M., Hauser, M., Braverman, E. R., Baron, D., Steinberg, B., Laughlin, T. M., … Badgaiyan, R. D. (2018). Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis. Biomedical journal of scientific & technical research, 2(2), 1-4.
• Blum, K., Modestino, E. J., Gondré-Lewis, M., Downs, B. W., Baron, D., Steinberg, B., Siwicki, D., Giordano, J., McLaughlin, T., Neary, J., Hauser, M., Fried, L., … Badgaiyan, R. D. (2017). "Dopamine homeostasis" requires balanced polypharmacy: Issue with destructive, powerful dopamine agents to combat America's drug epidemic. Journal of systems and integrative neuroscience, 3(6), 10.15761/JSIN.1000183.
• Blum, K., Jacobs, W., Modestino, E. J., DiNubile, N., Baron, D., McLaughlin, T., Siwicki, D., Elman, I., Moran, M., Braverman, E. R., Thanos, P. K., … Badgaiyan, R. D. (2018). Insurance Companies Fighting the Peer Review Empire without any Validity: the Case for Addiction and Pain Modalities in the face of an American Drug Epidemic. SEJ surgery and pain, 1(1), 1-11.
• McLaughlin, T., Han, D., Nicholson, J., Steinberg, B., Blum, K., Febo, M., Braverman, E., Li, M., Fried, L., … Badgaiyan, R. (2017). Improvement of long-term memory access with a pro-dopamine regulator in an elderly male: Are we targeting dopamine tone? Journal of systems and integrative neuroscience, 3(3), 10.15761/JSIN.1000165.
• Baron D, Blum, K, Chen A, Gold M, Badgaiyan RD (2018). Conceptualizing Addiction From an Osteopathic Perspective: Dopamine Homeostasis. J Am Osteopath Assoc. 2018 Feb 1;118(2):115-118. doi: 10.7556/jaoa.2018.026.
• Blum, K., Madigan, M. A., Fried, L., Braverman, E. R., Giordano, J., & Badgaiyan, R. D. (2017). Coupling Genetic Addiction Risk Score (GARS) and Pro Dopamine Regulation (KB220) to Combat Substance Use Disorder (SUD). Global journal of addiction & rehabilitation medicine, 1(2), 555556.
• Blum, K., Modestino, E. J., Gondré-Lewis, M. C., Neary, J., Siwicki, D., Hauser, M., Barh, D., Steinberg, B., … Badgaiyan, R. D. (2017). GLOBAL OPIOID EPIDEMIC: DOOMED TO FAIL WITHOUT GENETICALLY BASED PRECISION ADDICTION MEDICINE (PAM™): LESSONS LEARNED FROM AMERICA. Precision medicine, 2(1), 17-22.
• Figueiredo, A., Hamilton, J., Marion, M., Blum, K., Kaczocha, M., Haj-Dahmane, S., Deutsch, D., … Thanos, P. K. (2017). Pharmacological Inhibition of Brain Fatty Acid Binding Protein Reduces Ethanol Consumption in Mice. Journal of reward deficiency syndrome and addiction science, 3(2), 21-27.
• McLaughlin, T., Blum, K., Steinberg, B., Modestino, E. J., Fried, L., Baron, D., Siwicki, D., Braverman, E. R., … Badgaiyan, R. D. (2018). Pro-dopamine regulator, KB220Z, attenuates hoarding and shopping behavior in a female, diagnosed with SUD and ADHD. Journal of behavioral addictions, 7(1), 192-203.
• Modestino EJ, Reinhofer A, Blum, K, Amenechi C, O'Toole P (2018) . Hoehn and Yahr staging of Parkinson's disease in relation to neuropsychological measures. Front Biosci (Landmark Ed). 2018 Mar 1;23:1370-1379.
• Gold MS, Blum, K, Febo M, Baron D, Modestino EJ, Elman I, Badgaiyan RD(2018). Molecular role of dopamine in anhedonia linked to reward deficiency syndrome (RDS) and anti- reward systems. Front Biosci (Schol Ed). 2018 Mar 1;10:309-325.
• Blum, K, Han D, Modestino EJ, Saunders S, Roy AK 3rd, Jacobs W, Inaba DS, Baron D, Oscar-Berman M, Hauser M, Badgaiyan RD, Smith DE, Femino J, Gold MS (2018). A Systematic, Intensive Statistical Investigation of Data from the Comprehensive Analysis of Reported Drugs (CARD) for Compliance and Illicit Opioid Abstinence in Substance Addiction Treatment with Buprenorphine/naloxone. Subst Use Misuse. 2018 Jan 28;53(2):220-229. doi: 10.1080/10826084.2017.1400064.
• Blum, K., Fried, L., Madigan, M. A., Giordano, J., Modestino, E. J., Steinberg, B., Baron, D., DeLeon, M., McLaughlin, T., Hauser, M. Badgaiyan, R. D. (2017). Critical Analysis of White House Anti-Drug Plan. Global journal of addiction & rehabilitation medicine, 1(4), 555568.
• Archer, T., Badgaiyan, R. D., &Blum, K. (2017). Physical Exercise Interventions for Drug Addictive Disorders. Journal of reward deficiency syndrome and addiction science, 3(1), 17-20.
• Blum, K, Badgaiyan RD, Dunston GM, Baron D, Modestino EJ, McLaughlin T, Steinberg B, Gold MS, Gondré-Lewis MC (2018) . The DRD2 Taq1A A1 Allele May Magnify the Risk of Alzheimer's in Aging African Americans. Mol Neurobiol. 2018 Jul;55(7):5526-5536. doi: 10.1007/s12035-017-0758-1
• Barh, D., García-Solano, M. E., Tiwari, S., Bhattacharya, A., Jain, N., Torres-Moreno, D., Ferri, B., Silva, A., Azevedo, V., Ghosh, P., Blum, K., Conesa-Zamora, P., … Perry, G. (2017). BARHL1 Is Downregulated in Alzheimer's Disease and May Regulate Cognitive Functions through ESR1 and Multiple Pathways. Genes, 8(10), 245. doi:10.3390/genes8100245
• Blum, K, Chen ALC, Thanos PK, Febo M, Demetrovics Z, Dushaj K, Kovoor A, Baron D, Smith DE, Roy AK III, Fried L, Chen TJH, Chapman E Sr, Modestino EJ, Steinberg B, Badgaiyan RD(2018). Genetic addiction risk score (GARS) ™, a predictor of vulnerability to opioid dependence. Front Biosci (Elite Ed). 2018 Jan 1;10:175-196.
• Schoenthaler, S. J., Blum, K., Fried, L., Oscar-Berman, M., Giordano, J., Modestino, E. J., & Badgaiyan, R. (2017). The effects of residential dual diagnosis treatment on alcohol abuse. Journal of systems and integrative neuroscience, 3(4), 10.15761/JSIN.1000169. 
• Blum, K, Thanos PK, Wang GJ, Febo M, Demetrovics Z, Modestino EJ, Braverman ER, Baron D, Badgaiyan RD, Gold MS (2018). The Food and Drug Addiction Epidemic: Targeting Dopamine Homeostasis. Curr Pharm Des. 2018 Feb 12;23(39):6050-6061. doi: 10.2174/1381612823666170823101713.
• Blum, K., Febo, M., Fried, L., Baron, D., Braverman, E. R., Dushaj, K., Li, M., Demetrovics, Z., … Badgaiyan, R. D. (2017). Pro-Dopamine Regulator - (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome (RDS). Journal of reward deficiency syndrome and addiction science, 3(1), 3-13.
• Blum, K., Modestino, E. J., Febo, M., Steinberg, B., McLaughlin, T., Fried, L., Baron, D., Siwicki, D., … Badgaiyan, R. D. (2017). Lyme and Dopaminergic Function: Hypothesizing Reduced Reward Deficiency Symptomatology by Regulating Dopamine Transmission. Journal of systems and integrative neuroscience, 3(3), 10.15761/JSIN.1000163.
• Blum, K., Marcelo, F., Dushaj, K., Fried, L., & Badgaiyan, R. D. (2016). "Pro-dopamine regulation (KB220Z™)" as a long-term therapeutic modality to overcome reduced resting state dopamine tone in opiate/opioid epidemic in America. Journal of systems and integrative neuroscience, 2(3), 162-165.
• Febo, M., Blum, K., Badgaiyan, R. D., Perez, P. D., Colon-Perez, L. M., Thanos, P. K., Ferris, C. F., Kulkarni, P., Giordano, J., Baron, D., … Gold, M. S. (2017). Enhanced functional connectivity and volume between cognitive and reward centers of naïve rodent brain produced by pro-dopaminergic agent KB220Z. PloS one, 12(4), e0174774. doi:10.1371/journal.pone.0174774
• Blum, K, Gold M, Demetrovics Z, Archer T, Thanos PK, Baron D, Badgaiyan RD (2017) . Substance use disorder a bio-directional subset of reward deficiency syndrome. Front Biosci (Landmark Ed). 2017 Jun 1;22:1534-1548.
• McLaughlin, T., Febo, M., Badgaiyan, R. D., Barh, D., Dushaj, K., Braverman, E. R., Li, M., Madigan, M. A., … Blum, K. (2016). KB220Z™ a Pro-Dopamine Regulator Associated with the Protracted, Alleviation of Terrifying Lucid Dreams. Can We Infer Neuroplasticity-induced Changes in the Reward Circuit? Journal of reward deficiency syndrome and addiction science, 2(1), 3-13.
• Blum, K, Gold MS, Jacobs W, McCall WV, Febo M, Baron D, Dushaj K, Demetrovics Z, Badgaiyan RD(2017). Neurogenetics of acute and chronic opiate/opioid abstinence: treating symptoms and the cause. Front Biosci (Landmark Ed). 2017 Mar 1;22:1247-1288.
• Vitali, M., Napolitano, C., Berman, M. O., Minuto, S. F., Battagliese, G., Attilia, M. L., Braverman, E. R., Romeo, M., Blum, K., … Ceccanti, M. (2016). Neurophysiological Measures and Alcohol Use Disorder (AUD): Hypothesizing Links between Clinical Severity Index and Molecular Neurobiological Patterns. Journal of addiction research & therapy, 5(2), 182. 
• Blum, K., Downs, B. W., Dushaj, K., Li, M., Braverman, E. R., Fried, L., Waite, R., Demetrovics, Z., … Badgaiyan, R. D. (2016). THE BENEFITS OF CUSTOMIZED DNA DIRECTED NUTRITION TO BALANCE THE BRAIN REWARD CIRCUITRY AND REDUCE ADDICTIVE BEHAVIORS. Precision medicine, 1(1), 18-33.
• McLaughlin, T., Blum, K., Steinberg, B., Siwicki, D., Campione, J., Badgaiyan, R. D., Braverman, E. R., Modestino, E. J., Gondré-Lewis, M. C., Baron, D., Mash, D. C., Giordano, J., … Thanos, P. K. (2017). Hypothesizing Las Vegas and Sutherland Springs Mass Shooters Suffer from Reward Deficiency Syndrome: "Born Bad". Journal of reward deficiency syndrome and addiction science, 3(2), 28-31.
• Blum, K., Febo, M., Fried, L., Li, M., Dushaj, K., Braverman, E. R., McLaughlin, T., Steinberg, B., … Badgaiyan, R. D. (2016). Hypothesizing That Neuropharmacological and Neuroimaging Studies of Glutaminergic-Dopaminergic Optimization Complex (KB220Z) Are Associated With "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS). Substance use & misuse, 52(4), 535-547.
• Blum, K., Febo, M., & Badgaiyan, R. D. (2016). Fifty Years in the Development of a Glutaminergic-Dopaminergic Optimization Complex (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome: A Pictorial. Austin addiction sciences, 1(2), 1006.
• Febo M, Blum, K, Badgaiyan RD, Baron D, Thanos PK, Colon-Perez LM, Demetrovics Z, Gold MS (2017), Dopamine homeostasis: brain functional connectivity in reward deficiency syndrome. Front Biosci (Landmark Ed). 2017 Jan 1;22:669-691. 
• Steinberg, B., Blum, K., McLaughlin, T., Lubar, J., Febo, M., Braverman, E. R., & Badgaiyan, R. D. (2016). Low-Resolution Electromagnetic Tomography (LORETA) of changed Brain Function Provoked by Pro-Dopamine Regulator (KB220z) in one Adult ADHD case. Open journal of clinical & medical case reports, 2(11), 1121.
• Blum, K, Febo M, Badgaiyan RD, Braverman ER, Dushaj K, Li M, Demetrovics Z.(2016) Neuronutrient Amino-Acid Therapy Protects Against Reward Deficiency Syndrome: Dopaminergic Key to Homeostasis and Neuroplasticity. Curr Pharm Des. 2016;22(38):5837-5854. 
• Beitscher-Campbell, H., Blum, K., Febo, M., Madigan, M. A., Giordano, J., Badgaiyan, R. D., Braverman, E. R., Dushaj, K., Li, M., … Gold, M. S. (2016). Pilot clinical observations between food and drug seeking derived from fifty cases attending an eating disorder clinic. Journal of behavioral addictions, 5(3), 533-41.
• Blum, K., Gold, M., Clark, H. W., Dushaj, K., & Badgaiyan, R. D. (2016). Should the United States Government Repeal Restrictions on Buprenorphine/Naloxone Treatment? Substance Use & Misuse, 51(12), 1674-1679.
• Blum, K, Gondré-Lewis MC, Modestino EJ, Lott L, Baron D, Siwicki D, McLaughlin T, Howeedy A, Krengel MH, Oscar-Berman M, Thanos PK, Elman I, Hauser M, Fried L, Bowirrat A, Badgaiyan RD. Understanding the Scientific Basis of Post-traumatic Stress Disorder (PTSD): Precision Behavioral Management Overrides Stigmatization. Mol Neurobiol. 2019 May 23. doi: 10.1007/s12035-019-1600-8. 
• Blum, K, Gondré-Lewis M, Steinberg B, Elman I, Baron D, Modestino EJ, Badgaiyan RD, Gold MS. Our evolved unique pleasure circuit makes humans different from apes: Reconsideration of data derived from animal studies. J Syst Integr Neurosci. 2018 Jun;4(1). doi: 10.15761/JSIN.1000191. 
• Blum, K, Lott L, Siwicki D, Fried L, Hauser M, Simpatico T, Baron D, Howeedy A, Badgaiyan RD. Genetic Addiction Risk Score (GARS™) as a Predictor of Substance Use Disorder: Identifying Predisposition Not Diagnosis. Curr Trends Med Diagn Methods. 2018;1(1). pii: 101. doi: 10.29011/CTMDM-101.100001.
• Blum, K, Modestino EJ, Neary J, Gondré-Lewis MC, Siwicki D, Moran M, Hauser M, Braverman ER, Baron D, Steinberg B, Laughlin TM, Badgaiyan RD. Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis. Biomed J Sci Tech Res. 2018 Jan 7;2(2):1-4. doi: 10.26717/BJSTR.2018.02.000738. PMID: 30370423; PMCID: PMC6201280.
• Blum, K, Gondré-Lewis MC, Baron D, Thanos PK, Braverman ER, Neary J, Elman I, Badgaiyan RD. Introducing Precision Addiction Management of Reward Deficiency Syndrome, the Construct That Underpins All Addictive Behaviors. Front Psychiatry. 2018 Nov 27;9:548. doi: 10.3389/fpsyt.2018.00548. PMID: 30542299; PMCID: PMC6277779.
• Blum, K, Modestino EJ, Lott L, Siwicki D, Baron D, Howeedy A, Badgaiyan RD. Introducing "Precision Addiction Management (PAM®)" as an Adjunctive Genetic Guided Therapy for Abusable Drugs in America. Open Access J Behav Sci Psychol. 2018 Nov 20;1(2):1-4. PMID: 30662982; PMCID: PMC6335959.
• Blum, K. and David Baron, “Opioid Substitution Therapy: Achieving Harm Reduction While Searching for a Prophylactic Solution”, Current Pharmaceutical Biotechnology (2019) 20: 180. 10.1016/j.bbr.2020.112563
• Downs BW, Blum, K, Baron D, Bowirrat A, Lott L, Brewer R, Boyett B, Siwicki D, Roy AK, Podesta A, Badgaiyan S, Hajela R, Fried L, Badgaiyan RD. Death by Opioids: Are there non-addictive scientific solutions? J Syst Integr Neurosci. 2019 Jun;5:10.15761/JSIN.1000211. doi: 10.15761/JSIN.1000211. Epub 2019 Oct 31. PMID: 31824737; PMCID: PMC6904107
• Abijo T, Blum, K, Gondré-Lewis MC. Neuropharmacological and Neurogenetic Correlates of Opioid Use Disorder (OUD) As A Function of Ethnicity: Relevance to Precision Addiction Medicine. Curr Neuropharmacol. 2019 Nov 18. doi: 10.2174/1570159X17666191118125702. PMID:31744450
• Blum, K, Siwicki D, Baron D, Modestino EJ, Badgaiyan RD. The benefits of genetic addiction risk score (GARS™) and pro-dopamine regulation in combating suicide in the American Indian population. J Syst Integr Neurosci. 2018 Sep 14;4:10.15761/JSIN.1000195. doi: 10.15761/JSIN.1000195. PMID: 31660252; PMCID: PMC6816273.
• Colon-Perez LM, Tran K, Thompson K, et al. The Psychoactive Designer Drug and Bath Salt Constituent MDPV Causes Widespread Disruption of Brain Functional Connectivity. Neuropsychopharmacology. 2016;41(9):2352-2365. doi:10.1038/npp.2016.40
• Schoenthaler SJ, Blum, K, Braverman ER, et al. NIDA-Drug Addiction Treatment Outcome Study (DATOS) Relapse as a Function of Spirituality/Religiosity. J Reward Defic Syndr. 2015;1(1):36-45. doi:10.17756/jrds.2015-007
• Braverman ER, Blum, K, Hussman KL, et al. Evoked Potentials and Memory/Cognition Tests Validate Brain Atrophy as Measured by 3T MRI (NeuroQuant) in Cognitively Impaired Patients. PLoS One. 2015;10(8):e0133609. Published 2015 Aug 5. doi:10.1371/journal.pone.0133609
• Gondré-Lewis MC, Bassey R, Blum, K. Pre-clinical models of reward deficiency syndrome: A behavioral octopus. Neurosci Biobehav Rev. 2020 Aug;115:164-188. doi: 10.1016/j.neubiorev.2020.04.021. Epub 2020 Apr 28. PMID: 32360413.
• Swenson S, Blum, K, McLaughlin T, Gold MS, Thanos PK. The therapeutic potential of exercise for neuropsychiatric diseases: A review. J Neurol Sci. 2020 May 15;412:116763. doi: 10.1016/j.jns.2020.116763. Epub 2020 Mar 4. PMID: 32305746.
• Blum, K, Baron D, McLaughlin T, Gold MS. Molecular neurological correlates of endorphinergic/dopaminergic mechanisms in reward circuitry linked to endorphinergic deficiency syndrome (EDS). J Neurol Sci. 2020 Apr 15;411:116733. doi: 10.1016/j.jns.2020.116733. Epub 2020 Feb 14. PMID: 32088516.
• Abijo T, Blum, K, Gondré-Lewis MC. Neuropharmacological and Neurogenetic Correlates of Opioid Use Disorder (OUD) As a Function of Ethnicity: Relevance to Precision Addiction Medicine. Curr Neuropharmacol. 2020;18(7):578-595. doi: 10.2174/1570159X17666191118125702. PMID: 31744450; PMCID: PMC7457418.
• Fried L, Modestino EJ, Siwicki D, Lott L, Thanos PK, Baron D, Badgaiyan RD, Ponce JV, Giordano J, Downs WB, Gondré-Lewis MC, Bruce S, Braverman ER, Boyett B, Blum, K. Hypodopaminergia and "Precision Behavioral Management" (PBM): It is a Generational Family Affair. Curr Pharm Biotechnol. 2020;21(6):528-541. doi: 10.2174/1389201021666191210112108. PMID: 31820688.
• Gold MS, Baron D, Bowirrat A, Blum, K. Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): Do homo sapiens acquire or have a reward deficiency syndrome? J Neurol Sci. 2020 Sep 15;418:117137. doi: 10.1016/j.jns.2020.117137. Epub ahead of print. PMID: 32957037; PMCID: PMC7490287.Edwards D, Roy AK 3rd, Boyett B, Badgaiyan RD, Thanos PK, Baron D, Hauser M, Badgaiyan S, Brewer R, Siwicki DB, Downs W, Smith DE,
• Blum, K. Addiction by Any Other Name is Still Addiction: Embracing Molecular Neurogenetic/Epigenetic Basis of Reward Deficiency. J Addict Sci. 2020 Jan 1;6(1):1-4. PMID: 32432229; PMCID: PMC7236379.Kotyuk E, Magi A, Eisinger A, Király O, Vereczkei A, Barta C, Griffiths MD, Székely A, Kökönyei G, Farkas J, Kun B, Badgaiyan RD, Urbán R,
• Blum, K, Demetrovics Z. Co-occurrences of substance use and other potentially addictive behaviors: Epidemiological results from the Psychological and Genetic Factors of the Addictive Behaviors (PGA) Study. J Behav Addict. 2020 Jun 26;9(2):272-288. doi: 10.1556/2006.2020.00033. PMID: 32609628.
• Blum, K, Baron D, Lott L, Ponce JV, Siwicki D, Boyett B, Steinberg B, Modestino EJ, Fried L, Hauser M, Simpatico T, Downs BW, McLaughlin T, Hajela R, Badgaiyan RD. In Search of Reward Deficiency Syndrome (RDS)-free Controls: The "Holy Grail" in Genetic Addiction Risk Testing. Curr Psychopharmacol. 2020;9(1):7-21. PMID: 32432025; PMCID: PMC7236426.
• Blum, K, Cadet JL, Baron D, Badgaiyan RD, Brewer R, Modestino EJ, Gold MS. Putative COVID- 19 Induction of Reward Deficiency Syndrome (RDS) and Associated Behavioral Addictions with Potential Concomitant Dopamine Depletion: Is COVID-19 Social Distancing a Double Edged Sword? Subst Use Misuse. 2020 Sep 22:1-5. doi: 10.1080/10826084.2020.1817086. Epub ahead of print. PMID: 32957797.
• Blum, K, Bowirrat A, Baron D, Lott L, Ponce JV, Brewer R, Siwicki D, Boyett B, Gondre-Lewis MC, Smith DE, Panayotis K T, Badgaiyan S, Hauser M, Fried L, A R 3rd, Downs BW, Badgaiyan RD.J Syst Integr Neurosci. 2020 Aug;6(2):10.15761/JSIN.1000221. doi: 10.15761/JSIN.1000221. Epub 2019 Dec 19.PMID: 33614164 
• Abijo T, Blum, K, Gondré-Lewis MC.Neuropharmacological and Neurogenetic Correlates of Opioid Use Disorder (OUD) As a Function of Ethnicity: Relevance to Precision Addiction Medicine.Curr Neuropharmacol. 2020;18(7):578-595. doi: 10.2174/1570159X17666191118125702.PMID: 31744450 
• Fried L, Modestino EJ, Siwicki D, Lott L, Thanos PK, Baron D, Badgaiyan RD, Ponce JV, Giordano J, Downs WB, Gondré-Lewis MC, Bruce S, Braverman ER, Boyett B, Blum, K.Hypodopaminergia and "Precision Behavioral Management" (PBM): It is a Generational Family Affair.Curr Pharm Biotechnol. 2020;21(6):528-541. doi: 10.2174/1389201021666191210112108.PMID: 31820688
• Blum, K, Baron D, Lott L, Ponce JV, Siwicki D, Boyett B, Steinberg B, Modestino EJ, Fried L, Hauser M, Simpatico T, Downs BW, McLaughlin T, Hajela R, Badgaiyan RD. In Search of Reward Deficiency Syndrome (RDS)-free Controls: The "Holy Grail" in Genetic Addiction Risk Testing Curr Psychopharmacol. 2020;9(1):7-21.PMID: 32432025 
• Edwards D, Roy AK 3rd, Boyett B, Badgaiyan RD, Thanos PK, Baron D, Hauser M, Badgaiyan S, Brewer R, Siwicki DB, Downs W, Smith DE, Blum, K.Addiction by any other name is still addiction. Embracing Molecular /Epigenetic Basis of RDS.J Addict Sci. 2020 Jan 1;6(1):1-4.PMID: 32432229 
• Blum, K, Baron D, McLaughlin T, Gold MSMolecular neurological correlates of endorphinergic/dopaminergic mechanisms in reward circuitry linked to endorphinergic deficiency syndrome (EDS)..J Neurol Sci. 2020 Apr 15;411:116733. doi: 10.1016/j.jns.2020.116733. Epub 2020 Feb 14.PMID: 32088516 Review.
• Swenson S, Blum, K, McLaughlin T, Gold MS, Thanos PKThe therapeutic potential of exercise for neuropsychiatric diseases: A review.J Neurol Sci. 2020 May 15;412:116763. doi: 10.1016/j.jns.2020.116763. Epub 2020 Mar 4.PMID: 32305746 
• Gondré-Lewis MC, Bassey R, Blum, K.Pre-clinical models of reward deficiency syndrome: A behavioral octopus.Neurosci Biobehav Rev. 2020 Aug;115:164-188. doi: 10.1016/j.neubiorev.2020.04.021. Epub 2020 Apr 28.PMID: 32360413 
• Downs BW, Blum, K, Bagchi D, Kushner S, Bagchi M, Galvin JM, Lewis M, Siwicki D, Brewer R, Boyett B, Baron D, Giordano J, Badgaiyan RD.Molecular neuro-biological and systemic health benefits of achieving dopamine homeostasis in the face of a catastrophic pandemic (COVID- 19): A mechanistic exploration.J Syst Integr Neurosci. 2020 Apr 30;7:10.15761/JSIN.1000228. doi: 10.15761/JSIN.1000228.PMID: 
• Blum, K, Lott L, Baron D, Smith DE, Badgaiyan RD, Gold Improving naltrexone compliance and outcomes with putative pro- dopamine regulator KB220, compared to treatment as usual.J Syst Integr Neurosci. 2020 May 30;7:10.15761/JSIN.1000229. doi: 10.15761/JSIN.1000229.PMID: 32934823 
• Blum, K, Lott L, Baron D, Smith DE, Badgaiyan RD, Gold MS. Improving naltrexone compliance and outcomes with putative pro- dopamine regulator KB220, compared to treatment as usual. J Syst Integr Neurosci. 2020 May 30;7:10.15761/JSIN.1000229. doi: 10.15761/JSIN.1000229. PMID: 32934823; PMCID: PMC7489288.
• Kotyuk E, Magi A, Eisinger A, Király O, Vereczkei A, Barta C, Griffiths MD, Székely A, Kökönyei G, Farkas J, Kun B, Badgaiyan RD, Urbán R, Blum, K, Demetrovics Z. Co-occurrences of substance use and other potentially addictive behaviors: Epidemiological results from the Psychological and Genetic Factors of the Addictive Behaviors (PGA) Study. J Behav Addict. 2020 Jun 26;9(2):272-288. doi: 10.1556/2006.2020.00033. PMID: 32609628.
• Gold MS, Baron D, Bowirrat A,Blum, K.Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): Do homo sapiens acquire or have a reward deficiency syndrome?J Neurol Sci. 2020 Nov 15;418:117137. doi: 10.1016/j.jns.2020.117137. Epub 2020 Sep 15.PMID: 32957037
• Blum, K, Cadet JL, Baron D, Badgaiyan RD, Brewer R, Modestino EJ, Gold MS. Putative COVID- 19 Induction of Reward Deficiency Syndrome (RDS) and Associated Behavioral Addictions with Potential Concomitant Dopamine Depletion: Is COVID-19 Social Distancing a Double Edged Sword? Subst Use Misuse. 2020;55(14):2438-2442. doi: 10.1080/10826084.2020.1817086. Epub 2020 Sep 22. PMID: 32957797. 
• Blum, K, Raza A, Schultz T, Jalali R, Green R, Brewer R, Thanos PK, McLaughlin T, Baron D, Bowirrat A, Elman I, Downs BW, Bagchi D, Badgaiyan RD. Should We Embrace the Incorporation of Genetically Guided "Dopamine Homeostasis" in the Treatment of Reward Deficiency Syndrome (RSD) as a Frontline Therapeutic Modality? Acta Sci Neurol. 2021 Feb 2;4(2):17-24. PMID: 33681869; PMCID: PMC7931265.
• Moran M, Blum, K, Ponce JV, Lott L, Gondré-Lewis MC, Badgaiyan S, Brewer R, Downs BW, Fynman P, Weingarten A, Cadet JL, Smith DE, Baron D, Thanos PK, Modestino EJ, Badgaiyan RD, Elman I, Gold MS. High Genetic Addiction Risk Score (GARS) in Chronically Prescribed Severe Chronic Opioid Probands Attending Multi-pain Clinics: an Open Clinical Pilot Trial. Mol Neurobiol. 2021 Mar 8. doi: 10.1007/s12035-021-02312-1. Epub ahead of print. PMID: 33683627.
• Blum, K, Kazmi S, Modestino EJ, Downs BW, Bagchi D, Baron D, McLaughlin T, Green R, Jalali R, Thanos PK, Elman I, Badgaiyan RD, Bowirrat A, Gold MS. A Novel Precision Approach to Overcome the "Addiction Pandemic" by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration. J Pers Med. 2021 Mar 16;11(3):212. doi: 10.3390/jpm11030212. PMID: 33809702; PMCID: PMC8002215.
• Blum, K, Morgan J, Cadet JL, Baron D, Carney PR, Khalsa J, Badgaiyan RD, Gold MS. Psychoactive Drugs Like Cannabis -Induce Hypodopaminergic Anhedonia and Neuropsychological Dysfunction in Humans: Putative Induction of Dopamine Homeostasis via Coupling of Genetic Addiction Risk Severity (GARS) testing and Precision Pro-dopamine Regulation (KB220). Neurology (E Cronicon). 2021 Apr;13(4):86-92. Epub 2021 Mar 31. PMID: 34085060; PMCID: PMC8171216.
• Blum, K, Khalsa J, Cadet JL, Baron D, Bowirrat A, Boyett B, Lott L, Brewer R, Gondré-Lewis M, Bunt G, Kazmi S, Gold MS. Cannabis-Induced Hypodopaminergic Anhedonia and Cognitive Decline in Humans: Embracing Putative Induction of Dopamine Homeostasis. Front Psychiatry. 2021 Mar 30;12:623403. doi: 10.3389/fpsyt.2021.623403. PMID: 33868044; PMCID: PMC8044913.
• Blum, K, Cadet JL, Gold MS. Psychostimulant use disorder emphasizing methamphetamine and the opioid -dopamine connection: Digging out of a hypodopaminergic ditch. J Neurol Sci. 2021 Jan 15;420:117252. doi: 10.1016/j.jns.2020.117252. Epub 2020 Nov 28. PMID: 33279726.
• Downs BW, Blum, K, Bagchi D, Kushner S, Bagchi M, Galvin JM, et al. (2020) Molecular neuro-biological and systemic health benefits of achieving dopamine homeostasis in the face of a catastrophic pandemic (COVID- 19): A mechanistic exploration. J Syst Integr Neurosci 7: DOI: 10.15761/JSIN.1000228.
• Blum, K, Bernard W Downs, Manashi Bagchi, Steve Kushner, Bruce S Morrison, et al. (2020) Induction of homeostatic biological parameters in reward deficiency as a function of an iron-free multi-nutrient complex: Promoting hemoglobinization, aerobic metabolism, viral immuno-competence, and neuroinflammatory regulation. J Syst Integr Neurosci 7: DOI: 10.15761/JSIN.1000234.
• Blum, K, Giordano J, Baron D., McLaughlin T, Badgaiyan RD. Proposing FDA consideration for the treatment and prophylaxis of opioid and psychostimulant abuse to incorporate the induction of DNA guided dopamine homeostasis: Anti-reward deficiency restoration solution (ARDS). .J Syst Integr Neurosci (in press).
• Thanos P, Gold MS, Blum, K, Badgaiyan Rd, Avene M. Bariatric surgery: Potential post-operative heightened sensitivity to substance use disorder. .J Syst Integr Neurosci (in press).
• Blum, K, Cadet JL, Baron, D, Badgaiyan RD, Gold MS. Opioid and dopamine genes interact to predict precision naltrexone response in alcohol use disorder: Interpretation misfire. J Syst Integr Neurosci (in press).
• Schultz T., Raza AR, Mars J, Scott C, Han D, Baron D, Greem R, Brewer R, Jalali R, Badgaiyan Rd, Elman I, Braverman Er, Barh D, Blum, K. IV1114589NAD infusions improves clinical outcome in Substance Use Disorder (SUD): Descriptive annotation in fifty cases. J Syst Integr Neurosci (in press).
• Blum, K, Soni D, Badgaiyan RD, Baron D. Overcoming Reward Deficiency Syndrome (RDS) by the Induction of “Dopamine homeostasis” Instead of Opioids for Opioids: Illusion or Reality? JOM (IP)
• Barh D, Tiwari S, Andrade BS, Weener ME, Góes-Neto A, Azevedo V, Ghosh P, Blum, K, Ganguly NK. A novel multi-omics-based highly accurate prediction of symptoms, comorbid conditions, and possible long-term complications of COVID-19. Mol Omics. 2021 Apr 1;17(2):317-337. doi: 10.1039/d0mo00189a. Epub 2021 Mar 8. PMID: 33683246.
• Blum, K, Edward J. Modestino, David Baron, Raymond Brewer, Panayotis Thanos, Igor Elman, Rajendra DBadgaiyan, B. William Downs, Debasis Bagchi, Thomas McLaughlin, Abdalla Bowirrat, A. Kenison Roy and Mark S. Gold, “Endorphinergic Enhancement Attenuation of Post-traumatic Stress Disorder (PTSD) via Activation of Neuro-immunological Function in the Face of a Viral Pandemic”, Current Psychopharmacology 2021; 10(2) .
• Blum, K, Thomas McLaughlin, Edward J. Modestino, David Baron, Abdalla Bowirrat, Raymond Brewer, Bruce Steinberg, A. Kenison Roy, Marcello Febo, Rajendra D. Badgaiyan and Marks S. Gold, “Epigenetic Repair of Terrifying Lucid Dreams by Enhanced Brain Reward Functional Connectivity and Induction of Dopaminergic Homeostatic Signaling”, Current Psychopharmacology 2021; 10(2)
• Blum, K, Mark S. Gold, Jean L. Cadet, David Baron, Abdalla Bowirrat, Panayotis K. Thanos, Raymond Brewer, Rajendra D. Badgaiyan and Marjorie C. Gondré–Lewis, “Dopaminylation in Psychostimulant Use Disorder Protects Against Psychostimulant Seeking Behavior by Normalizing Nucleus Accumbens (NAc) Dopamine Expression”, Current Psychopharmacology 2021; 10() . https://doi.org/10.2174/2211556009666210108112737
• Blum, K Abdalla Bowirrat, Marjorie C. Gondre Lewis, Thomas A. Simpatico, Mauro Ceccanti, Bruce Steinberg, Edward J Modestino, Panayotis K Thanos, David Baron, Thomas McLaughlin, Raymond Brewer, Rajendra D. Badgaiyan, Jessica Valdez Ponce, Lisa Lott and Mark S Gold, “Exploration of Epigenetic State Hyperdopaminergia (Surfeit) and Genetic Trait Hypodopaminergia (Deficit) During Adolescent Brain Development”, Current Psychopharmacology 2021; 10() . https://doi.org/10.2174/2211556010666210215155509
• Blum, K, Thomas McLaughlin, Edward J. Modestino, David Baron, Abdalla Bowirrat, Raymond Brewer, Bruce Steinberg, A. Kenison Roy, Marcello Febo, Rajendra D. Badgaiyan and Marks S. Gold, “Epigenetic Repair of Terrifying Lucid Dreams by Enhanced Brain Reward Functional Connectivity and Induction of Dopaminergic Homeostatic Signaling”, Current Psychopharmacology 2021; 10() . https://doi.org/10.2174/2211556010666210215153513
• Madigan MA, Badgaiyan RD, Baron D, Blum, K., Precision Behavioral Management (PBM) A Novel Approach to Combat Post-Traumatic Stress Disorder (PTSD). SOJ Psychol. 2018;5(2):10.15226/2374-6874/5/2/00148. doi: 10.15226/2374-6874/5/2/00148. Epub 2018 Aug 6. PMID: 31440582; PMCID: PMC6706091.
• Blum, K., Baron D, Bowirrat A, Thanos PK., Braverman Er, Giordano J, Downs BW, Simpatico TA, Smith De, Roy Ak, Green R, Raza A, Jalai R, Schultz T, Brewer R, Mullen P, McLaughlin T, Badgaiyan RD, Bagchi D. Cyto-archival Evidence for the Role of the Dopamine D2 receptor Polymorphisms in Reward Deficiency Syndrome (RDS): Annotated bibliography, J Syst Integr Neurosci (in press).
• Blum K., Bowirrat A, Braverman Er, Baron D, Cadet JL, Kazmi S, Elman E, Thanos PK, Badgaiyan RD, Downs BW, Bagchi D, Llanos-Gomez L, Gold M. Reward Deficiency Syndrome (RDS): “A Cytoarchitectural Common Neurobiological Trait of All Addictions.” Journal Personalized Medicine (revision in review)
• Downs BW, Kushner S, Bagchi M, Blum K., Badgaiyan RD, Bagchi D. Etiology of Neuroinflammatory Pathologies in Neurodegenerative Diseases: A Treatise. Current Psychopharmacology, 2021, 10, 1-15 1
• Blum K, Thanos PK, Oscar-Berman M, Febo M, Baron D, Badgaiyan RD, Gardner E, Demetrovics Z, Fahlke C, Haberstick BC, Dushaj K, Gold MS. Dopamine in the Brain: Hypothesizing Surfeit or Deficit Links to Reward and Addiction. J Reward Defic Syndr. 2015;1(3):95-104. doi: 10.17756/jrds.2015-016. Epub 2015 Oct 23. PMID: 27398406; PMCID: PMC4936401.
• Blum K, Cadet JL, Gold MS. Psychostimulant use disorder emphasizing methamphetamine and the opioid -dopamine connection: Digging out of a hypodopaminergic ditch. J Neurol Sci. 2021 Jan 15;420:117252. doi: 10.1016/j.jns.2020.117252. Epub 2020 Nov 28. PMID: 33279726.
• Blum K, Morgan J, Cadet JL, Baron D, Carney PR, Khalsa J, Badgaiyan RD, Gold MS. Psychoactive Drugs Like Cannabis -Induce Hypodopaminergic Anhedonia and Neuropsychological Dysfunction in Humans: Putative Induction of Dopamine Homeostasis via Coupling of Genetic Addiction Risk Severity (GARS) testing and Precision Pro-dopamine Regulation (KB220). Neurology (ECronicon). 2021 Apr;13(4):86-92. Epub 2021 Mar 31. PMID: 34085060; PMCID: PMC8171216.
• Blum K, Kazmi S, Modestino EJ, Downs BW, Bagchi D, Baron D, McLaughlin T, Green R, Jalali R, Thanos PK, Elman I, Badgaiyan RD, Bowirrat A, Gold MS. A Novel Precision Approach to Overcome the "Addiction Pandemic" by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration. J Pers Med. 2021 Mar 16;11(3):212. doi: 10.3390/jpm11030212. PMID: 33809702; PMCID: PMC8002215.
• Moran M, Blum K, Ponce JV, Lott L, Gondré-Lewis MC, Badgaiyan S, Brewer R, Downs BW, Fynman P, Weingarten A, Cadet JL, Smith DE, Baron D, Thanos PK, Modestino EJ, Badgaiyan RD, Elman I, Gold MS. High Genetic Addiction Risk Score (GARS) in Chronically Prescribed Severe Chronic Opioid Probands Attending Multi-pain Clinics: an Open Clinical Pilot Trial. Mol Neurobiol. 2021 Jul;58(7):3335-3346. doi: 10.1007/s12035-021-02312-1. Epub 2021 Mar 8. PMID: 33683627; PMCID: PMC8257535.
• Blum K, Khalsa J, Cadet JL, Baron D, Bowirrat A, Boyett B, Lott L, Brewer R, Gondré-Lewis M, Bunt G, Kazmi S, Gold MS. Cannabis-Induced Hypodopaminergic Anhedonia and Cognitive Decline in Humans: Embracing Putative Induction of Dopamine Homeostasis. Front Psychiatry. 2021 Mar 30;12:623403. doi: 10.3389/fpsyt.2021.623403. PMID: 33868044; PMCID: PMC8044913.
• Blum K, Raza A, Schultz T, Jalali R, Green R, Brewer R, Thanos PK, McLaughlin T, Baron D, Bowirrat A, Elman I, Downs BW, Bagchi D, Badgaiyan RD. Should We Embrace the Incorporation of Genetically Guided "Dopamine Homeostasis" in the Treatment of Reward Deficiency Syndrome (RSD) as a Frontline Therapeutic Modality? Acta Sci Neurol. 2021 Feb 2;4(2):17-24. PMID: 33681869; PMCID: PMC7931265.
• Richardson B, Swenson S, Hamilton J, Leonard K, Delis F, Gold M, Blum K, Thanos PK. Chronic neuroleptic treatment combined with a high fat diet elevated [3H] flunitrazepam binding in the cerebellum. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jul 25;112:110407. doi: 10.1016/j.pnpbp.2021.110407. Epub ahead of print. PMID: 34320402.
• Brittany Richardson, Sabrina Swenson, John Hamilton, Ken Leonard, Foteini Delis, Mark Gold, Ken Blum, Panayotis K. Thanos, Chronic neuroleptic treatment combined with a high fat diet elevated [3H] flunitrazepam binding in the cerebellum, Progress in Neuro-Psychopharmacology and Biological Psychiatry, Volume 112,2022,110407,ISSN 0278-5846,https://doi.org/10.1016/j.pnpbp.2021.110407.
• Blum K, Chen TJ, Morse S, Giordano J, Chen AL, Thompson J, Allen C, Smolen A, Lubar J, Stice E, Downs BW, Waite RL, Madigan MA, Kerner M, Fornari F, Braverman ER. Overcoming qEEG abnormalities and reward gene deficits during protracted abstinence in male psychostimulant and polydrug abusers utilizing putative dopamine D₂ agonist therapy: part 2. Postgrad Med. 2010 Nov;122(6):214-26. doi: 10.3810/pgm.2010.11.2237. PMID: 21084796.
• Blum K, Kazmi S, Modestino EJ, Downs BW, Bagchi D, Baron D, McLaughlin T, Green R, Jalali R, Thanos PK, Elman I, Badgaiyan RD, Bowirrat A, Gold MS. A Novel Precision Approach to Overcome the “Addiction Pandemic” by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration. Journal of Personalized Medicine. 2021; 11(3):212. https://doi.org/10.3390/jpm11030212
• Chen TJ, Blum K, Mathews D, Fisher L, Schnautz N, Braverman ER, Schoolfield J, Downs BW, Comings DE. Are dopaminergic genes involved in a predisposition to pathological aggression? Hypothesizing the importance of "super normal controls" in psychiatricgenetic research of complex behavioral disorders. Med Hypotheses. 2005;65(4):703-7. doi: 10.1016/j.mehy.2005.04.037. PMID: 15964153.
• Blum K, Gold MS, Mitchell LG, Washington KW, Baron D, Thanos PK, et al. Global Evidence for the Key Role of the Dopamine D2 Receptor Gene (DRD2) and DRD2 Receptors in Alcoholism.SM J Neurol Neurosci. 2017; 3(1): 1006s.
• Kenneth Blum, Panayotis K. Thanos, Gene -Jack Wang, Abdalla Bowirrat, Luis Llanos Gomez, David Baron, Rehan Jalali, Marjorie C Gondré-Lewis & Mark S Gold (2021) Dopaminergic and Other Genes Related to Reward Induced Overeating, Bulimia, Anorexia Nervosa, and Binge Eating, Expert Review of Precision Medicine and Drug Development, DOI: 10.1080/23808993.2021.1994186
• Blum K, Badgaiyan RD. Translational and Molecular Cytoarchitectural Genetic Guided Therapy to Induce Dopamine Homeostatic Neuro-signaling in Reward Deficiency and Associated Drug and Behavioral Addiction Seeking: A 60 Year Sojourn the Future is Now. EC Psychol Psychiatr. 2021 Jul 29;10(8):1-4. PMID: 34708222; PMCID: PMC8547334.
• Blum K, Modestino EJ, Neary J, Gondré-Lewis MC, Siwicki D, Moran M, Hauser M, Braverman ER, Baron D, Steinberg B, Laughlin TM, Badgaiyan RD. Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis. Biomed J Sci Tech Res. 2018 Jan 7;2(2):1-4. doi: 10.26717/BJSTR.2018.02.000738. PMID: 30370423; PMCID: PMC6201280.
• Blum K, Bowirrat A, Braverman ER, Baron D, Cadet JL, Kazmi S, Elman I, Thanos PK, Badgaiyan RD, Downs WB, Bagchi D, Llanos-Gomez L, Gold MS. Reward Deficiency Syndrome (RDS): A Cytoarchitectural Common Neurobiological Trait of All Addictions. Int J Environ Res Public Health. 2021 Nov 2;18(21):11529. doi: 10.3390/ijerph182111529. PMID: 34770047; PMCID: PMC8582845.
• Blum K, Morgan J, Cadet JL, Baron D, Carney PR, Khalsa J, Badgaiyan RD, Gold MS. Psychoactive Drugs Like Cannabis -Induce Hypodopaminergic Anhedonia and Neuropsychological Dysfunction in Humans: Putative Induction of Dopamine Homeostasis via Coupling of Genetic Addiction Risk Severity (GARS) testing and Precision Pro-dopamine Regulation (KB220). Neurology (ECronicon). 2021 Apr;13(4):86-92. Epub 2021 Mar 31. PMID: 34085060; PMCID: PMC8171216.
• Kótyuk E., Potenza M.N., Blum K., Demetrovics Z. (2022) The Reward Deficiency Syndrome and Links with Addictive and Related Behaviors. In: Patel V.B., Preedy V.R. (eds) Handbook of Substance Misuse and Addictions. Springer, Cham. https://doi.org/10.1007/978-3-030-67928-6_3-1
• Blum K, Steinberg B, Gondre-Lewis MC, Baron D, Modestino EJ, Badgaiyan RD, Downs BW, Bagchi D, Brewer R, McLaughlin T, Bowirrat A, Gold M. A Review of DNA Risk Alleles to Determine Epigenetic Repair of mRNA Expression to Prove Therapeutic Effectiveness in Reward Deficiency Syndrome (RDS): Embracing "Precision Behavioral Management". Psychol Res Behav Manag. 2021 Dec 17;14:2115-2134. doi: 10.2147/PRBM.S292958. PMID: 34949945; PMCID: PMC8691196.
• Gupta A, Bowirrat A, Gomez LL, Baron D, Elman I, Giordano J, Jalali R, Badgaiyan RD, Modestino EJ, Gold MS, Braverman ER, Bajaj A, Blum K. Hypothesizing in the Face of the Opioid Crisis Coupling Genetic Addiction Risk Severity (GARS) Testing with Electrotherapeutic Nonopioid Modalities Such as H-Wave Could Attenuate Both Pain and Hedonic Addictive Behaviors. International Journal of Environmental Research and Public Health. 2022; 19(1):552. https://doi.org/10.3390/ijerph1901055
• Blum, Kenneth, Thomas McLaughlin, Abdalla Bowirrat, Edward J. Modestino, David Baron, Luis L. Gomez, Mauro Ceccanti, Eric R. Braverman, Panayotis K. Thanos, Jean L. Cadet, Igor Elman, Rajendra D. Badgaiyan, Rehan Jalali, Richard Green, Thomas A. Simpatico, Ashim Gupta, and Mark S. Gold. 2022. "Reward Deficiency Syndrome (RDS) Surprisingly Is Evolutionary and Found Everywhere: Is It “Blowin’ in the Wind”?" Journal of Personalized Medicine 12, no. 2: 321. https://doi.org/10.3390/jpm12020321
• Blum Kenneth *, Gold S. Mark, Cadet L. Jean, Baron David, Bowirrat Abdalla, Thanos K. Panayotis, Brewer Raymond, Badgaiyan D. Rajendra and Gondré–Lewis C. Marjorie, Dopaminylation in Psychostimulant Use Disorder Protects Against Psychostimulant Seeking Behavior by Normalizing Nucleus Accumbens (NAc) Dopamine Expression, Current Psychopharmacology 2021; 10() . https://dx.doi.org/10.2174/2211556009666210108112737
• Kótyuk, E., Urbán, R., Hende, B., Richman, M., Magi, A., Király, O., Barta, C., Griffiths, M. D., Potenza, M. N., Badgaiyan, R. D., Blum, K., & Demetrovics, Z. (2022). Development and validation of the Reward Deficiency Syndrome Questionnaire (RDSQ-29). Journal of Psychopharmacology, 36(3), 409–422. https://doi.org/10.1177/02698811211069102
• Kaleigh Richer, John Hamilton, Foteini Delis, Connor Martin, Dennis Fricke, Rutao Yao, Munawwar Sajjad, Kenneth Blum, Michael Hadjiargyrou, David Komatsu, Panayotis K. Thanos,Chronic treatment and abstinence from methylphenidate exposure dose-dependently changes glucose metabolism in the rat brain,Brain Research,Volume 1780,2022,147799,ISSN 0006-8993, https://doi.org/10.1016/j.brainres.2022.147799.
• Blum Kenneth *, Gold S. Mark, Cadet L. Jean, Baron David, Bowirrat Abdalla, Thanos K. Panayotis, Brewer Raymond, Badgaiyan D. Rajendra and Gondré–Lewis C. Marjorie, Dopaminylation in Psychostimulant Use Disorder Protects Against Psychostimulant Seeking Behavior by Normalizing Nucleus Accumbens (NAc) Dopamine Expression, Current Psychopharmacology 2021; 10() . https://dx.doi.org/10.2174/2211556009666210108112737
• Blum K, Green R, Smith J, Llanos-Gomez L, Baron D, Badgaiyan RD. Hypothesizing High Negative Emotionality as a Function of Genetic Addiction Risk Severity (GARS) Testing in Alcohol Use Disorder (AUD). J Syst Integr Neurosci. 2020;7:10.15761/jsin.1000245. doi:10.15761/jsin.1000245
• Blum K, Downs BW, Bagchi M, et al. Induction of homeostatic biological parameters in reward deficiency as a function of an iron-free multi-nutrient complex: Promoting hemoglobinization, aerobic metabolism, viral immuno-competence, and neuroinflammatory regulation. J Syst Integr Neurosci. 2020;7:10.15761/JSIN.1000234. doi:10.15761/JSIN.1000234
• Blum K, Badgaiyan RD. Translational and Molecular Cytoarchitectural Genetic Guided Therapy to Induce Dopamine Homeostatic Neuro-signaling in Reward Deficiency and Associated Drug and Behavioral Addiction Seeking: A 60 Year Sojourn the Future is Now. EC Psychol Psychiatr. 2021 Jul 29;10(8):1-4. PMID: 34708222; PMCID: PMC8547334.
• Roy AK, Bowirrat A, Smith DE, Braverman ER, Jalali R, Badgaiyan RD, Baron D, Llanos-Gomez L, Barh D, Blum K. Neurobiology and Spirituality in Addiction Recovery. Acta Sci Neurol. 2021 Aug 28;4(9):64-71. PMID: 35098052; PMCID: PMC8793770.
• Kótyuk E., Potenza M.N., Blum K., Demetrovics Z. (2022) The Reward Deficiency Syndrome and Links with Addictive and Related Behaviors. In: Patel V.B., Preedy V.R. (eds) Handbook of Substance Misuse and Addictions. Springer, Cham. https://doi.org/10.1007/978-3-030-67928-6_3-1
• Blum K, Bowirrat A, Gomez LL, Downs BW, Bagchi D, Barh D, Modestino EJ, Baron D, McLaughlin T, Thanos P, Ceccanti M, Elman I, Badgaiyan RD, Dennen C, Gupta A, Braverman ER, Gold MS. Why haven't we solved the addiction crisis? J Neurol Sci. 2022 Nov 15;442:120404. doi: 10.1016/j.jns.2022.120404. Epub 2022 Sep 2. PMID: 36084363.
• Khalsa JH, Bunt G, Blum K, Maggirwar SB, Galanter M, Potenza MN. Review: Cannabinoids as Medicinals. Curr Addict Rep. 2022;9(4):630-646. doi: 10.1007/s40429-022-00438-3. Epub 2022 Sep 7. PMID: 36093358; PMCID: PMC9449267.
• White O, Roeder N, Blum K, Eiden RD, Thanos PK. Prenatal Effects of Nicotine on Obesity Risks: A Narrative Review. Int J Environ Res Public Health. 2022 Aug 2;19(15):9477. doi: 10.3390/ijerph19159477. PMID: 35954830; PMCID: PMC9368674.
• Dennen CA, Blum K, Bowirrat A, Khalsa J, Thanos PK, Baron D, Badgaiyan RD, Gupta A, Braverman ER, Gold MS. Neurogenetic and Epigenetic Aspects of Cannabinoids. Epigenomes. 2022 Aug 26;6(3):27. doi: 10.3390/epigenomes6030027. PMID: 36135314; PMCID: PMC9498086.
• Blum K, Han D, Bowirrat A, Downs BW, Bagchi D, Thanos PK, Baron D, Braverman ER, Dennen CA, Gupta A, Elman I, Badgaiyan RD, Llanos-Gomez L, Khalsa J, Barh D, McLaughlin T, Gold MS. Genetic Addiction Risk and Psychological Profiling Analyses for "Preaddiction" Severity Index. J Pers Med. 2022 Oct 27;12(11):1772. doi: 10.3390/jpm12111772. PMID: 36579510; PMCID: PMC9696872.
• Ceccanti M, Blum K, Bowirrat A, Dennen CA, Braverman ER, Baron D, Mclaughlin T, Giordano J, Gupta A, Downs BW, Bagchi D, Barh D, Elman I, Thanos PK, Badgaiyan RD, Edwards D, Gold MS. Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids. J Pers Med. 2022 Dec 6;12(12):2015. doi: 10.3390/jpm12122015. PMID: 36556236; PMCID: PMC9782293.
• Blum K, Elman I, Dennen CA, McLaughlin T, Thanos PK, Baron D, Gold MS, Badgaiyan RD. "Preaddiction" construct and reward deficiency syndrome: genetic link via dopaminergic dysregulation. Ann Transl Med. 2022 Nov;10(21):1181. doi: 10.21037/atm-2022-32. PMID: 36467361; PMCID: PMC9708493.
• Kotyuk E, Urbán R, Hende B, Richman M, Magi A, Király O, Barta C, Griffiths MD, Potenza MN, Badgaiyan RD, Blum K, Demetrovics Z. Development and validation of the Reward Deficiency Syndrome Questionnaire (RDSQ-29). J Psychopharmacol. 2022 Mar;36(3):409-422. doi: 10.1177/02698811211069102. Epub 2022 Feb 1. PMID: 35102768.
• Madigan MA, Gupta A, Bowirrat A, Baron D, Badgaiyan RD, Elman I, Dennen CA, Braverman ER, Gold MS, Blum K. Precision Behavioral Management (PBM) and Cognitive Control as a Potential Therapeutic and Prophylactic Modality for Reward Deficiency Syndrome (RDS): Is There Enough Evidence? Int J Environ Res Public Health. 2022 May 24;19(11):6395. doi: 10.3390/ijerph19116395. PMID: 35681980; PMCID: PMC9180535.
• Vereczkei A, Barta C, Magi A, Farkas J, Eisinger A, Király O, Belik A, Griffiths MD, Szekely A, Sasvári-Székely M, Urbán R, Potenza MN, Badgaiyan RD, Blum K, Demetrovics Z, Kotyuk E. FOXN3 and GDNF Polymorphisms as Common Genetic Factors of Substance Use and Addictive Behaviors. J Pers Med. 2022 Apr 26;12(5):690. doi: 10.3390/jpm12050690. PMID: 35629112; PMCID: PMC9144496.
• Modestino EJ, Blum K, Dennen CA, Downs BW, Bagchi D, Llanos-Gomez L, Elman I, Baron D, Thanos PK, Badgaiyan RD, Braverman ER, Gupta A, Gold MS, Bowirrat A. Theorizing the Role of Dopaminergic Polymorphic Risk Alleles with Intermittent Explosive Disorder (IED), Violent/Aggressive Behavior and Addiction: Justification of Genetic Addiction Risk Severity (GARS) Testing. J Pers Med. 2022 Nov 23;12(12):1946. doi: 10.3390/jpm12121946. PMID: 36556167; PMCID: PMC9784939.
• Blum K, Brodie MS, Pandey SC, Cadet JL, Gupta A, Elman I, Thanos PK, Gondre-Lewis MC, Baron D, Kazmi S, Bowirrat A, Febo M, Badgaiyan RD, Braverman ER, Dennen CA, Gold MS. Researching Mitigation of Alcohol Binge Drinking in Polydrug Abuse: KCNK13 and RASGRF2 Gene(s) Risk Polymorphisms Coupled with Genetic Addiction Risk Severity (GARS) Guiding Precision Pro-Dopamine Regulation. J Pers Med. 2022 Jun 20;12(6):1009. doi: 10.3390/jpm12061009. PMID: 35743793; PMCID: PMC9224860.
• Nami M, Thatcher R, Kashou N, Lopes D, Lobo M, Bolanos JF, Morris K, Sadri M, Bustos T, Sanchez GE, Mohd-Yusof A, Fiallos J, Dye J, Guo X, Peatfield N, Asiryan M, Mayuku-Dore A, Krakauskaite S, Soler EP, Cramer SC, Besio WG, Berenyi A, Tripathi M, Hagedorn D, Ingemanson M, Gombosev M, Liker M, Salimpour Y, Mortazavi M, Braverman E, Prichep LS, Chopra D, Eliashiv DS, Hariri R, Tiwari A, Green K, Cormier J, Hussain N, Tarhan N, Sipple D, Roy M, Yu JS, Filler A, Chen M, Wheeler C, Ashford JW, Blum K, Zelinsky D, Yamamoto V, Kateb B. A Proposed Brain-, Spine-, and Mental- Health Screening Methodology (NEUROSCREEN) for Healthcare Systems: Position of the Society for Brain Mapping and Therapeutics. J Alzheimer’s Dis. 2022;86(1):21-42. doi: 10.3233/JAD-215240. PMID: 35034899.
• Blum K, Ashford JW, Kateb B, Sipple D, Braverman E, Dennen CA, Baron D, Badgaiyan R, Elman I, Cadet JL, Thanos PK, Hanna C, Bowirrat A, Modestino EJ, Yamamoto V, Gupta A, McLaughlin T, Makale M, Gold MS. Dopaminergic dysfunction: Role for genetic & epigenetic testing in the new psychiatry. J Neurol Sci. 2023 Oct 15;453:120809. doi: 10.1016/j.jns.2023.120809. Epub 2023 Sep 23. PMID: 37774561.
• Hanna C, Hamilton J, Blum K, Badgaiyan RD, Thanos PK. Exercise Modulates Brain Glucose Utilization Response to Acute Cocaine. J Pers Med. 2022 Nov 30;12(12):1976. doi: 10.3390/jpm12121976. PMID: 36556197; PMCID: PMC9788493.
• Gupta A, Bowirrat A, Gomez LL, Baron D, Elman I, Giordano J, Jalali R, Badgaiyan RD, Modestino EJ, Gold MS, Braverman ER, Bajaj A, Blum K. Hypothesizing in the Face of the Opioid Crisis Coupling Genetic Addiction Risk Severity (GARS) Testing with Electrotherapeutic Nonopioid Modalities Such as H-Wave Could Attenuate Both Pain and Hedonic Addictive Behaviors. Int J Environ Res Public Health. 2022 Jan 4;19(1):552. doi: 10.3390/ijerph19010552. PMID: 35010811; PMCID: PMC8744782.
• Blum K, McLaughlin T, Bowirrat A, Modestino EJ, Baron D, Gomez LL, Ceccanti M, Braverman ER, Thanos PK, Cadet JL, Elman I, Badgaiyan RD, Jalali R, Green R, Simpatico TA, Gupta A, Gold MS. Reward Deficiency Syndrome (RDS) Surprisingly Is Evolutionary and Found Everywhere: Is It "Blowin' in the Wind"? J Pers Med. 2022 Feb 21;12(2):321. doi: 10.3390/jpm12020321. PMID: 35207809; PMCID: PMC8875142.
• Hanna C, Hamilton J, Arnavut E, Blum K, Thanos PK. Brain Mapping the Effects of Chronic Aerobic Exercise in the Rat Brain Using FDG PET. J Pers Med. 2022 May 25;12(6):860. doi: 10.3390/jpm12060860. PMID: 35743644; PMCID: PMC9224807.
• Blum K, Dennen CA, Baron D, Thanos PK, Badgaiyan RD. Offering a putative neurobiological "dopamine homeostatic" solution to overcome the perils of the reward deficiency syndrome pandemic: emergence of "precision behavioral management". Ann Transl Med. 2022 Dec;10(23):1291. doi: 10.21037/atm-2022-67. PMID: 36618806; PMCID: PMC9816827.
• Rapp C, Hamilton J, Blum K, Thanos PK. The long-term interaction of diet and dopamine D2 gene expression on brain microglial activation. Psychiatry Res Neuroimaging. 2022 Mar;320:111430. doi: 10.1016/j.pscychresns.2021.111430. Epub 2021 Dec 20. PMID: 34953329.
• Dennen CA, Blum K, Bowirrat A, Thanos PK, Elman I, Ceccanti M, Badgaiyan RD, McLaughlin T, Gupta A, Bajaj A, Baron D, Downs BW, Bagchi D, Gold MS. Genetic Addiction Risk Severity Assessment Identifies Polymorphic Reward Genes as Antecedents to Reward Deficiency Syndrome (RDS) Hypodopaminergia's Effect on Addictive and Non-Addictive Behaviors in a Nuclear Family. J Pers Med. 2022 Nov 8;12(11):1864. doi: 10.3390/jpm12111864. PMID: 36579592; PMCID: PMC9694640.
• Richardson B, Swenson S, Hamilton J, Leonard K, Delis F, Gold M, Blum K, Thanos PK. Chronic neuroleptic treatment combined with a high fat diet elevated [3H] flunitrazepam binding in the cerebellum. Prog Neuropsychopharmacol Biol Psychiatry. 2022 Jan 10;112:110407. doi: 10.1016/j.pnpbp.2021.110407. Epub 2021 Jul 25. PMID: 34320402.
• Richer K, Hamilton J, Delis F, Martin C, Fricke D, Yao R, Sajjad M, Blum K, Hadjiargyrou M, Komatsu D, Thanos PK. Chronic treatment and abstinence from methylphenidate exposure dose-dependently changes glucose metabolism in the rat brain. Brain Res. 2022 Apr 1;1780:147799. doi: 10.1016/j.brainres.2022.147799. Epub 2022 Jan 21. PMID: 35074404.
• Bajaj A, Blum K, Bowirrat A, Gupta A, Baron D, Fugel D, Nicholson A, Fitch T, Downs BW, Bagchi D, Dennen CA, Badgaiyan RD. DNA Directed Pro-Dopamine Regulation Coupling Subluxation Repair, H-Wave® and Other Neurobiologically Based Modalities to Address Complexities of Chronic Pain in a Female Diagnosed with Reward Deficiency Syndrome (RDS): Emergence of Induction of "Dopamine Homeostasis" in the Face of the Opioid Crisis. J Pers Med. 2022 Aug 30;12(9):1416. doi: 10.3390/jpm12091416. PMID: 36143203; PMCID: PMC9503998.
• Blum K, Soni D, Badgaiyan RD, Baron D. Overcoming reward deficiency syndrome by the induction of "dopamine homeostasis" instead of opioids for addiction: illusion or reality? J Osteopath Med. 2022 Apr 12;122(7):333-337. doi: 10.1515/jom-2021-0026. PMID: 35411759.
• Blum K, Dennen CA, Elman I, Bowirrat A, Thanos PK, Badgaiyan RD, Downs BW, Bagchi D, Baron D, Braverman ER, Gupta A, Green R, McLaughlin T, Barh D, Gold MS. Should Reward Deficiency Syndrome (RDS) Be Considered an Umbrella Disorder for Mental Illness and Associated Genetic and Epigenetic Induced Dysregulation of Brain Reward Circuitry? J Pers Med. 2022 Oct 14;12(10):1719. doi: 10.3390/jpm12101719. PMID: 36294858; PMCID: PMC9604605.
• Blum K, Gold MS, Cadet JL, Baron D, Bowirrat A, Thanos PK, Brewer R, Badgaiyan RD, Gondré-Lewis MC. Dopaminylation in Psychostimulant Use Disorder Protects Against Psychostimulant Seeking Behavior by Normalizing Nucleus Accumbens (NAc) Dopamine Expression. Curr Psychopharmacol. 2022;11(1):11-17. doi: 10.2174/2211556009666210108112737. Epub 2021 Jan 8. PMID: 36046837; PMCID: PMC9426774.
• Braverman ER, Dennen CA, Gold MS, Bowirrat A, Gupta A, Baron D, Roy AK, Smith DE, Cadet JL, Blum K. Proposing a "Brain Health Checkup (BHC)" as a Global Potential "Standard of Care" to Overcome Reward Dysregulation in Primary Care Medicine: Coupling Genetic Risk Testing and Induction of "Dopamine Homeostasis". Int J Environ Res Public Health. 2022 Apr 30;19(9):5480. doi: 10.3390/ijerph19095480. PMID: 35564876; PMCID: PMC9099927.
• Blum K, Han D, Baron D, Kazmi S, Elman I, Gomez LL, Gondre-Lewis MC, Thanos PK, Braverman ER, Badgaiyan RD. Nicotinamide Adenine Dinucleotide (NAD+) and Enkephalinase Inhibition (IV1114589NAD) Infusions Significantly Attenuate Psychiatric Burden Sequalae in Substance Use Disorder (SUD) in Fifty Cases. Curr Psychiatry Res Rev. 2022 Jul;18(2):125-143. doi: 10.2174/2666082218666220527114427. Epub 2022 Jun 21. PMID: 36118157; PMCID: PMC9474872.
• Blum K, Han D, Gupta A, Baron D, Braverman ER, Dennen CA, Kazmi S, Llanos-Gomez L, Badgaiyan RD, Elman I, Thanos PK, Downs BW, Bagchi D, Gondre-Lewis MC, Gold MS, Bowirrat A. Statistical Validation of Risk Alleles in Genetic Addiction Risk Severity (GARS) Test: Early Identification of Risk for Alcohol Use Disorder (AUD) in 74,566 Case-Control Subjects. J Pers Med. 2022 Aug 26;12(9):1385. doi: 10.3390/jpm12091385. PMID: 36143170; PMCID: PMC9505592.
• Blum K, Dennen CA, Braverman ER, Gupta A, Baron D, Downs BW, Bagchi D, Thanos P, Pollock M, Khalsa J, Elman I, Bowirrat A, Badgaiyan RA. Hypothesizing That Pediatric Autoimmune Neuropsychiatric Associated Streptococcal (PANDAS) Causes Rapid Onset of Reward Deficiency Syndrome (RDS) Behaviors and May Require Induction of "Dopamine Homeostasis". Open J Immunol. 2022 Sep;12(3):65-75. doi: 10.4236/oji.2022.123004. PMID: 36407790; PMCID: PMC9670240.
• Gondré-Lewis MC, Elman I, Alim T, Chapman E, Settles-Reaves B, Galvao C, Gold MS, Baron D, Kazmi S, Gardner E, Gupta A, Dennen C, Blum K. Frequency of the Dopamine Receptor D3 (rs6280) vs. Opioid Receptor µ1 (rs1799971) Polymorphic Risk Alleles in Patients with Opioid Use Disorder: A Preponderance of Dopaminergic Mechanisms? Biomedicines. 2022 Apr 7;10(4):870. doi: 10.3390/biomedicines10040870. PMID: 35453620; PMCID: PMC9027142.
• Bowirrat A, Elman I, Dennen CA, Gondré-Lewis MC, Cadet JL, Khalsa J, Baron D, Soni D, Gold MS, McLaughlin TJ, Bagchi D, Braverman ER, Ceccanti M, Thanos PK, Modestino EJ, Sunder K, Jafari N, Zeine F, Badgaiyan RD, Barh D, Makale M, Murphy KT, Blum K. Neurogenetics and Epigenetics of Loneliness. Psychol Res Behav Manag. 2023 Nov 29;16:4839-4857. doi: 10.2147/PRBM.S423802. PMID: 38050640; PMCID: PMC10693768.
• Ahmed R, Blum K, Thanos PK. Epigenetic Effects of Psychoactive Drugs. Curr Pharm Des. 2023;29(27):2124-2139. doi: 10.2174/1381612829666230706143026. PMID: 37415372.
• Dennen A C, Blum K, Braverman R E, Bowirrat A, Gold M, Elman I, Thanos K P, Baron D, Gupta A, Edwards D, Badgaiyan D R. How to Combat the Global Opioid Crisis. CPQ Neurol Psychol. 2023;5(4):93. Epub 2023 Jan 23. PMID: 36812107; PMCID: PMC9937628.
• Blum K, Elman I, Bowirrat A, Baron D, Thanos PK, Hanna C, Badgaiyan RD, Gold MS. Futuristic Exploration of Addiction Neuroscience in the Genomic Era. Psychol Res Behav Manag. 2023 Dec 9;16:4989-4991. doi: 10.2147/PRBM.S439837. PMID: 38094658; PMCID: PMC10717929.
• Senior D, Ahmed R, Arnavut E, Carvalho A, Lee WX, Blum K, Komatsu DE, Hadjiargyrou M, Badgaiyan RD, Thanos PK. Behavioral, Neurochemical and Developmental Effects of Chronic Oral Methylphenidate: A Review. J Pers Med. 2023 Mar 23;13(4):574. doi: 10.3390/jpm13040574. PMID: 37108960; PMCID: PMC10144804.
• Thanos PK, McCarthy M, Senior D, Watts S, Connor C, Hammond N, Blum K, Hadjiargyrou M, Komatsu D, Steiner H. Combined Chronic Oral Methylphenidate and Fluoxetine Treatment During Adolescence: Effects on Behavior. Curr Pharm Biotechnol. 2023;24(10):1307-1314. doi: 10.2174/1389201024666221028092342. PMID: 36306463.
• Blum K, Dennen C, Carney PR, Gilley E, Thanos PK, Braverman ER, Baron D, Hanna C, Modestino EJ, Gold MS, Elman I, Badgaiyan RD. Psychostimulants for Children: Are We Over or Under Dosing? J Addict Psychiatry. 2023;7(1):1-4. Epub 2023 Apr 22. PMID: 37560458; PMCID: PMC10411151.
• Blum K, Gold MS, Cadet JL, Gondre-Lewis MC, McLaughlin T, Braverman ER, Elman I, Paul Carney B, Cortese R, Abijo T, Bagchi D, Giordano J, Dennen CA, Baron D, Thanos PK, Soni D, Makale MT, Makale M, Murphy KT, Jafari N, Sunder K, Zeine F, Ceccanti M, Bowirrat A, Badgaiyan RD. Invited Expert Opinion- Bioinformatic and Limitation Directives to Help Adopt Genetic Addiction Risk Screening and Identify Preaddictive Reward Dysregulation: Required Analytic Evidence to Induce Dopamine Homeostasis. Med Res Arch. 2023 Sep 14;11(8):10.18103/mra.v11i8.4211. doi: 10.18103/mra.v11i8.4211. PMID: 37885438; PMCID: PMC10601302.
• Thanos PK, Hanna C, Mihalkovic A, Hoffman A, Posner A, Butsch J, Blum K, Georger L, Mastrandrea LD, Quattrin T. Genetic Correlates as a Predictor of Bariatric Surgery Outcomes after 1 Year. Biomedicines. 2023 Sep 27;11(10):2644. doi: 10.3390/biomedicines11102644. PMID: 37893019; PMCID: PMC10603884.
• Hanna C, Yao R, Sajjad M, Gold M, Blum K, Thanos PK. Exercise Modifies the Brain Metabolic Response to Chronic Cocaine Exposure Inhibiting the Stria Terminalis. Brain Sci. 2023 Dec 11;13(12):1705. doi: 10.3390/brainsci13121705. PMID: 38137153; PMCID: PMC10742065.
• Blum K, Mclaughlin T, Gold MS, Gondre-Lewis MC, Thanos PK, Elman I, Baron D, Bowirrat A, Barh D, Khalsa J, Hanna C, Jafari N, Zeine F, Braverman ER, Dennen C, Makale MT, Makale M, Sunder K, Murphy KT, Badgaiyan RD. Are We Getting High Cause the Thrill is Gone? J Addict Psychiatry. 2023;7(1):5-516. Epub 2023 Dec 8. PMID: 38164471; PMCID: PMC10758019.
• Blum K, Bowirrat A, Elman I, Baron D, Thanos PK, Gold MS, Hanna C, Makale MT, Sunder K, Jafari N, Zeine F, Murphy KT, Makale M, Badgaiyan RD. Evidence for the DRD2 Gene as a Determinant of Reward Deficiency Syndrome (RDS). Clin Exp Psychol. 2023 Jun 29;9(4):8-11. PMID: 37560184; PMCID: PMC10411139.
• Blum K, Thanos PK, Hanna C, Gold MS, Baron D, Elman I. "TO BE OR NOT TO BE" GWAS Ends the Controversy about the DRD2 Gene as a Determinant of Reward Deficiency Syndrome (RDS). Psychol Res Behav Manag. 2023 Oct 20;16:4287-4291. doi: 10.2147/PRBM.S428841. PMID: 37885829; PMCID: PMC10597772.
• Blum K, Bowirrat A, Braverman ER, Dennen C, Zeine F, Jafari N, Sunder K, Thanos PK, Baron D, Barh D, Gupta A, Bagchi D, Gold MS, Badgaiyan RD. Beyond Mor: Can Induction of Dopamine Homeostasis Along with Electrotherapy Attenuate the Opioid Crisis? Clin Exp Psychol. 2023 Mar 2;9(2):1-3. PMID: 37363693; PMCID: PMC10288571.
• Tyler J, Podaras M, Richardson B, Roeder N, Hammond N, Hamilton J, Blum K, Gold M, Baron DA, Thanos PK. High intensity interval training exercise increases dopamine D2 levels and modulates brain dopamine signaling. Front Public Health. 2023 Dec 19;11:1257629. doi: 10.3389/fpubh.2023.1257629. PMID: 38192549; PMCID: PMC10773799.
• Gilley ED, Bowirrat A, Gupta A, Giordano J, A Dennen C, R Braverman E, D Badgaiyan R, McLaughlin T, Baron D, Blum K. The Future is Now for Precision Genomic Addiction Medicine as a Frontline Modality for Inducing "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS). Curr Pharm Biotechnol. 2023 Apr 27. doi: 10.2174/1389201024666230427111117. Epub ahead of print. PMID: 37102488.
• Makale MT, Nybo C, Keifer J, Blum K, Dennen CA, Baron D, Sunder K, Elman I, Makale MR, Thanos PK, Murphy KT. Preliminary Observations of Personalized Repetitive Magnetic Stimulation (PrTMS) Guided by EEG Spectra for Concussion. Brain Sci. 2023 Aug 9;13(8):1179. doi:10.3390/brainsci13081179. PMID: 37626535; PMCID: PMC10452199.
• Blum K, McLaughlin T, Bowirrat A, Bagchi D, Braverman ER, Gupta A, Baron D, Thanos PK, Khalsa J, Jafari N, Zeine F, Giordano J, Dennen CA, Madigan MA, Carney P, Gold MS, Sunder K, Badgaiyan RD. Futuristic Thinking about Engineering "Geneospirituality" to Help Prevent Relapse of Reward Deficiency Syndrome (RDS) Behaviors. EC Psychol Psychiatr. 2023 Feb 16;12(3):26-32. PMID: 37361347; PMCID: PMC10288602.
• Penman SL, Berthold EC, Mihalkovic A, Hammond N, McCurdy CR, Blum K, Eiden RD, Sharma A, Thanos PK. Vaporized Delta-9-tetrahydrocannabinol Inhalation in Female Sprague Dawley Rats: A Pharmacokinetic and Behavioral Assessment. Curr Pharm Des. 2023;29(27):2149-2160. doi: 10.2174/1381612829666230419093809. PMID: 37114788.
• Makale MT, Abbasi S, Nybo C, Keifer J, Christman L, Fairchild JK, Yesavage J, Blum K, Gold MS, Baron D, Cadet JL, Elman I, Dennen CA, Murphy KT. Personalized repetitive transcranial magnetic stimulation (prtms®) for post-traumatic stress disorder (ptsd) in military combat veterans. Heliyon. 2023 Aug 8;9(8):e18943. doi: 10.1016/j.heliyon.2023.e18943. PMID: 37609394; PMCID: PMC10440537.
• Ortiz LM, O'Malley N, Blum K, Hadjiargyrou M, Komatsu DE, Thanos PK. Psychostimulants prescribed to children for ADHD following distal radius fractures significantly reduce bone density as a function of duration. J Pediatr Orthop B. 2023 Sep 22. doi: 10.1097/BPB.0000000000001125. Epub ahead of print. PMID: 37751375.
• Thanos PK, Hanna C, Mihalkovic A, Hoffman AB, Posner AR, Busch J, Smith C, Badgaiyan RD, Blum K, Baron D, Mastrandrea LD, Quattrin T. The First Exploratory Personalized Medicine Approach to Improve Bariatric Surgery Outcomes Utilizing Psychosocial and Genetic Risk Assessments: Encouraging Clinical Research. J Pers Med. 2023 Jul 20;13(7):1164. doi: 10.3390/jpm13071164. PMID: 37511777; PMCID: PMC10381606.
• Pierce S, Blum K, Baron D, Giordano J, Elman I, Badgaiyan RD, Gupta A, Dennen C, Bajaj A, Bowirrat A. EPIC Spinal Procedure with Sound Wave Technology Induces Biomechanical Alignment Putatively Influencing Pain Response. Am J Biomed Sci Res. 2023;19(6):709-715. Epub 2023 Aug 16. PMID: 37885606; PMCID: PMC10601340.
• Roeder N, Richardson B, Mihalkovic A, Penman S, White O, Hamilton J, Gupta A, Blum K, Gold MS, Thanos PK. Fatty Acid-Binding Protein 5 Gene Deletion Enhances Nicotine-Conditioned Place Preference: Illuminating the Putative Gateway Mechanisms. Future Pharmacol. 2023 Mar;3(1):108-116. doi: 10.3390/futurepharmacol3010007. Epub 2023 Jan 9. PMID: 36864947; PMCID: PMC9969817.
• Bajaj A, Han D, Elman I, Thanos PK, Dennen CA, Badgaiyan RD, Bowirrat A, Barh D, Blum K. Positive Clinical Outcomes for Severe Reported Pain Using Robust Non-Addictive Home Electrotherapy-A Case-Series. J Pers Med. 2023 Feb 15;13(2):336. doi: 10.3390/jpm13020336. PMID: 36836570; PMCID: PMC9965228.
• Blum K, Elman I, Dennen CA, McLaughlin T, Thanos PK, Baron D, Gold MS, Badgaiyan RD. "Preaddiction" construct and reward deficiency syndrome: genetic link via dopaminergic dysregulation. Ann Transl Med. 2022 Nov;10(21):1181. doi: 10.21037/atm-2022-32. PMID: 36467361; PMCID: PMC9708493.
• Blum K, Dennen CA, Baron D, Thanos PK, Badgaiyan RD. Offering a putative neurobiological "dopamine homeostatic" solution to overcome the perils of the reward deficiency syndrome pandemic: emergence of "precision behavioral management". Ann Transl Med. 2022 Dec;10(23):1291. doi: 10.21037/atm-2022-67. PMID: 36618806; PMCID: PMC9816827.
• Ahmed R, Zyla S, Hammond N, Blum K, Thanos PK. The Role of Estrogen Signaling and Exercise in Drug Abuse: A Review. Clin Pract. 2024 Jan 8;14(1):148-163. doi: 10.3390/clinpract14010012. PMID: 38248436; PMCID: PMC10801537.
• Lee YK, Gold MS, Blum K, Thanos PK, Hanna C, Fuehrlein B. Opioid use disorder: current trends and potential treatments; Front. Public Health, Sec. Substance Use Disorders and Behavioral Addictions; Volume 11 - 2023 | https://doi.org/10.3389/fpubh.2023.1274719
• Foojan Zeine, Nicole Jafari, David Baron, Abdalla Bowirrat, Brian Norling, Kathleen Carter Martinez, Mohammad Nami, Nima Manavi, Keerthy Sunder, David M. Rabin, Debasis Bagchi, Mark S Gold, Daniel Sipple, Mojtaba Barzegar, Jothsna Bodhanapati, Waseem Khader, Paul Carney, Catherine A. Dennen, Ashim Gupta, Igor Elman, Rajendra D Badgaiyan, Edward J. Modestino, Panayotis K. Thanos,Colin Hanna, Thomas McLaughlin, Jean Lud Cadet, Diwanshu Soni, Eric R. Braverman,Debmalya Barh, John Giordano, Drew Edwards, Wesson Ashford, Marjorie C. Gondre-Lewis, Elizebeth Gilley,Kevin T Murphy, Kenneth Blum; Solving the Global Opioid Crisis: Incorporating Genetic Addiction Risk Assessment with Personalized Dopaminergic Homeostatic Therapy and Awareness Integration Therapy ; Brain Sci (MINOR REVISION) 2024
• Kai-Uwe Lewandrowski, Alireza Sharafshah, Rossano Kepler, Alvim Fiorelli, Francisco José Barcellos Sampaio, Mauricio G Pereira, Sergio Luis Schmidt, and Kenneth Blum; Personalized Postoperative Pain Management And Therapies Based On Pharmacogenomics; Brazilian National Academy Of Science; 2024 (In Press)
• Zeine F, Jafari N, Nami M, Blum K ; Awareness Integration Theory : A Psychological and Genetic Path to Self-Directed Neuroplasticity; Health Sci Rev (2024) in review
• Edward Justin Modestino, Abdalla Bowirrat, David Baron, PanayotisK. Thanos, Colin Hanna, Debasis Bagchi, Eric R. Braverman, Catherine A.Dennen, Rajendra D. Badgaiyan, Mark S. Gold, Kenneth Blum;  Is There A Natural, Non-Addicting, And Non-Anti -Reward SafeGene-Based Solution To Treat Reward Deficiency Syndrome (RDS)? JPM (2024) in review
• Blum, K., Abdalla Bowirrat,Keerthy Sunder, Panayotis K. Thanos, Colin Hanna, Miles R. Makale, Mark S. Gold, Catherine Dennen, Igor Elman, Kevin T. Murphy, David Baron,Milan T. Makale.Dopamine Dysregulation In Reward And Autism Spectrum Disorder (Asd): To Be Or Not To Be?Nature Neurosciences (2024) submitted
• Makale M, Blum K., Bowirrat A. Sunder K., Malale MR., Gold MS., Elman I, Dennen CA, Murphy KT: Personalized Repetitive Transcranial Magnetic Stimulation (Prtms) Guided By Genetic Testing And The Spectral EGG Is A Novel Combinatorial Approach That Can Alleviate The Treatment Refractoriness Of Autism Spectrum Disorder (ASD)
• Keerthy Sunder, Milan Makale, Miles Makale, Jothsna Bodhanapati, Kevin T. Murphy, Catherine Dennen, David Barom, Panayotis K. Thanos, John Wesson Ashford, Kenneth Blum; A novel combination of NuCalm® with Dual Hemispheric repetitive Transcranial Magnetic (rTMS) Stimulation attenuates comorbid Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD). Journal Of Psychology Research & Behavioral Management (2024) in review
• Lee YK, Gold MS, Blum K, Thanos PK, Hanna C, Fuehrlein BS. Opioid use disorder: current trends and potential treatments. Front Public Health. 2024 Jan 25;11:1274719. doi: 10.3389/fpubh.2023.1274719. PMID: 38332941; PMCID: PMC10850316.
• Blum K, Elman I, Dennen CA, McLaughlin T, Thanos PK, Baron D, Gold MS, Badgaiyan RD. "Preaddiction" construct and reward deficiency syndrome: genetic link via dopaminergic dysregulation. Ann Transl Med. 2022 Nov;10(21):1181. doi: 10.21037/atm-2022-32. PMID: 36467361; PMCID: PMC9708493.
• Blum K, Dennen CA, Baron D, Thanos PK, Badgaiyan RD. Offering a putative neurobiological "dopamine homeostatic" solution to overcome the perils of the reward deficiency syndrome pandemic: emergence of "precision behavioral management". Ann Transl Med. 2022 Dec;10(23):1291. doi: 10.21037/atm-2022-67. PMID: 36618806; PMCID: PMC9816827.
• Ahmed R, Zyla S, Hammond N, Blum K, Thanos PK. The Role of Estrogen Signaling and Exercise in Drug Abuse: A Review. Clin Pract. 2024 Jan 8;14(1):148-163. doi: 10.3390/clinpract14010012. PMID: 38248436; PMCID: PMC10801537.
• Klein SR, Blum K, Gold MS, Thanos PK. Chronic Methylphenidate Effects on Brain Gene Expression: An Exploratory Review. Psychol Res Behav Manag. 2024 Feb 15;17:577-592. doi: 10.2147/PRBM.S445719. PMID: 38379637; PMCID: PMC10876479.
• Blum K, Bowirrat A, Thanos PK, Hanna C, Khalsa J, Baron D, Elman I, Badgaiyan RD, Dennen C, Braverman ER, Carney P, Lewandrowski KU, Sharafshah A, Gold MS. Evidence Based Clinical Analytics Supporting the Genetic Addiction Risk Severity (GARS) Assessment to Early Identify Probands in Preaddiction. EC Psychol Psychiatr. 2024 Dec 26;13(1):1-3. PMID: 38298272; PMCID: PMC10825809.

• Blum, K., McDonald, L., Maddux, J. and Wallace, J.E. Production of "wet‑dog" shakes by chronic administration of methadone in female rats. In: Singh, J.M., Lal, H., ed., Drug Addiction. Vol. 4: New Aspects of Analytical and Clinical Toxicology, pp. 123‑6, 1974. New York, Stratton.
• Blum, K., Hudson, K.C., Friedman, R.N. and Wallace, J.E. Tetrahydrocannabinol: Inhibition of alco­hol‑induced withdrawal symptoms in mice. In: Singh, J.M., Lal, H., ed., Drug Addiction. Vol. 3: Neurobiology and Influences on Behavior, pp. 39‑53, 1974. New York, Stratton.
• Wallace, J.E., Blum, K. and Singh, J.M. The determination of drugs in biologic specimens: A review. In Singh, J.M., Lal, H., ed., Drug Addiction. Vol. 4: New Aspects of Analytical and Clinical Toxicology, pp. 175‑92, 1974. New York, Stratton.
• Wallace, J.E., Blum, K. and Singh, J.M. The determination of drugs in biological specimens──a review. In: Winek, C.L., ed., Toxicology Annual 1974, pp. 167‑85, 1975. New York, Dekker.
• Blum, K. Neurochemical and behavioral considerations on the relationship between ethanol and opiate dependence. In: J.H. Lowinson (Ed.). Proc. of the National Drug Abuse Conference. Marcel Dekker, New York, 1976.
• Blum, K. Evidence for a relationship between alcohol and opiate dependence in mice. In: Seventh Technical Review on Drug Interaction, M.C. Braude, Moderator, sponsored by NIDA, May 6, 1976.
• Blum, K., Hamilton, M.G. and Wallace, J.E. Alcohol and Opiates: A Review of Common Neuro­chemical and Behavioral Mechanisms. Editor: K. Blum. Academic Press, New York, pp. 203, 1977.
• Alcohol and Opiates: Neurochemical and Behavioral Mechanisms; Symposium on Alcohol and Opiates; Neurochemical and Behavioral Mechanisms of Alcohol and Opiate Dependence. Edited by Blum, K. Associate Editors, Bard, Diana L. and Hamilton, Murray G. Academic Press, New York, pp. 403, 1977.
• Blum, K., Briggs, A.H., Elston, S.F.A., Hirst, M., Hamilton, M.G. and Vereby, K. Common denominator theory for alcohol and opiate dependence: A review of similarities and differences. In: Alcohol Tolerance and Dependence. Editors: H. Rigter and J. Crabbe. Elsevier‑Netherlands, Chapter 15: 371‑396, 1980.
• Blum, K., Briggs, A.H., Elston, S.F.A., DeLallo, L. and Hirst, M. Validation of central and peripheral models to evaluate alcohol sensitivity and opiate‑membrane interactions as function of genotype‑dependent responses in three different strains of mice. Academic Press, NY, pp. 84‑91, 1980.
• Blum, K. Alcohol and Opiates: A review of common mechanisms. Proc. Internat. Neurotoxi­cology Congress, Pergamon Press, Edited by Y. Lacasse, W. Levy and L. Manzo, 1980.
• Hamilton, M.G., Blum, K. and Hirst, M. In vivo formation of isoquinolines during chronic exposure of rodents to ethanol. In: Alcoholism: A Perspective. Editors: F.S. Messiha and G. Tyner. Spectrum Press, New York, pp. 373‑382, 1980.
• Blum, K., Hamilton, M.G., Briggs, A.H. and Hirst, M. Calcium gluconate and phenoxybenzamine: Paradoxical modification of ethanol dependence in mice. In: Alcoholism: A Perspective. Editors: F.S. Messiha and G. Tyner. Spectrum Press, New York, pp. 234‑246, 1980.
• Hamilton, M.G., Blum, K. and Hirst, M. In vivo isoquinoline formation: Effect of time and route of ethanol administration. In: Advances in Exp. Med. Biol., Plenum Press, New York, pp. 73‑86, 1981.
• Blum, K. and Tilton, J.E. Understanding the high mind. In: Folk Healing and Herbal Medicine. Editors: G. Meyer, K. Blum, and J.G. Cull, Charles C. Thomas and Company, 261‑274, 1981.
• Blum, K. Neurophysical effects of ethanol. In: American Encyclopedia of Alcoholism. Editors: E.M. Pattison and E. Kaufman. Gardner Press, New York, 1982.
• Blum, K. "The Background for Abuse." In: Handbook of Abu sable Drugs, Gardner Press, New York, pp. 1‑16, 1984.
• Blum, K. "Some General Social Pharmacologic Aspects of Substance Abuse." In: Handbook of Abu sable Drugs, Gardner Press, New York, pp. 17‑28, 1984.
• Blum, K. "Basic Pharmacological Considerations and Principles." In: Handbook of Abu sable Drugs, Gardner Press, New York, pp. 29‑44, 1984.
• Blum, K. "Classification of Psychoactive Drugs." In: Handbook of Abu sable Drugs, Gardner Press, New York, pp. 45‑52, 1984.
• Blum, K. "Narcotics." In: Handbook of Abu sable Drugs, Gardner Press, New York, pp. 53‑80, 1984.
• Blum, K. "Pharmacology and Clinical Applications of Narcotic Antagonists." In: Handbook of Abusable Drugs, Gardner Press, New York, pp. 91‑100, 1984.
• Blum, K. "Methadone and Other Narcotic Maintenance Drugs: Pharmacologic Issues, Myths and Realities." In: Handbook of Abusable Drugs, Gardner Press, New York, pp. 101‑144, 1984.
• Blum, K. "Internal Opioids: A Look into the Future." In: Handbook of Abusable Drugs, Gardner Press, New York, pp. 145‑164, 1984.
• Blum, K. "CNS Depressants: Sedative, Hypnotics (Barbiturates and Non‑Barbiturates)." In: Handbook of Abusable Drugs, Gardner Press, New York, pp. 165‑210, 1984.
• Blum, K. "Solvent and Aerosol Inhalants ("Glue Sniffing")." In: Handbook of Abusable Drugs, Gardner Press, New York, pp. 211‑236, 1984.
• Blum, K. "Alcohol: The World's Most Devastating Drug." In: Handbook of Abusable Drugs, Gardner Press, New York, pp. 237‑304, 1984.
• Blum, K. "Central Nervous System Stimulants ("The Uppers")." In: Handbook of Abusable Drugs, Gardner Press, New York, pp. 305‑351, 1984.
• Blum, K. "Tranquilizing Agents." In: Handbook of Abusable Drugs, Gardner Press, New York, pp. 352‑376, 1984.
• Blum, K. "Antidepressants and Antimania Drugs (Mood Elevators and Stabilizers)." In: Handbook of Abusable Drugs, Gardner Press, New York, pp. 377‑394, 1984.
• Blum, K. "Tobacco and Smoking Behavior." In: Handbook of Abusable Drugs, Gardner Press, New York, pp. 355‑420, 1984.
• Blum, K. "Over‑the‑Counter (OTC) Drugs." In: Handbook of Abusable Drugs, Gardner Press, New York, pp. 421‑446, 1984.
• Blum, K. "Marihuana: Heaven or Hell." In: Handbook of Abusable Drugs, Gardner Press, New York, pp. 447‑507, 1984.
• Blum, K. "Psychedelics: Brave Old World." In: Handbook of Abusable Drugs, Gardner Press, New York, pp. 535‑594, 1984.
• Blum, K. "Psychotropic Drug Interactions." In: Handbook of Abusable Drugs, Gardner Press, New York, pp. 595‑644, 1984.
• Blum, K. "Influence of Psychopharmacologic Agents on Sexual Function: Psychopharmacosexology." In: Handbook of Abusable Drugs, Gardner Press, New York, pp. 645‑662, 1984.
• Blum, K Drug odyssey 2001." In: Handbook of Abusable Drugs, Gardner Press, New York, pp. 663‑676, 1984.
• Blum, K. The cytogenetics of alcoholism: The role of opioid peptides. Substance Abuse, AMERSA Publication, 1985.
• Blum, K. The Role of Opioid Peptides In Alcohol Seeking Behavior. Invited participant in "Alcoholism Bridging the Gap." Friends Hospital, October 9‑10, 1985.
• Blum, K. The "Genotype Theory" in Alcohol and Drug Seeking Behavior. Keynote address. In "Currents in Alcohol and Drug Abuse Research." Youth Projects, Oakland, California, July 1985.
• Blum., K., Trachtenberg, M.C. Addicts may lack some neurotransmitters. U.S. J. Drugs and Alc. Dep., pp. 16, 1987.
• Blum, K. Alcoholism and Drug Abuse (Close‑up). World Book Encyclopedia Annals Health and Medicine, pp. 217‑222, 1987.
• Blum, K. "Alcoholism." Worldbook Encyclopedia. Submitted as Invited Contributor, 1988.
• Manzo, L., Blum, K., Sabbioni, E. Neurotoxicity of Selected Metals. In: Neurotoxicology, edited by Blum, K. and Manzo, L., Marcel Dekker, Inc., New York, 1985.
• Sheridan, P.J., Martin, P.M. and Blum, K. Steroid receptor dynamics: A function of cellular equilibrium. In: Steroid Receptors and Disease. Eds. P.J. Sheridan, K. Blum and M.C. Trachtenberg, pp. 49‑70, 1988.
• Blum, K. The disease process in alcoholism. Alco. and Addic. May 1988.
• Blum, K. A commentary on ethanol ‑ neuromodulator mechanism: Theoretical and clinical implications. In: Neurodegenerative Disorders: The Role Played by Endotoxins and Xenobiotics. Ed. G. Nappi et al., Raven Press, New York, pp. 269‑285, 1988.
• Sheridan, P.J., Blum, K. and Trachtenberg, M.C. Cancer, Autoimmune, Bone and Circulatory Disorders. In: Steroid Receptors and Disease. Eds. P.J. Sheridan, K. Blum and M.C. Trachtenberg, Marcel Dekker, New York, 1988.
• Blum, K., Trachtenberg, M.C. and Kozlowski, G.P. Cocaine Therapy: The "Reward Cascade" link. Professional Counselor Jan. 1989.
• Sheridan, P.J., Blum, K. and Trachtenberg, M.C. A look to the future. In: Steroid Receptors and Disease. Eds. P.J. Sheridan, K. Blum and M.C. Trachten­berg, Marcel Dekker, New York and Basel, pp. VII‑X, 1988.
• Blum, K. and Kozlowski, G.P. Ethanol and neuromodulator interactions: A cascade model of reward. Prog. Alcohol Res. 2 Ollat et al. (Eds), VSP, Utrecht, pp 131‑149, 1990.
• Blum, K. Some general social pharmacologic aspects of substance abuse. Sixth Edition of the Psychiatric Knowledge and Skills Self‑Assessment Program VI (PKSAP VI) pp 61‑71, 1990
• Blum, K., Sheridan, P.J. and Noble, E.P. The A1 allele of the dopamine D2 receptor gene as a genetic marker for risk of severe alcoholism. In: Biological Psychiatry (Racagnie, G., Brunello, N. and Fukudo, T.) 2:14‑17, Elsevier Science Publishers B.V., Amsterdam, 1991.
• Blum, K., Noble, E.P. and Sheridan, P.J. Association of the A1 allele of the D2 dopamine receptor gene with severe alcoholism. In: Biological Psychiatry (Racagni, R., Brunello, N. and Fukuda, T.) 29(11S):711S, Elsevier Science Publisher B.V., Amsterdam, 1991.
• Braverman, ER, Swartz, K., Blum, K., Moss, R, "Electrotherapy for Addictions," Addiction and Recovery, pp. 34-36, May/June 1992.
• Blum, K., Braverman, E., Loeblich, L., and Payne, J.D. Neurogenetics of compulsive disease: neuronutrients as adjuncts to recovery. In: The Chemically Dependent: Phases of Treatment and Recovery (B.C. Wallace, Ed). Brunner‑Mazel Inc., New York, N.Y. 1992.
• Blum, K., Cull, J.G, and Sheridan, P.J. Genetic screening: To be or not to be. Genetic Engineering News. November 1995.
• Blum, K. Cull, J.G., Braverman, E.R., Chen, T.H.J. and Comings, D.E. Reward deficiency syndrome: Neurobiological genetic aspects in Handbook of Psychiatric Genetics (Blum, K., and Noble, E.P., Eds), Chapter 18, pp 311-332, CRC Press, Boca Raton, Florida, 1997
• Blum, K. Sheridan, Ph.J. Chen, THJ, Wood, R.C., Braverman, Cull, J.G. and Comings, D.E. The dopamine d2 receptor gene locus in reward deficiency syndrome: Meta analyses. In: Handbook of Psychiatric Genetics (Blum, K. and Noble, E.P., Eds) chapter 24, pp. 407-434, CRC Press, Boca Raton, Florida 1997
• Blum K, Sheridan P, Wood R, Braverman E, Chen T, Comings D. “Dopamine D2 receptor gene variants association and linkage studies in impulsive-addictive-compulsive behavior.”Chapman & Hall, Ltd, 1994
• Archer T and Blum, K. Epigenetics in Neuropsychiatry. In: Barh D, Blum, K, Madigan MA (Eds) Omics: Biomedical Perspectives and Applications CRC Pres (Taylor Francis) 2012, Boca, Raton, Florida,
• Blum, K. Neurogenetics and Nutrigenomics of Reward Deficiency Syndrome. In: Barh D, Blum, K, Madigan MA (Eds) Omics: Biomedical Perspectives and Applications CRC Pres (Taylor Francis) 2012, Boca, Raton, Florida,
• Barh D, Madigan MA and Blum, K. Future Perspective: Paving a Path to Optimization of Health. In: Barh D, Blum, K, Madigan MA (Eds) Omics: Biomedical Perspectives and Applications CRC Pres (Taylor Francis) 2012, Boca, Raton, Florida,
• Blum, K, Oscar-Berman M, Gardner E, Simpatico T, Braverman ER, Gold MS. Neurogentics& Neurobiology of Dopamine in Anhedonia. In Ritsner MS (ED). Anhedonia: A Comprehensive Handbook Vol 1. Springer, New York, 2014
• Oscar-Berman-M, Femino J, Blum, K. Genes and Reward Dependence Circuitry: importance of Dopamine. Chapter in Neurocognition and Neuroscience Book (in press). 2015.
• Blum, K, Giordano J, Borsten J, Hauser M. Braverman ER, Barh D, Han D, Simpatico T.(2015) Challenging the Recovery Landscape to Incorporate Reward Gene Diagnosis and Meso-Limbic Manipulation of Hypodopaminergic Function in Reward Deficiency Syndrome (RDS): Neuroadaptagen Amino-Acid Therapy (NAAT) To Be or Not To Be? In: Pharamcogenomics: Ed D Barh (springer) New York.
• Blum, K., B.W. Downs, Kristina Dushaj, Mona Li, Eric R. Braverman, Lyle Fried, Roger Waite, Zsolt Demetrovics, Rajendra D. Badgaiyan. The benefits of customized DNA directed nutrition to balance the brain reward circuitry and reduce addictive behaviors. Precision Medicine Journal.
• Blum, K., Mark S. Gold, Igor Elman, David Baron, Rajendra D. Badgaiyan (2018) Depression, Reward Genes and DNA Polymorphic Targeted Nutrigenomic Resolution. In: Nomikos & Feltner: Translational Medicine in CNS Drug Development Handbook of Behavioral Neuroscience, volume 26.
• K. Blum, A K. Roy III, A. Podesta, E.J., Modestino, B. Steinberg, M.C. Gondré-Lewis, D. Baron, P.K, Thanos, L. Lott, J. Valdez Ponce, B. Boyett, D. Siwicki, M. Moran, I. Elman, D. Edwards, T. McLaughlin, E.R. Braverman, T. Simpatico, M. Hauser, B.W. Downs, R.D. Badgaiyan. Precision Behavioral Management (PBM) A Novel Genetically Guided Therapy To Combat Reward Deficiency Syndrome (RDS). Book Chapter-Cambridge Handbook on SUD and Behavioral Addictions.
• Blum, K “Staying Blind to RDS is Synonymous with Dark Ages –World is Flat. In: Evaluating The Brain Disease Model of Addiction. Routledge.
• Blum, K et al. “Genetic opioid risk system panel (GORS) provides a common paradigm understanding of genetic polymorphisms linked to “Reward Deficiency Syndrome” as a path to translational precision therapeutics to overcome Food / Opioid/Alcohol Addiction” Taylor Francis Book on Precision Medicine 2021.
• Blum, K et al. “Neurogenetics of Alcohol Use Disorder (AUD) a subset of Reward Deficiency Syndrome (RDS): Candidate Genes to be or not to be?” Elsevier Psychiatric Genomics, 20201.
• Gold MS and Blum, K “Clonidine: The Locus Coeruleus & Noradrenergic Hyperactivity Theory for Opioid and other Drug Withdrawal from 1977 to Present” Oxford Press, 2021.
• Blum, K, Gold M, Fuehrlein B“Genes and Genetic Testing in Addiction Medicine –Encyclopedia of Neurological Sciences (2024).

No content available to display!!!